Standing Orders for Immunizations
2020-2021
Defense Health Agency
Immunization Healthcare Division
Table of Contents

Memorandum for Appointment of Medical Director (Examples) ......................... 1
Information Paper: How to Use Standing Orders for Vaccine Delivery in the Department of Defense (DoD) .......................................................... 3
Anatomic Site Map ............................................................................................. 6
CDC Injection Safety Guidelines ........................................................................ 15
Recent Changes to Pediatric Standing Orders .................................................... 19
Recent Changes to Adult Standing Orders ......................................................... 23

Pediatric Standing Orders
  Diphtheria Tetanus and Pertussis Vaccine ..................................................... 27
  Hepatitis A Vaccine ....................................................................................... 30
  Hepatitis B Vaccine ....................................................................................... 33
  Haemophilus influenza type b Vaccine ............................................................ 36
  Human Papillomavirus Vaccine ...................................................................... 40
  Inactivated Polio Vaccine ............................................................................. 43
  Japanese Encephalitis Vaccine ....................................................................... 46
  Measles, Mumps, Rubella Vaccine ................................................................. 49
  Measles-Mumps-Rubella-Varicella Vaccine ................................................... 51
  Meninogococcal ACWY Vaccine ................................................................. 53
  Meningococcal Group B Vaccine .................................................................... 56
  Pneumococcal Conjugate (PCV13) Vaccine ................................................... 59
  Pneumococcal Polysaccharide (PPSV23) Vaccine ........................................... 63
  Rotavirus Vaccine ......................................................................................... 66
  Tetanus Diphtheria and Pertussis Vaccine ...................................................... 68
  Typhoid Vaccine ............................................................................................ 73
  Varicella (Chickenpox) Vaccine ...................................................................... 76
  Yellow Fever Vaccine ..................................................................................... 79

Adult Standing Orders
  Anthrax Vaccine ............................................................................................ 83
  Hepatitis A Vaccine ......................................................................................... 85
Every attempt was made by the project clinical working group to assure accuracy of content. Changes in immunization healthcare guidelines and vaccine-related alerts occur frequently. It is important for users of this resource to understand that full review of the vaccine package insert and relevant alerts at www.health.mil/vaccines are required by clinical staff responsible for vaccine administration. Competency training should not be limited to the use of this resource in the delivery of immunization healthcare.
MEMORANDUM FOR

SUBJECT: Standing Orders for Immunizations and Appointment of Medical Director

REFERENCE: Immunizations and Chemoprophylaxis for the Prevention of Infectious Diseases
AR 40-562
BUMEDINST 6230.15B AFI 48-110_IP
CG COMDTINST M6230.4G
7 OCTOBER 2013

The following standing orders have been updated and will be the standard of care for administering vaccinations at the (name of clinic).

The following individual has been appointed as Medical Director:

Medical Director:
Title:
Phone:
Clinic:

Responsibilities for this individual and all immunization staff are outlined in the Immunizations and Chemoprophylaxis for the Prevention of Infectious Diseases regulation/instruction referenced above, and this resource should be reviewed in its entirety by the appointed individual.

This appointment is current as the above indicated date and shall remain valid until rescinded or removed from the appointment.

Signature Block
MEMORANDUM FOR

SUBJECT: Appointment of Medical Director

REFERENCE: Immunizations and Chemoprophylaxis for the Prevention of Infectious Diseases
AR 40-562
BUMEDINST 6230.15B AFI 48-110_IP
CG COMDTINST M6230.4G
7 OCTOBER 2013

The following standing orders have been updated and will be the standard of care for administering vaccinations at the (name of the clinic).

The following individual has been appointed as Medical Director:

Medical Director:
Title:
Phone:
Clinic:

Responsibilities for this individual and all immunization staff are outlined in the Immunizations and Chemoprophylaxis for the Prevention of Infectious Diseases regulation/instruction referenced above, and this resource should be reviewed in its entirety by the appointed individual.

This appointment is current as the above indicated date and shall remain valid until rescinded or removed from the appointment.

Signature Block
SUBJECT: Standing Orders for Vaccine Delivery

1. Purpose. To provide an overview of Standing Orders for vaccine delivery within the DoD.

2. Facts.

   a. In the United States, federal law prohibits dispensing human vaccines or immune globulins without a prescription of a practitioner licensed by law to administer such drug (Federal Food, Drug, and Cosmetic Act, 21USC 353, 21CFR 610.60[a][6]).

   b. Standing Order programs authorize the administration of immunizations based on approved protocols without the need for a written physician order or referral from a primary care provider.

   c. Standing Orders are written protocols that delineate the circumstances under which appropriately trained healthcare personnel, other than a privileged provider, can engage in the legal practice of medicine. Standing Orders describe the specific type of medical practice that will be delegated, delineate the procedures that personnel must follow, identify the patient population that may be served, specify the level of provider supervision required, and govern the locations where the services may occur.

   d. Standing Orders are intended to remove administrative barriers to immunizations that are routinely administered in low-risk settings. They are recommended for use by properly trained health care personnel working within their scope of practice as determined by their license and each Service and/or the Defense Health Agency (DHA). Individuals must be trained in screening patients for contraindications, administering vaccines, and monitoring patients for adverse events in accordance with DoD, United States Coast Guard, and Centers for Disease Control and Prevention (CDC) guidelines. Training standards include documentation of comprehensive orientation and annual refresher training IAW Service and/or DHA requirements.

   e. Standing Orders do not dictate immunization requirements. Rather, they provide guidance by the privileged physician with medical oversight over the immunization activity to the immunization personnel, for the vaccines administered by that activity. As such, Standing Orders facilitate high quality immunization healthcare by reducing unnecessary
barriers. DoD vaccine requirements are established by DoD Health Affairs, the Multi-Service Regulation on Immunizations and Chemoprophylaxis, as well as the various Service-specific polices and Combatant Commands’ force health protection policies.

f. Successful Standing Order programs for immunizations should include protocols that:

1. Identify persons eligible for vaccination based on age, vaccination status, occupational or travel requirements and/or medical conditions that put them at high risk for infection.
2. Provide adequate information to patients or their guardians regarding the risks and benefits of a vaccine (e.g., Vaccine Information Statements) and documentation of that information in compliance with Federal, DoD, and Service-specific guidelines.
3. Record patient refusals or medical and administrative exemptions in the appropriate, Service-specific Immunization Tracking System (ITS) and the individual medical record.
4. Document vaccine administration within DoD and Service-specific ITS (e.g., MEDPROS (Army), ASIMS (Air Force), MRRS (Navy, Marine Corps), SAMS (ships afloat)) and any post-vaccination adverse events to the Vaccine Adverse Event Reporting System. Immunizations and adverse events should also be documented in the patient’s Electronic Health Record.
5. Address a quality assurance process to maintain appropriate standards of care for immunization delivery by health care personnel.

g. A Standing Order must be available for every vaccination that is administered without an individual order made by a privileged provider. The smallpox vaccine, ACAM2000, is ineligible to have standing orders, as each individual must be screened by a privileged provider to ensure there is not a contraindication to administration of this unique vaccine.

h. Standing Orders must be signed by a privileged physician with medical oversight over any clinic or activity that administers immunizations. In order to remain valid, standing orders must be renewed at least annually, or changes in oversight responsibilities, vaccine administration methods, and/or when updates in vaccine recommendations are made by the CDC’s Advisory Committee on Immunization Practices.

i. Examples of Standing Orders (not all-inclusive) may be found at https://health.mil/standingorders.
3. References.


g. Multiple resources assembled by DHA-IHD: https://www.health.mil/vaccines.
Anatomic Site Map
Suggested Sites for Immunization
Hib—*Haemophilus influenzae* type b Vaccine
PCV13—Pneumococcal Conjugate Vaccine
DTaP—Diphtheria Toxoid, Tetanus Toxoid and Acellular Pertussis Vaccine
IPV—Inactivated Polio Vaccine
HepB—Hepatitis B Vaccine
IM—Intramuscular

Note: “If more than 2 vaccines are in injected in a single limb, the injections should be sufficiently separated (separate anatomic sites [i.e. ≥1 inch] if possible) so that any local reactions can be differentiated” (ACIP)
Right Vastus Lateralis (IM)
PCV13

Left Vastus Lateralis (IM)
DTaP+IPV+HepB
(Combination Vaccine)

PCV13—Pneumococcal Conjugate Vaccine
DTaP—Diphtheria Toxoid, Tetanus Toxoid and Acellular Pertussis Vaccine
IPV—Inactivated Polio Vaccine
HepB—Hepatitis B Vaccine
IM—Intramuscular

Note: “If more than 2 vaccines are in injected in a single limb, the injections should be sufficiently separated (separate anatomic sites [i.e. ≥1 inch] if possible) so that any local reactions can be differentiated” (ACIP)

*6 months and older: flu vaccine (if indicated) in left vastus lateralis (IM) and/or opposite of PCV13
Anatomic Site Map
Suggested sites for Immunizations

12 Months

PCV13—Pneumococcal Conjugate Vaccine
HepA—Hepatitis A Vaccine
MMR—Measles, Mumps, and Rubella Vaccine
IM—Intramuscular
SC—Subcutaneous

Right Vastus Lateralis (IM)
PCV13

Right Fatty Tissue Overlying Anterolateral Muscle (SC)
Varicella

Left Fatty Tissue Overlying Anterolateral Muscle (SC)
MMR (Combination Vaccine)

Left Vastus Lateralis (IM)
HepA

Note: “If more than 2 vaccines are injected in a single limb, the injections should be sufficiently separated (separate anatomic sites [i.e. ≥1 inch] if possible) so that any local reactions can be differentiated” (ACIP)

*6 months and older: flu vaccine (if indicated) in left vastus lateralis (IM) and/or opposite of PCV13

15 Months

Left Vastus Lateralis (IM)
DTaP (Combination Vaccine)

Right Vastus Lateralis (IM)
Hib

Hib—*Haemophilus influenzae* type b Vaccine
DTaP—Diphtheria Toxoid, Tetanus Toxoid and Acellular Pertussis Vaccine
IM—Intramuscular

Note: “If more than 2 vaccines are in injected in a single limb, the injections should be sufficiently separated (separate anatomic sites [i.e. ≥1 inch] if possible) so that any local reactions can be differentiated” (ACIP)

*6 months and older: flu vaccine (if indicated) in left vastus lateralis (IM)
HepA - Hepatitis A Vaccine
IM—Intramuscular

Note: “If more than 2 vaccines are injected in a single limb, the injections should be sufficiently separated (separate anatomic sites [i.e. ≥1 inch] if possible) so that any local reactions can be differentiated” (ACIP)

*6 months and older: flu vaccine (if indicated) in left vastus lateralis (IM)
MRRV—Measles, Mumps, and Rubella and Varicella Vaccine
DTaP—Diphtheria Toxoid, Tetanus Toxoid and Acellular Pertussis Vaccine
IPV—Inactivated Polio Vaccine
IM—Intramuscular
SC—Subcutaneous
Note: “If more than 2 vaccines are injected in a single limb, the injections should be sufficiently separated (separate anatomic sites [i.e. ≥1 inch] if possible) so that any local reactions can be differentiated” (ACIP)

*6 months and older: flu vaccine (if indicated) in left deltoid (IM)
**11 - 12 years**

**Right Deltoid (IM)**
- HPV
- Tdap

**Left Deltoid (IM)**
- MenACWY

---

**HPV—Human Papillomavirus Vaccine**
**Tdap—Tetanus and Diphtheria Toxoids and Acellular Pertussis Vaccine**
**MenACWY—Meningococcal (A,C,W,Y) Vaccine**
**IM—Intramuscular**

*Note: “If more than 2 vaccines are injected in a single limb, the injections should be sufficiently separated (separate anatomic sites [i.e. ≥1 inch] if possible) so that any local reactions can be differentiated” (ACIP)*

*6 months and older: flu vaccine (if indicated) in left deltoid (IM)*

---

Tdap—Tetanus and Diphtheria Toxoids and Acellular Pertussis Vaccine
MenACWY—Meningococcal (ACWY) Vaccine
IM—Intramuscular
Note: “If more than 2 vaccines are injected in a single limb, the injections should be sufficiently separated (separate anatomic sites [i.e. ≥1 inch] if possible) so that any local reactions can be differentiated” (ACIP)

*6 months and older: flu vaccine (if indicated) in left deltoid (IM)
Rx for Safe Injections in Healthcare

1 Needle
1 Syringe
+ 1 Time

O Infections

Safe injection practices prevent transmission of infectious diseases. Patients and healthcare providers must insist on nothing less than One Needle, One Syringe, Only One Time for each and every injection.

For more information, please visit:
www.cdc.gov/injectionsafety/1anonly.html
Injection Safety Guidelines from CDC

- Follow proper infection control practices and maintain aseptic technique during the preparation and administration of injected medications (e.g., perform hand hygiene).
- Never administer medications from the same syringe to more than one patient, even if the needle is changed.
- Never enter a vial with a used syringe or needle.
- Do not use medications packaged as single-dose or single-use for more than one patient.
- Do not use bags of intravenous solution as a common source of supply for more than one patient.
- Limit the use of multi-dose vials and dedicate them to a single patient whenever possible.
- Always use facemasks when injecting material or inserting a catheter into the epidural or subdural space.

2020 Updates to Pediatric and Adult Standing Orders
DHA-IHD Updates to Pediatric Standing Orders

All standing orders (pediatric and adult) are no longer brand specific and needle length and injection site information has been added to each order. Also, latex-specific information has been added. In addition, the following updates have been made:

<table>
<thead>
<tr>
<th>VACCINE</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
</table>
| DTaP    | • Age 6 weeks - 6 years  
         | • Catch-up schedule for those who didn’t receive DTaP at recommended ages not covered in this standing order | • Age 2 months – 6 years to reflect routine use  
         | • Contraindications more detailed to include neomycin, polymycin B, streptomycin and yeast  
         | • Latex info included for each brand  
         | • Included routine and catch-up schedule for all licensed DTaP vaccines | |
| HepA    | • Age - 12-23 months & 2 years older  
         | • Age 2 years or older who live in communities, regions, or states where routine vaccination is recommended  
         | • Children aged 6-11 months with international travel off-label and is not covered under these standing orders | • Age updated to 1-18 years who has not completed a complete series and those with:  
         | • Anticipated travel  
         | • Pregnant  
         | • Altered immunosuppression  
         | • Occupational exposure  
         | • Incarceration or homelessness  
         | • In settings such as group homes, nonresidential day care for developmentally disabled  
         | • Deleted diagnosis of a clotting-factor disorder, such as hemophilia  
         | • Added 6-11 months of age pending international travel  
         | • Latex info added  
         | • Dosing schedule for brands HAVRIX and VAQTA added | |
| HepB    | • Latex info added  
         | • Dosing schedule for all HepB vaccine brands (COMVAX no longer available) | |
| Hib     | • Age covered 2-71 months | • Age more specific and updated to 2-59 months and 2 – 17 years  
         | | • Added 2-59 months (who didn’t complete series) and are immunoglobulin deficient, complement deficiency, receiving chemotherapy or radiation therapy  
         | | • Added 2-17 years who are HIV+, anatomic or functional asplenia, undergoing splenectomy, or recipient of a hematopoietic stem cell transplant |
### HPV
- **Dosing schedule**
  - 2 dose series - 2nd dose given minimum of 5 months after 1st – if given too soon give a 3rd dose at least 4 months after 2nd dose
  - 3 dose series (0, 2, and 6 months) with minimal interval of 4 weeks between 1st and 2nd dose, 12 weeks between the 2nd and 3rd dose and at least 24 weeks between 1st and 3rd dose

### Polio
- New for 2020

### JEV
- Booster dose recommended for persons 14 months and older if more than 11 months have passed since completing the primary series and risk of exposure to the JE virus continues
- Deleted the following precautions
  - Immunocompromised children
  - Breastfeeding women

- Booster is updated for ages 2 months to 17 years

### MMR
- Procedure is more detailed to include
  - Age 4 years or older with no documentation; 6 months and older with international travel, 12 months or older with 1 dose given younger than 12 months; and history of 2 doses but identified as increased risk to mumps outbreak

- Added TB skin test precautions

### MMRV
- Added TB skin test precautions

### Meningococcal ACWY
- Indicated for ages
  - 11-17 years unvaccinated
  - 17 years unvaccinated and 1st year college student living in a residence hall
  - 2 months through 17 years with a diagnosis of persistent complement component deficiency (an immune system disorder)

- Age updated to 2 months – 18 years and not completed 2 dose series and risk based vaccination is indicated for those
  - Have not completed the recommended series by 2 yrs of age
  - Anticipated travel to country where meningococcal disease is hyperendemic
<table>
<thead>
<tr>
<th>Condition</th>
<th>Actions/Notes</th>
</tr>
</thead>
</table>
| or diagnosis of anatomic or functional asplenia (including sickle-cell disease) | • Exposure to meningitis as an outbreak  
• Routine and catch-up schedule has been updated to 2 doses for 11-18 years  
• Dosing schedule for high risk groups age 24 months and older have been added and updated  
• High-risk updated to include those with complement deficiency (an immune system disorder) or diagnosis of anatomic or functional asplenia (including sickle-cell disease) |
| • age 2 months through 17 years who are part of an outbreak attributable to a vaccine serogroup | • Routine and catch-up schedule for ages 11-17 indicates 1 dose  
• Dosing schedule does not cover dose #2 in high-risk groups age 24 months and older |
| • age 2 months through 17 years with anticipated travel to a country where meningococcal disease is hyperendemic or epidemic |  |
| • MenB                                                                 | • Indicated for ages updated to:  
  • 10-18 years with certain high-risk conditions  
  • Added healthy 16-18 yr olds not at increased risk but want protection  
  • Ravulizumab (Ultomiris) added as high-risk condition under indications  
  • Updated and added serious reaction to kanamycin as a contraindication  
  • Latex info added for Bexsero® and Trumenba®  
  • Added dosing for Trumenba  
  • Added new ACIP recommendations  
  • ≥10 years with complement deficiency or inhibitor use, asplenia, or microbiologists receive a booster 1 yr following the completion of MenB primary series followed by booster every 2-3 years if risk remains  
  • Added ≥10 yrs who are at risk during outbreak – administer 1 time booster if it has been ≥1 yr since completing MenB primary series |
<p>| • PCV13                                                                  | • Deleted indication/procedure to administer to persons with diabetes mellitus |</p>
<table>
<thead>
<tr>
<th>Vaccination</th>
<th>Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PPSV23</strong></td>
<td>New for 2020</td>
</tr>
<tr>
<td><strong>Rotarix</strong></td>
<td>- Indication to administer ROTARIX® after 24 weeks of age not covered under SO</td>
</tr>
<tr>
<td></td>
<td>- Indication updated to cover ages 24 weeks to 8 months who have not completed series</td>
</tr>
<tr>
<td></td>
<td>- Added latex info ROTARIX® and RotaTeq®</td>
</tr>
<tr>
<td></td>
<td>- Added more detailed dosing schedule for ROTARIX® and included RotaTeq® dosing schedule</td>
</tr>
<tr>
<td><strong>Td/Tdap</strong></td>
<td>- Indications for dosing updated to</td>
</tr>
<tr>
<td></td>
<td>- Can begin as early as age 7</td>
</tr>
<tr>
<td></td>
<td>- Added pregnant females between 27-36 weeks</td>
</tr>
<tr>
<td></td>
<td>- Added latex info for Adacel® and Boostrix®</td>
</tr>
<tr>
<td></td>
<td>- Dosing schedule updated and added</td>
</tr>
<tr>
<td></td>
<td>- Td/Tdap can be used for boosters every 10 years</td>
</tr>
<tr>
<td></td>
<td>- Pregnant patients – 1 dose for each pregnancy during 27-36 weeks gestation</td>
</tr>
<tr>
<td></td>
<td>- Dosing schedule updated provided for DTaP, DT, Td, or Tdap for ages 7-18 yrs</td>
</tr>
<tr>
<td><strong>Typhoid</strong></td>
<td>- Added contraindication of immunocompromised for oral typhoid</td>
</tr>
<tr>
<td></td>
<td>- Added precaution – oral typhoid should not be given within 3 days of antimicrobial agent</td>
</tr>
<tr>
<td></td>
<td>- Added dosing schedule for oral typhoid</td>
</tr>
<tr>
<td><strong>Varicella</strong></td>
<td>- Added precautions - TB skin test and aspirin or aspirin containing products</td>
</tr>
<tr>
<td><strong>Yellow Fever</strong></td>
<td>New for 2020</td>
</tr>
</tbody>
</table>
DHA-IHD Updates to Adult Standing Orders

All standing orders (pediatric and adult) are no longer brand specific and needle length and injection site information has been added to each order. Also, latex-specific information has been added. In addition, the following updates have been made:

<table>
<thead>
<tr>
<th>VACCINE</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthrax</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Breastfeeding added to precautions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Added latex info for BioThrax®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Guillain-Barré Syndrome (GBS) deleted from precautions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Added Anthrax vaccine pregnancy registry info/contact</td>
</tr>
<tr>
<td>HepA</td>
<td>Procedure/indication included</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• age 18 years or older who live in communities, regions, or states where routine vaccination is recommended</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• diagnosis of a clotting-factor disorder, such as hemophilia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Procedure/indication updated to:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Age updated to ≥19 years who has not completed series and persons age &gt; 40 at increased risk</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pregnant and those with</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Altered immunosuppression</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Occupational exposure</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Incarceration or homelessness</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• In settings such as group homes, nonresidential day care for developmentally disabled</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Deleted diagnosis of a clotting-factor disorder, such as hemophilia as indication</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Latex info added for HAVRIX® and VAQTA®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Added dosing schedule for VAQTA®</td>
</tr>
<tr>
<td>HepB</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Procedure/Indications updated and added more details and travel to country with high endemicity of HBV, HIV infection, chronic liver disease, diabetes, use of injectable street drugs, person with exposure to STDs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Added dosing schedule for Recombivax HB® and Heplisav-B</td>
</tr>
<tr>
<td>Twinrix</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Procedure/indications added – end stage renal disease, hemodialysis, HIV infection, diabetes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Latex info added for TWINRIX®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Updated dosing schedule and added info for the interchangeability of TWINRIX® and single antigen HepA and B vaccines</td>
</tr>
<tr>
<td>Hib</td>
<td>New SO for 2020</td>
<td></td>
</tr>
<tr>
<td>HPV</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dosing schedule</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Provide 9vHPV vaccine in a 3-dose schedule at 0, 2, and 6 calendar months for all males and females aged</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Dosing schedule updated to:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Age 15-26 initial vaccination and 9-26 with impaired immunity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Updated to - 3 dose series at 0, 2, and 6 months (minimum interval of 4 weeks between dose 1 and 2, 12 weeks between 2-3 dose, and</td>
</tr>
<tr>
<td>Vaccine</td>
<td>Procedure/Indication</td>
<td>Procedure/Indication updated to:</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Polio</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>JEV</td>
<td></td>
<td>Deleted breastfeeding and immunocompromised from precautions</td>
</tr>
</tbody>
</table>
| MeaslesMumpsRubella | ▪ Procedure/indication  
▪ Identify patients 18 years of age and older in need of vaccination against measles, mumps, and rubella | ▪ Procedure/Indication updated with clearer definition of who needs 2 doses  
▪ Lack of documentation of 2 doses, positive titer or born before 1957 (excludes HC workers) and those who have history of 2 doses but are at increased risk during mumps outbreak  
▪ Added possible interference of TB skin test to precautions |
| Meningococcal ACWY | ▪ Procedure/indication  
▪ age 18 years and anticipated first-year college student living in a residence hall and unvaccinated  
▪ Dosing schedule  
▪ 2 dose for high risk patients 24 months and older and routine booster for teens ages 16-18 who did not receive initial Menveo dose at age 11-12, and a 2nd dose for those ages 18-55 is not covered in this SO | ▪ Procedure/indication updated to:  
▪ age 19-21 years and anticipated first-year college student living in a residence hall and last vaccinated before age 16 years of age  
▪ Added HIV infection  
▪ Dosing schedule updated to  
▪ Added booster every 5 years for travelers or residents of endemic area, during outbreak, or occupational exposure  
▪ Added 2 dose and booster every 5 years for immunocompromised, asplenia including sickle cell  
▪ Added that standard of care/ACIP recommends MenACWY for 56 and older at increased risk even though package insert indicates through age 55 |
<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Procedure/indication</th>
<th>Additional Information</th>
</tr>
</thead>
</table>
| MenB     | Procedure/indication added persons 18-23 years of age who are not at increased risk who want protection against MenB  
Added dosing schedule for Trumemb® | |
| PCV13/PPSV 23 | Procedure/indication updated to include:  
organ or bone marrow transplant for procedure for PPSV23 (for 19-64 yr olds)  
Updated dosing for 65 and older and PCV13 to 1 time dose based on shared clinical decision  
Updated dosing charts for PCV13 and PPSV23 based on age, risk factors, and shared clinical decisions for ages 19-64 and 65 and older | |
| Rabies   | N/A                   | |
| Td/Tdap  | Procedure/indication updated and include:  
pregnant women who have not received Tdap during current pregnancy  
Dosing updated to  
Booster dose every 10 years of either Td or Tdap  
Pregnant women should receive one dose of Tdap at each pregnancy during 27-36 weeks gestation | |
| Typhoid  | Precaution updated and added - oral typhoid vaccine should not be given within 3 days (before or after) of an antimicrobial agent  
Dosing schedule includes both Typhim Vi® and Vivotif® | |
| Varicella | Updated precaution and added  
TB skin testing  
use of aspirin or aspirin containing products | |
| Yellow Fever | Deleted precaution - individuals with a history of allergic reactions to eggs, chickens, and gelatin  
Added precaution - asymptomatic HIV infection with CD4 T lymphocyte values 200-499 mm³  
Added note (recommendation) to separate MMR and YF vaccines at least 30 days apart | |
| Zoster   | Added precaution that an acute episode of herpes zoster - RZV is not a treatment for herpes zoster or post-herpetic neuralgia | |
Pediatric Standing Orders

Diphtheria Tetanus and Pertussis Vaccine
Hepatitis A Vaccine
Hepatitis B Vaccine
*Haemophilus influenzae* type b Vaccine
Human Papillomavirus Vaccine
Inactivated Polio Vaccine
Japanese Encephalitis Vaccine
Meningococcal ACWY Vaccine
Meningococcal Group B Vaccine
Measles Mumps Rubella Vaccine
Measles Mumps Rubella Varicella Vaccine
Pneumococcal Conjugate (PCV13) Vaccine
Pneumococcal Polysaccharide (PPSV23) Vaccine
Rotavirus Vaccine
Tetanus Diphtheria and Pertussis Vaccine
Typhoid Vaccine
Varicella (Chickenpox) Vaccine
Yellow Fever Vaccine
Purpose: To reduce morbidity and mortality from tetanus, diphtheria and pertussis disease by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

Policy: Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

Procedure
1. Identify patients 2 months to 6 years of age in need of vaccination against tetanus, diphtheria, and pertussis based on the following criteria:
   - Lack of documentation of completion of a 5-dose series of diphtheria, tetanus and pertussis-containing vaccine (DTaP)

2. Screen all patients for contraindications and precautions to DTaP:
   **Contraindications:**
   - History of a serious reaction (e.g., anaphylaxis) after a previous dose of a vaccine containing tetanus or diphtheria toxoid or to a vaccine component (to include neomycin, polymyxin B, streptomycin, or yeast)
   - For information on vaccine components, refer to the manufacturer's package insert or go to [https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf](https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf)
   - History of encephalopathy (e.g. coma, decreased level of consciousness, prolonged seizures) within 7 days following a pertussis-containing vaccine not attributable to another identifiable cause

   **Precautions:**
   - History of Guillain-Barré syndrome within 6 weeks of a previous dose of tetanus toxoid-containing vaccine
   - History of an Arthus-type hypersensitivity reaction after a previous dose of tetanus or diphtheria toxoid-containing vaccine: defer vaccination until at least 10 years have elapsed since the last tetanus toxoid-containing vaccine
   - Moderate or severe acute illness with or without fever
   - Progressive or unstable neurologic disorder, uncontrolled seizures or progressive encephalopathy: defer vaccination until a treatment regimen has been established and the condition has stabilized
   - The tip caps of the prefilled syringes of Infanrix®, Kinrix®, and Pediarix® contain natural rubber latex and may cause allergic reactions in latex sensitive individuals. The vials of Infanrix®, Kinrix®, and Pediarix® do not contain latex. Daptacel® does not contain latex
   - Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
   - For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245
3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at [www.immunize.org/vis](http://www.immunize.org/vis).

4. Provide vaccine as follows:
   - Follow dosing schedule as below. DTaP consists of a 3-dose primary series (2, 4, and 6 months of age) and 2 boosters (15-18 months and 4-6 years of age). DTaP may be given as a stand-alone vaccine, or as part of a combination vaccine (a type of vaccine that combines more than one vaccine together into one shot).
   - Administer 0.5mL intramuscularly in the preferred site (anterolateral thigh for infants and toddlers or in the deltoid for children and adolescents). The alternate site (anterolateral thigh muscle or deltoid muscle) may be used if the preferred site is inadequate. Choose needle gauge and length appropriate to administration route and the patient’s age and/or body mass according to the IM injection table below.

### Schedule for routine vaccination

| Currently Licensed Vaccines containing Diphtheria, Tetanus, & Acellular Pertussis (DTaP) |
|-----------------------------------------------|-------------------|-----------------|-------|------|------|------|------|
| Vaccine type               | Trade name     | Manufacturer                  | 2 mos | 4 mos | 6 mos | 15–18 mos | 4–6 yrs |
| DTaP vaccines             |                |                               |       |       |       |       |       |
| DTaP                      | Infanrix/ Daptacel | GlaxoSmithKline/ Sanofi Pasteur | X     | X     | X     | X     | X     |
| Combination vaccines with DTaP |                  |                               |       |       |       |       |       |
| DTaP-IPV-HepB (3 dose series) | Pediarix (6 wks – 6 yrs) | GlaxoSmithKline | X     | X     | X     |       |       |
| DTaP-IPV-Hib (4 dose series) | Pentacel (6 wks – 4 yrs) | Sanofi Pasteur | X     | X     | X     | X     |       |
| DTaP-IPV-Hib-HepB (3 dose series) | Vaxelis (6 wks – 4 yrs) | Sanofi Pasteur | X     | X     | X     |       |       |
| DTaP-IPV                   | Kinrix/ Quadracel | GlaxoSmithKline/ Sanofi Pasteur |       |       |       | X     |       |
| DT vaccine                | No trade name  | Sanofi Pasteur               | X     | X     | X     | X     | X     |
Needle Length and Injection Site of IM Injections for Children

Use a 22 – 25 gauge needle. Choose needle gauge and length appropriate to administration route and the patient’s age and body mass.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants (1-12 months)</td>
<td>1 inch</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>Toddlers (1-2 years)</td>
<td>1 - 1.25 inch</td>
<td>Anterolateral thigh*</td>
</tr>
<tr>
<td></td>
<td>5/8† - 1 inch</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Children (3-10 years)</td>
<td>5/8† - 1 inch</td>
<td>Deltoid muscle of arm*</td>
</tr>
<tr>
<td></td>
<td>1 - 1.25 inch</td>
<td>Anterolateral thigh</td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration
https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html.
†If skin is stretched tightly and subcutaneous tissues are not bunched
*Preferred site

5. For persons who did not receive DTaP at the ages/intervals specified in #4, provide catch-up doses according to the following:

<table>
<thead>
<tr>
<th>Dose</th>
<th>Recommended age</th>
<th>Minimum age</th>
<th>Recommended interval to next dose</th>
<th>Minimum interval to next dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>DTaP #1</td>
<td>2 months</td>
<td>6 weeks</td>
<td>8 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td>DTaP #2</td>
<td>4 months</td>
<td>10 weeks</td>
<td>8 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td>DTaP #3</td>
<td>6 months</td>
<td>14 weeks</td>
<td>6-12 months†</td>
<td>6 months†</td>
</tr>
<tr>
<td>DTaP #4</td>
<td>15-18 months</td>
<td>15 months</td>
<td>3 years</td>
<td>6 months</td>
</tr>
<tr>
<td>DTaP #5*</td>
<td>4-6 years</td>
<td>4 years</td>
<td>*Dose #5 is not necessary if dose 4 was administered at age ≥4 years and at least 6 months after dose #3</td>
<td></td>
</tr>
</tbody>
</table>

†If a child age ≥12 months received dose #4 with an interval of less than 6 months but more than 4 months, the dose does not need to be repeated.

6. Document all immunizations administered in the patient’s electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

7. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

8. Adverse Events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

9. This policy and procedure shall remain in effect for all patients of the __________________________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

Medical Director’s Signature __________________ Date ___________
Standing Orders for Administering Hepatitis A Vaccine (Pediatric)

**Purpose:** To reduce morbidity and mortality from Hepatitis A virus infection by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other healthcare professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure:**
1. Identify all persons 1 to 18 years of age* in need of vaccination against hepatitis A virus (HAV) based on the following criteria:
   - Has not completed a hepatitis A vaccine (HepA) series
   - Anticipated international travel; see CDC Traveler’s Health for updates
   - Pregnant and non-pregnant persons identified to be at risk for an infection or severe outcome from HAV:
     - altered immunocompetence (e.g., congenital, drug-induced, or acquired, such as HIV)
     - use of injection or non-injection illegal drugs
     - occupational risk (i.e., in a HAV research lab or with primates)
     - close contact with an international adoptee during the first 60 days after the arrival of the adoptee in the United States
     - males who have sex with other males (MSM)
     - incarceration or homelessness
     - chronic liver disease (e.g., hepatitis B or C, cirrhosis, fatty or alcoholic liver disease, autoimmune hepatitis, or ALT/AST levels persistently greater than twice the upper limit of normal)
   - In settings providing services for at-risk persons as defined above, such as group homes and nonresidential day care facilities for developmentally disabled persons
   - At-risk persons (as defined above) during a hepatitis A outbreak
   - Unvaccinated persons possibly exposed to HAV within the last two weeks. Persons younger than 12 months of age should be given immune globulin (IG 0.1mL/kg) instead of vaccine
   - Any other child, adolescent or teen who wants to be protected from HAV
   - *Persons 6-11 months of age pending international travel

*Note: persons aged 6-11 months may receive HepA for international travel (children younger than 6 months of age should be given intramuscular IG instead of vaccine). Though an off-label use of the vaccine, this is consistent with best practices and current DoD and ACIP guidelines.

2. Screen all patients for contraindications and precautions to HepA:
   **Contraindications:**
   - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of HepA or to a vaccine component (to include neomycin)
   - For information on vaccine components, refer to the [manufacturer’s package insert](#) or go to

*Reviewed by DHA-IHD July 2020*
Precautions:

- Moderate or severe acute illness with or without fever
- The tip caps of the prefilled syringes of HAVRIX® and VAQTA®, and the vials of VAQTA®, contain natural rubber latex and may cause allergic reactions in latex sensitive individuals. The vials of HAVRIX® do not contain latex.
- Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
- For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccine as follows:
HepA consists of a 2-dose series (HAVRIX®: 0, 6-12 months; VAQTA®: 0, 6-18 months) recommended between 12-23 months of age. Administer 0.5mL of HepA intramuscularly in the preferred site (anterolateral thigh for infants and toddlers or in the deltoid for children and adolescents). The alternate site (anterolateral thigh muscle or deltoid muscle) may be used if the preferred site is inadequate.

Note: Persons 12 months – 18 years of age receive a 0.5mL dose; persons 19 years of age and older receive a 1mL dose. Please see the appropriate standing order for administration of HepA to adults for details

### Needle Length and Injection Site of IM Injections for Children

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants (1-12 months)</td>
<td>1 inch</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>Toddlers (1-2 years)</td>
<td>1-1.25 inch</td>
<td>Anterolateral thigh*</td>
</tr>
<tr>
<td></td>
<td>5/8† – 1 inch</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Children (3-10 years)</td>
<td>5/8† inch- 1 inch</td>
<td>Deltoid muscle of arm*</td>
</tr>
<tr>
<td></td>
<td>1-1.25 inches</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>Children (11-18 years)</td>
<td>5/8† – 1 inch</td>
<td>Deltoid muscle of arm*</td>
</tr>
<tr>
<td></td>
<td>1-1.5 inches</td>
<td>Anterolateral thigh</td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration
https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html.

†If skin is stretched tightly and subcutaneous tissues are not bunched
*Preferred site
5. Document all immunizations administered in the patient’s electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

7. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

8. This policy and procedure shall remain in effect for all patients of the ____________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

_________________________________________  ______________________________
Medical Director’s Signature                Date
Standing Orders for Administering Hepatitis B Vaccine (Pediatric)

**Purpose:** To reduce morbidity and mortality from hepatitis B virus infection by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure:**
1. Identify persons birth - 19 years of age in need of vaccination against hepatitis B based on the following criteria:
   - Have not received at least 3 doses of hepatitis B vaccine (HepB) at the appropriate ages/intervals

2. Screen all patients for contraindications and precautions to HepB:
   - **Contraindications:**
     - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of HepB or to a vaccine component (to include yeast)
   - **Precautions:**
     - Moderate or severe acute illness with or without fever
     - The tip caps of the prefilled syringes of Engerix-B® and Recombivax HB®, and the vials of Recombivax HB®, contain natural rubber latex and may cause allergic reactions in latex sensitive individuals. The vials of Engerix-B® do not contain latex
     - Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
     - For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at [www.immunize.org/vis](http://www.immunize.org/vis).
4. Provide vaccine as follows:
HepB (Engerix-B®, Recombivax HB®) consists of a 3-dose series at 0, 1-2 and 6-18 months of age. Administer 0.5mL intramuscularly in the preferred site (anterolateral thigh for infants and toddlers or in the deltoid for children and adolescents). The alternate site (anterolateral thigh muscle or deltoid muscle) may be used if the preferred site is inadequate. Choose needle gauge and length appropriate to administration route and the patient’s age and/or body mass according to the chart below

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neonates (0-28 days)</td>
<td>5/8† inch</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>Infants (1-12 months)</td>
<td>1 inch</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>Toddlers (1-2 years)</td>
<td>1-1.25 inch</td>
<td>Anterolateral thigh*</td>
</tr>
<tr>
<td></td>
<td>5/8† – 1 inch</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Children (3-10 years)</td>
<td>5/8† inch- 1 inch</td>
<td>Deltoid muscle of arm*</td>
</tr>
<tr>
<td></td>
<td>1-1.25 inches</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>Children (11-18 years)</td>
<td>5/8† – 1 inch</td>
<td>Deltoid muscle of arm*</td>
</tr>
<tr>
<td></td>
<td>1-1.5 inches</td>
<td>Anterolateral thigh</td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html.
†If skin is stretched tightly and subcutaneous tissues are not bunched
*Preferred site

Note: persons birth – 19 years of age receive a 0.5mL dose; persons 20 years of age and older receive a 1mL dose. Please see the appropriate standing order for administration of HepB to adults for information

Heplisav-B®-2-dose series at 0 and 1 month may be administered to teens ages 18 years and older.

5. Provide subsequent doses of HepB to complete each patient’s 3-dose schedule by observing a minimum interval of 4 weeks between the 1st and 2nd doses; 8 weeks between the 2nd and 3rd doses; and at least 16 weeks between the 1st and 3rd doses. The last dose in the pediatric series should not be administered earlier than 24 weeks of age. Patients will receive a total of 4 doses of hepatitis B-containing vaccine when combination vaccines (e.g., Pediarix®) are given after the birth dose of HepB which is still consistent with best practices.

Note: revaccination may be recommended for certain populations, including:
- Infants born to HBsAg-positive mothers
- Hemodialysis patients
- Other immunocompromised persons

Patients must obtain a written order from a privileged provider for these situations.
6. Document all immunizations administered in the patient’s electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

7. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

8. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

9. This policy and procedure shall remain in effect for all patients of the ___________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

________________________________________________________________________
Medical Director’s Signature                      Date
Standing Orders for Administering *Haemophilus influenzae* type b Vaccine (Pediatric)

**Purpose:** To reduce morbidity and mortality from *Haemophilus influenzae* type b disease by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure:**
1. Identify persons 2 months to 17 years of age in need of vaccination against *Haemophilus influenzae* type b based on the following criteria:
   - Age 2 - 59 months without prior Hib vaccination (or who did not complete the series), immunoglobulin deficiency, early component complement deficiency, or are receiving chemotherapy or radiation therapy
   - Age 2 months through 17 years with human immunodeficiency virus (HIV) infection, anatomic or functional asplenia (including sickle cell disease), undergoing elective splenectomy, or a recipient of a hematopoietic stem cell transplant

2. Screen all patients for contraindications and precautions to Hib:
   **Contraindications:**
   - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of Hib or to one of its components.

   **Precautions:**
   - Moderate or severe acute illness with or without fever
   - The vial stoppers for PedvaxHIB® and the DTaP-IPV and ActHIB vaccine components of Pentacel® contain natural rubber latex and may cause allergic reactions in latex sensitive individuals
   - Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
   - For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at [www.immunize.org/vis](http://www.immunize.org/vis).

4. Provide vaccine as follows:
   Routine Hib vaccination consists of a 3-dose (PedvaxHIB® at 2, 4 and 12-15 months
of age) or 4-dose series (ActHIB®, Hiberix®, Pentacel® at 2, 4, 6, and 12-15 months of age). Administer 0.5ml intramuscularly in the preferred site (anterolateral thigh for infants and toddlers or in the deltoid for children and adolescents). The alternate site (anterolateral thigh muscle or deltoid muscle) may be used if the preferred site is inadequate. Choose needle gauge and length appropriate to administration route and the patient’s age and/or body mass according to the chart below.

### Needle Length and Injection Site of IM Injections for Children

Use a 22 – 25 gauge needle. Choose needle gauge and length appropriate to administration route and the patient’s age and body mass.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants (1-12 months)</td>
<td>1 inch</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>Toddlers (1-2 years)</td>
<td>1-1.25 inch</td>
<td>Anterolateral thigh*</td>
</tr>
<tr>
<td></td>
<td>5/8† – 1 inch</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Children (3-10 years)</td>
<td>5/8† inch- 1 inch</td>
<td>Deltoid muscle of arm*</td>
</tr>
<tr>
<td></td>
<td>1-1.25 inches</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>Children (11-18 years)</td>
<td>5/8† – 1 inch</td>
<td>Deltoid muscle of arm*</td>
</tr>
<tr>
<td></td>
<td>1-1.5 inches</td>
<td>Anterolateral thigh</td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration [https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html](https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html).

† If skin is stretched tightly and subcutaneous tissues are not bunched
*Preferred site

### Routine Dosing

<table>
<thead>
<tr>
<th>Dose number</th>
<th>Recommended age for this dose</th>
<th>Minimum age for this dose</th>
<th>Recommended interval to next dose</th>
<th>Minimum interval to next dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2 months</td>
<td>6 weeks</td>
<td>8 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td>2</td>
<td>4 months</td>
<td>10 weeks</td>
<td>8 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td>3†</td>
<td>6 months</td>
<td>14 weeks</td>
<td>6-9 months</td>
<td>8 weeks</td>
</tr>
<tr>
<td>4</td>
<td>12-15 months</td>
<td>12 months</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

† ActHIB®, Hiberix®, Pentacel® only for dose # 3 at age 6 months

5. For persons who did not receive Hib at the ages/intervals specified in #4, give one dose at the earliest opportunity and then schedule subsequent doses according to the following:

### Catch-up Dosing (Immunocompetent)

<table>
<thead>
<tr>
<th>Current Age</th>
<th># of Prior Doses¹</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 1 year</td>
<td>0 or unknown</td>
<td>Follow routine dosing schedule and intervals</td>
</tr>
<tr>
<td>12-14 months</td>
<td>0 or unknown</td>
<td>Give dose #1, followed by dose #2 (final) in ≥ 8 weeks</td>
</tr>
<tr>
<td>1 dose before 12 months of age</td>
<td></td>
<td>Give dose #2, followed by dose #3 (final) in ≥ 8 weeks</td>
</tr>
<tr>
<td>Age Range</td>
<td>First Dose Requirements</td>
<td>Second Dose Requirements</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>2 doses, #1 before 12 months of age</td>
<td>Give dose #3 (final) at least 8 weeks after dose #2</td>
<td></td>
</tr>
<tr>
<td>1 dose at ≥12 months of age</td>
<td>Give dose #2 (final) at least 8 weeks after dose #1</td>
<td></td>
</tr>
<tr>
<td>2 doses, #1 at ≥12 months of age</td>
<td>No additional doses needed</td>
<td></td>
</tr>
<tr>
<td>3 doses before 12 months of age</td>
<td>Give dose #4 (final) at least 8 weeks after dose #3 (ActHib, Hiberix, or Pentacel series only)</td>
<td></td>
</tr>
<tr>
<td>15 – 59 months</td>
<td>1 dose before 12 months of age</td>
<td>Give dose #2 (final)</td>
</tr>
<tr>
<td></td>
<td>1 dose at 12-14 months of age</td>
<td>Give dose #2 (final) at least 8 weeks after dose #1</td>
</tr>
<tr>
<td></td>
<td>1 dose at age ≥15 months</td>
<td>No additional doses needed</td>
</tr>
<tr>
<td></td>
<td>2 doses, #1 before 12 months of age and #2 before 15 months of age</td>
<td>Give dose #3 (final) at least 8 weeks after dose #2</td>
</tr>
<tr>
<td></td>
<td>2 doses, #1 before 12 months of age and #2 after 15 months of age</td>
<td>No additional doses needed</td>
</tr>
<tr>
<td></td>
<td>2 doses, #1 at ≥12 months of age</td>
<td>No additional doses needed</td>
</tr>
<tr>
<td></td>
<td>3 doses before 12 months of age</td>
<td>Give dose #4 (final) at least 8 weeks after dose #3 (ActHib, Hiberix, or Pentacel only)</td>
</tr>
<tr>
<td></td>
<td>0 or unknown by ≥ 15 months of age</td>
<td>Give dose #1 (final)</td>
</tr>
</tbody>
</table>

1. Previous doses must meet minimum age requirements and minimum intervals

### Catch-up Dosing (High-risk Conditions)

<table>
<thead>
<tr>
<th>Medical Indication</th>
<th>Age and vaccination history</th>
</tr>
</thead>
<tbody>
<tr>
<td>12–59 months</td>
<td>12–59 months with ≥2 doses before age 12 months</td>
</tr>
<tr>
<td>12–59 months with 0-1 dose before age 12 months</td>
<td></td>
</tr>
<tr>
<td>Functional or anatomic Asplenia; HIV infection</td>
<td>Give 2 doses, 8 weeks apart</td>
</tr>
<tr>
<td>Immunoglobulin or early component complement deficiency; chemotherapy or radiation therapy§</td>
<td>Give 2 doses, 8 weeks apart§</td>
</tr>
<tr>
<td>Hematopoietic stem cell transplant</td>
<td>Give 3 doses (at least 4 weeks apart) beginning 6–12 months after transplant, regardless of Hib vaccination history</td>
</tr>
<tr>
<td>Elective splenectomy</td>
<td>For unvaccinated children age 15 months or older, give 1 dose, preferably at least 14 days before procedure</td>
</tr>
</tbody>
</table>

†Persons who have not received a primary series and booster or at least 1 dose of Hib vaccine by ≥15 months of age are considered unvaccinated.

§Persons vaccinated within 14 days of starting immunosuppressive therapy should be revaccinated ≥3 months after completion of therapy.
Note: Previously unvaccinated children age 60 months or older who are not considered high risk do not require catch-up vaccination

6. Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

7. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

8. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

9. This policy and procedure shall remain in effect for all patients of the ______________________________ rescinded and/or upon a change in the Medical Director, whichever is earlier.

__________________________________________________________________________
Medical Director’s Signature                      Date
Purpose: To reduce morbidity and mortality from human papillomavirus (HPV) infection by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

Policy: Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

Procedure
1. Identify all persons ages 9-17 years who have not completed the HPV vaccination series.

Note: HPV vaccine is FDA-approved for individuals 9-45 years of age. Please see HPV adult standing orders if vaccinating an individual 18 years or older

2. Screen all patients for contraindications and precautions to HPV vaccine:

   Contraindications:
   - A history of a severe allergic reaction (e.g., anaphylaxis) after a previous dose of HPV vaccine or to one of its components (including yeast)
   - Pregnancy: delay vaccination until after completion of pregnancy
   - For information on vaccine components, refer to the manufacturers’ package insert or go to http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf

   Precautions:
   - Moderate or severe acute illness with or without fever
   - Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
   - For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.
4. Provide vaccine as follows:
Routine vaccination is recommended at 11-12 years of age, but can start at 9 years of age if appropriate (i.e., history of sexual abuse or assault, parent/guardian wishes, etc.). The HPV vaccine (GARDASIL 9®) consists of a 2- or 3-dose series depending on age at time of initial vaccination:

- **Age 9-14 years at initial vaccination:** a 2-dose series at 0 and 6-12 months (minimum interval 5 months; repeat dose if given too soon)
- **Age 15-26 years at initial vaccination (or ages 9-26 with impaired immunity):** a 3-dose series at 0, 2, and 6 months (observe a minimum interval of 4 weeks between the 1st and 2nd doses, 12 weeks between the 2nd and 3rd doses, and at least 5 months between the 1st and 3rd dose; repeat dose if administered too soon)
- Administer 0.5mL of HPV vaccine intramuscularly in the deltoid for adolescents and adults

<table>
<thead>
<tr>
<th>Needle Length and Injection Site of IM Injections for Children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use a 22 – 25 gauge needle. Choose needle gauge and length appropriate to administration route and the patient’s age and body mass.</td>
</tr>
<tr>
<td>Age Group</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Children (3-10 years)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Children (11-18 years)</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html.
†If skin is stretched tightly and subcutaneous tissues are not bunched
*Preferred site

5. For persons 9-17 years of age who did not complete the HPV vaccine series as specified in #4:
- Administer one dose at the earliest opportunity and then schedule subsequent doses to complete the age-appropriate schedule
- Minimum intervals are specified in #4

**Note:** these minimum intervals are per ACIP recommendations and represent the current standard of care. These minimum intervals may not be reflected on the package insert of the HPV vaccine.

6. Document all immunizations administered in the patient’s electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

7. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.
8. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

9. This policy and procedure shall remain in effect for all patients of the ______________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

_________________________________________  ______________________________
Medical Director’s Signature                  Date
Standing Orders for Administering Inactivated Polio Vaccine (Pediatric)

Purpose: To reduce morbidity and mortality from poliomyelitis by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

Policy: Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

Procedure:
1. Identify persons 2 months – 17 years of age who have not completed an inactivated poliomyelitis vaccine (IPV) series.
2. Screen all patients for contraindications and precautions to polio vaccine: Contraindications:
   - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of polio vaccine or to a vaccine component (to include neomycin, streptomycin, or polymyxin B)
   - For information on vaccine components, refer to the manufacturer’s package insert or go to http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf
3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.
4. Provide vaccine as follows:
   - The monovalent polio vaccine (IPOL®) consists of a four dose series given at 2, 4, 6-18 months, and 4-6 years of age. If a catch-up schedule is required after 6 months of age, the minimum interval between dose 1 and dose 2 is 4 weeks; the minimum interval between dose 2 and dose 3 is 4 weeks; a minimum interval of 6 months should precede the final dose given after age 4 years

Note: In the first 6 months of life, minimum ages and intervals should only be used for travel to a polio-endemic region or during an outbreak. Such use is not covered under this standing order; patients must obtain an order from a privileged provider for this situation
If a child received 4 or more doses before the 4th birthday, an additional dose is still necessary after the 4th birthday and at least 6 months after the previous dose. If a child or teen received a 3rd dose at age 4 years or older, a 4th dose is not necessary as long as there is a 6-month interval between doses 2 and 3.

See table below for use of polio-containing combination vaccines. Administer 0.5mL of polio vaccine intramuscularly in the preferred site (anterolateral thigh for infants and toddlers or in the deltoid for children and adolescents). The alternate site (anterolateral thigh muscle or deltoid muscle) may be used if the preferred site is inadequate. Choose needle gauge and length appropriate to administration route and the patient’s age and/or body mass according to the chart below.

### Needle Length and Injection Site of IM Injections for Children

Use a 22 – 25 gauge needle. Choose needle gauge and length appropriate to administration route and the patient’s age and body mass.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants (1-12 months)</td>
<td>1 inch</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>Toddlers (1-2 years)</td>
<td>1-1.25 inch</td>
<td>Anterolateral thigh*</td>
</tr>
<tr>
<td></td>
<td>5/8† – 1 inch</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Children (3-10 years)</td>
<td>5/8† inch- 1 inch</td>
<td>Deltoid muscle of arm*</td>
</tr>
<tr>
<td></td>
<td>1-1.25 inches</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>Children (11-18 years)</td>
<td>5/8† – 1 inch</td>
<td>Deltoid muscle of arm*</td>
</tr>
<tr>
<td></td>
<td>1-1.5 inches</td>
<td>Anterolateral thigh</td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration [https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html](https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html).

†If skin is stretched tightly and subcutaneous tissues are not bunched

*Preferred site

<p>| Currently Licensed Vaccines containing Inactivated Poliovirus Vaccine (IPV) |
|-----------------------------|-------------------------------|---------------------|-----------------|------------------|</p>
<table>
<thead>
<tr>
<th>Vaccine Composition</th>
<th>Trade Name</th>
<th>Manufacturer</th>
<th>Age for use</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPV</td>
<td>IPOL</td>
<td>Sanofi Pasteur</td>
<td>2, 4, 6-18 mo, 4-6 yrs</td>
<td>Use in infants, children, and adults</td>
</tr>
<tr>
<td>DTaP-IPV-Hib-HepB</td>
<td>Vaxelis</td>
<td>Sanofi Pasteur</td>
<td>2, 4, and 6 mos</td>
<td>Use for first 3 doses of IPV through age 4 yrs</td>
</tr>
<tr>
<td>DTaP-HepB-IPV</td>
<td>Pediariix</td>
<td>GlaxoSmithKline</td>
<td>2, 4, and 6 mos</td>
<td>Use for first 3 doses of IPV through age 6 yrs</td>
</tr>
<tr>
<td>DTaP-IPV/Hib</td>
<td>Pentacel</td>
<td>Sanofi Pasteur</td>
<td>2, 4, 6, and 15-18 mo</td>
<td>Use for 4 doses of IPV through age 4 yrs</td>
</tr>
<tr>
<td>DTaP-IPV</td>
<td>Kinrix/ Quadracel</td>
<td>GlaxoSmithKline/ Sanofi Pasteur</td>
<td>4-6 yrs</td>
<td>Use for booster dose at age 4-6 yrs</td>
</tr>
</tbody>
</table>

5. Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.
6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

7. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

8. This policy and procedure shall remain in effect for all patients of the _______________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

_________________________________________  __________________________
Medical Director's Signature                  Date
Standing Orders for Administering Japanese Encephalitis Vaccine (Pediatric)

**Purpose:** To reduce the morbidity and mortality from Japanese encephalitis (JE) by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure:**
1. Identify all persons 2 months to 17 years of age in need of vaccination against JE based on the following criteria:
   - Vaccination is required for Service members and beneficiaries as indicated per Combatant Command (CCMD) force health protection requirements
   - Travelers who plan to spend 1 month or longer in endemic areas (per CDC Yellow Book, TRAVAX, or other travel medicine guidelines) during JE transmission season (including long-term travelers and recurrent travelers based in urban areas but likely to visit endemic or rural or agricultural areas)
   - Short-term (<1 month) travelers to endemic areas during the JE transmission season if they plan to travel outside of an urban area and will have increased risk for JE exposure
   - Travelers to an area with ongoing JE outbreak
   - Travelers to endemic area who are uncertain of specific destinations, activities, or duration of travel

2. Screen all persons for contraindications and precautions to the JE vaccine (JE-VC):
   - **Contraindications:**
     - A history of a serious allergic reaction (e.g., anaphylaxis) after a previous dose of JE-VC or to a vaccine component (to include protamine sulfate.) Ask parents of diabetic children about allergic reactions to their insulin (which also may contain protamine sulfate)
     - For information on vaccine components, refer to the manufacturer's package insert or go to http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf
   - **Precautions:**
     - Pregnancy: vaccination is generally deferred during pregnancy, though pregnant women traveling to a high-risk area may receive JE-VC if benefit outweighs risk
     - Moderate or severe acute illness with or without fever
     - Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope

*Note: Although JE-VC vaccination during pregnancy may be warranted, this is an off-label use of the vaccine and is not covered under these standing orders. Patients must obtain a written order from a privileged provider for this situation*
For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

3. Provide all persons (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the person’s medical record, the publication date of the VIS and the date it was given to the person (or parent/legal representative). Provide non-English speaking persons with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis

4. Provide vaccine as follows:
Follow dosing schedule as below. JE-VC (IXIARO®) consists of a 2-dose primary series and a single booster for continued risk. The primary series should be completed ≥1 week before travel. Follow the steps outlined in the package insert to prepare the 0.25 mL pediatric dose. Administer intramuscularly in the preferred site (anterolateral thigh for infants and toddlers or in the deltoid for children and adolescents). The alternate site (anterolateral thigh muscle or deltoid muscle) may be used if the preferred site is inadequate.

<table>
<thead>
<tr>
<th>AGE</th>
<th>DOSE</th>
<th>ROUTE</th>
<th>SCHEDULE</th>
<th>BOOSTER'</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-35 mo</td>
<td>0.25 mL</td>
<td>IM</td>
<td>0, 28 days</td>
<td>≥1 y after primary series</td>
</tr>
<tr>
<td>3–17 y</td>
<td>0.5 mL</td>
<td>IM</td>
<td>0, 28 days</td>
<td>≥1 y after primary series</td>
</tr>
</tbody>
</table>

*If potential for JEV exposure continues

5. Document all immunizations administered in the patient’s electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.
6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as appropriate equipment and medications.

7. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

8. This policy and procedure shall remain in effect for all patients of the ____________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

__________________________________________  __________________________
Medical Director’s Signature                Date
Standing Orders for Administering Measles Mumps Rubella Vaccine (Pediatric)

Purpose: To reduce morbidity and mortality from measles, mumps, and rubella virus (MMR) infection by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

Policy: Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

Procedure:
1. Identify all pediatric patients in need of vaccination against measles, mumps, and rubella (MMR) based on the following criteria:
   - Age 12 months or older with no documentation of MMR vaccine
   - Age 4 years or older with no documentation of two doses of MMR vaccine
   - Age 6 months or older with pending international travel
   - Age 12 months or older with documentation of only 1 dose of MMR vaccine given when younger than age12 months
   - History of two previous doses of MMR and identified by public health as being at increased risk during a mumps outbreak

   Note: persons aged 6-11 months may receive MMR vaccine for international travel according to current ACIP recommendations. This is an off-label use of the vaccine but represents the current standard of care and is covered under this standing order. Any dose of MMR vaccine prior to 12 months of age does not count toward the routine childhood immunization series for MMR.

2. Screen all patients for contraindications and precautions to MMR vaccine:
   
   Contraindications:
   - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of MMR vaccine or to a vaccine component (to include gelatin and neomycin)
   - For information on vaccine components, refer to the manufacturer’s package insert or go to http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf
   - Pregnancy (or may become pregnant in the next 30 days)
   - Immunosuppression (e.g., cancer or malignant neoplasms, immunosuppressive therapy [to include prolonged high-dose steroid therapy], etc.)
   - HIV infection in children or teens who are severely immunosuppressed as determined by a CD4+ T-lymphocyte count of <200 cells per microliter (or less than 15%)
   - A family history of congenital or hereditary immunodeficiency in first-degree relatives unless immune competence of the potential vaccine recipient has been clinically verified by a laboratory
   - Patients with any concerns about possible immunosuppression (from medical conditions or medications) should be referred to a privileged provider before administration of any live-virus vaccine (such as MMR)

   Precautions:
   - Moderate or severe acute illness with or without fever
   - Recent (≤11 months) receipt of an antibody-containing blood product
   - History of thrombocytopenia or thrombocytopenic purpura
• To prevent potential interference between MMR vaccine and TB testing (skin testing or interferon-gamma release assay [IGRA] testing), possibly causing false-negative results, TB testing should be performed before, on the same day (preferred), or postponed for at least 4 weeks after MMR vaccination.

• Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope.

• For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245.

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccine as follows:
   • MMR vaccine (M-M-R II®) consists of a 2-dose series routinely given at 12-15 months and 4-6 years of age. Administer 0.5mL of MMR vaccine subcutaneously in the preferred site (fatty tissue over the anterolateral thigh muscle for infants and toddlers or the fatty tissue over the triceps for children and adolescents). The alternate site (fatty tissue over anterolateral thigh muscle or triceps) may be used if the preferred site is inadequate. Use a 23–25 gauge 5/8” needle.

5. For persons who did not receive MMR at the ages specified in #4:
   • Give one dose at the earliest opportunity
   • Schedule the second dose (if needed) a minimum of 28 days later

6. Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

7. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

8. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

9. This policy and procedure shall remain in effect for all patients of the _______________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

Medical Director’s Signature ____________________________ Date ____________

Reviewed by DHA-IHD June 2020
Standing Orders for Administering Measles Mumps Rubella Varicella Vaccine (Pediatric)

**Purpose:** To reduce morbidity and mortality from measles, mumps, rubella and varicella virus infection by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other healthcare professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure:**
1. Identify all pediatric patients in need of vaccination against measles, mumps, rubella, and varicella (MMRV) based on the following criteria:
   - Age 12 months to 12 years with exactly one prior dose of MMR vaccine and one prior dose of VAR vaccine

   **Note:** Unless the parent or caregiver expresses a preference for MMRV vaccine, due to an increased risk for fever and febrile seizures when MMRV is given as the 1st dose, ACIP recommends that separate MMR and VAR vaccines should be administered for the 1st dose in persons 12 – 47 months of age. Administering MMRV as the 1st dose is not covered under this standing order: patients must obtain a written order from a privileged provider for this situation.

2. Screen all patients for contraindications and precautions to MMRV vaccine:

   **Contraindications:**
   - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of MMRV vaccine or to a vaccine component (to include gelatin and neomycin)
   - For information on vaccine components, refer to the manufacturer’s package insert or go to [http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf](http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf)
   - Pregnancy (or may become pregnant in the next 30 days)
   - Immunosuppression (e.g., cancer or malignant neoplasms, immunosuppressive therapy to include prolonged high-dose steroid therapy, etc.)
   - HIV infection in children or teens who are severely immunosuppressed as determined by a CD4+ T-lymphocyte count of <200 cells per microliter (or less than 15%)
   - A family history of congenital or hereditary immunodeficiency in first-degree relatives unless immune competence of the potential vaccine recipient has been clinically verified by a laboratory
   - Patients with any concerns about possible immunosuppression (from medical conditions or medications) should be referred to a privileged provider before administration of any live-virus vaccine (such as MMRV)

   **Precautions:**
   - Moderate or severe acute illness with or without fever
   - Recent (≤11 months) receipt of an antibody-containing blood product
   - History of thrombocytopenia or thrombocytopenic purpura
   - A personal or family (i.e., sibling or parent) history of seizures of any etiology
   - To prevent potential interference between MMRV vaccine and TB testing (skin testing or interferon-gamma release assay [IGRA] testing), possibly causing false-negative results, TB testing should be performed before, on the same day
(preferred), or postponed for at least 4 weeks after MMRV vaccination

- Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
- For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccine as follows:
   The MMRV vaccine (ProQuad®) is routinely given at 4-6 years of age. Administer 0.5mL of MMRV vaccine subcutaneously in the preferred site (fatty tissue over the anterolateral thigh muscle for infants and toddlers or the fatty tissue over the triceps for children and adolescents). The alternate site (fatty tissue over anterolateral thigh muscle or triceps) may be used if the preferred site is inadequate. Use a 23–25 gauge 5/8” needle

5. For persons who did not receive MMRV at the ages specified in #4:
   - give one dose at the earliest opportunity
   - schedule the second dose (if needed), observing a minimum interval of 28 days after receipt of a measles-containing vaccine and 90 days after a varicella-containing vaccine

6. Document all immunizations administered in the patient’s electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

7. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

8. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

9. This policy and procedure shall remain in effect for all patients of the ___________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

________________________________________  __________________________
Medical Director’s Signature                  Date
Standing Orders for Administering Meningococcal ACWY Vaccine (Pediatric)

Purpose: To reduce morbidity and mortality from meningococcal disease caused by *Neisseria meningitides* serogroups A, C, Y, and W-135 by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

Policy: Under these standing orders, eligible nurses and other healthcare professionals working within their scope of practice may vaccinate patients who meet the criteria below.

Procedure:

1. Identify persons 2 months – 18 years of age in need of vaccination against meningococcal disease based on the following criteria:
   - Routine meningococcal (MenACWY) vaccination
     - Have not completed the 2-dose series by 18 years of age
   - Risk-based meningococcal (MenACWY) vaccination
     - Have not completed the recommended series (2-4 doses) by 2 years of age
     - Anticipated travel to a country where meningococcal disease is hyperendemic or epidemic (e.g., the “meningitis belt” of sub-Saharan Africa), particularly if contact with the local population will be prolonged
     - Exposure to meningitis as part of an outbreak

2. Screen all patients for contraindications and precautions to MenACWY:
   - **Contraindications:**
     - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of MenACWY or to a vaccine component (to include diphtheria or tetanus toxoid)
     - For information on vaccine components, refer to the manufacturer’s package insert or go to [http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf](http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf)
   - **Precautions:**
     - Pregnancy should not preclude vaccination with MenACWY, if indicated
     - Moderate or severe acute illness with or without fever
     - Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
     - For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at [www.immunize.org/vis](http://www.immunize.org/vis).
4. Provide vaccine as follows:
Follow dosing schedule in table below. Administer 0.5mL of MenACWY intramuscularly in the preferred site (anterolateral thigh for infants and toddlers or in the deltoid for children and adolescents). The alternate site (anterolateral thigh muscle or deltoid muscle) may be used if the preferred site is inadequate. Choose needle gauge and length appropriate to administration route and the patient’s age and/or body mass according to the chart below.

### Needle Length and Injection Site of IM Injections for Children

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants (1-12 months)</td>
<td>1 inch</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>Toddlers (1-2 years)</td>
<td>1-1.25 inch</td>
<td>Anterolateral thigh*</td>
</tr>
<tr>
<td></td>
<td>5/8† – 1 inch</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Children (3-10 years)</td>
<td>5/8† inch- 1 inch</td>
<td>Deltoid muscle of arm*</td>
</tr>
<tr>
<td></td>
<td>1-1.25 inches</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>Children (11-18 years)</td>
<td>5/8† – 1 inch</td>
<td>Deltoid muscle of arm*</td>
</tr>
<tr>
<td></td>
<td>1-1.5 inches</td>
<td>Anterolateral thigh</td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html.

†If skin is stretched tightly and subcutaneous tissues are not bunched
*Preferred site

### Age Routine or Catch-Up Schedule

<table>
<thead>
<tr>
<th>Age</th>
<th>Routine or Catch-Up Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;10 years</td>
<td>Received 1 dose of MenACWY: follow routine schedule below</td>
</tr>
<tr>
<td>11 - 12 years</td>
<td>Give dose #1 of 2-dose series (dose #2 due at age 16 yrs)</td>
</tr>
<tr>
<td>13 - 15 years</td>
<td>Give catch-up dose #1 of 2-dose series (dose #2 due at age 16 yrs)</td>
</tr>
<tr>
<td>16 years</td>
<td>Give dose #2 (minimum interval: 8 weeks)</td>
</tr>
<tr>
<td>17 - 18 years</td>
<td>Give catch-up dose #2 (≥8 weeks after dose #1)</td>
</tr>
<tr>
<td>16 - 18 years</td>
<td>No history of prior vaccination: give 1 dose</td>
</tr>
</tbody>
</table>

### Risk Based Dosing:
travelers to/residents of countries where meningococcal disease is hyperendemic or epidemic (including countries in the African meningitis belt or during the Hajj); during outbreaks; occupational exposure; persistent complement component deficiencies or complement inhibitor use(e.g., eculizumab, ravulizumab); HIV infection; or functional or anatomic asplenia (including sickle cell disease)

<table>
<thead>
<tr>
<th>Age</th>
<th>Primary Dose(s)</th>
<th>Booster</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 - 6 months</td>
<td>Give 3 doses of Mencevo 8 weeks apart, and #4 at age 12–18 months. If possible, begin vaccination at age 2 months.</td>
<td>Initial booster after 3 years; repeat boosters every 5 years**</td>
</tr>
<tr>
<td>7 - 23 months</td>
<td>Give 2 doses of Mencevo (if 9–23 months, may give Menactra*) Dose #2 of series should be 12 weeks after dose 1 and after 12 months of age</td>
<td></td>
</tr>
<tr>
<td>2 years and older</td>
<td>Give 1 dose of MenACWY (either vaccine). If immunosuppressed, give 2 doses, 8 weeks apart.</td>
<td></td>
</tr>
</tbody>
</table>

*When using Menactra in immunosuppressed children: give dose #1 at least 4 weeks after completion of pneumococcal vaccine (PCV13) series and dose #2 at least 12 weeks after dose #1
** A booster dose should be administered every 5 years; children who receive the primary series before their seventh birthday should receive the first booster dose in 3 years and subsequent booster doses every 5 years

54 Reviewed by DHA-IHD June 2020
Note: While the MenACWY package inserts recommend a single dose of MenACWY after 2 years of age (Menveo allows for 2 doses in high-risk persons aged 2-5 years), the ACIP recommends a 2-dose primary series, 8-12 weeks apart for all high-risk patients 2 years of age and older. This represents the current standard of care and is permissible under this standing order.

Note: While MenACWY package inserts recommend only a single booster dose, the ACIP recommends a booster dose every 5 years for high-risk patients, as well as a booster dose for international travelers visiting parts of sub-Saharan Africa if the last dose was administered ≥5 years previously. This represents the current standard of care and is permissible under this standing order.

Note: In persons with anatomic or functional asplenia and/or HIV infection, MenACWY-D, (Menactra®) and pneumococcal conjugate vaccine (PCV13, (Prevnar13) should not be administered simultaneously PCV13 should be administered first and MenACWY-D should be administered 4 weeks later.

5. Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

7. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

8. This policy and procedure shall remain in effect for all patients of the ____________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

________________________________________  ______________________
Medical Director’s Signature                    Date
Standing Orders for Administering Meningococcal Group B Vaccine (Pediatric)

**Purpose:** To reduce morbidity and mortality from serogroup B meningococcal disease by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure:**
1. Identify persons 10 - 18 years of age in need of vaccination against meningococcal disease based on the following criteria:
   - Persons 10 – 18 years of age with:
     - Diagnosis of persistent complement component deficiency (e.g., deficiencies in C3, C5-9, factor D, factor H, or properdin)
     - Anatomic or functional asplenia
     - Taking eculizumab (Soliris®) or ravulizumab (Ultomiris®)
     - Laboratory workers routinely exposed to *Neisseria meningitidis*
     - Increased risk due to serogroup B meningococcal disease outbreak
   - Persons 16 – 18 years of age not at increased risk who want protection against serogroup B meningococcal disease*

*Note: the decision to vaccinate persons not at increased risk should be based on shared clinical decision-making and is not covered under these standing orders. Patients must obtain a written order from a privileged provider for this situation

2. Screen all patients for contraindications and precautions to meningococcal B vaccine (MenB):
   **Contraindications:**
   - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of MenB or to a vaccine component (to include kanamycin)
   **Precautions:**
   - Moderate or severe acute illness with or without fever
   - The tip caps of the prefilled syringes of Bexsero® contain natural rubber latex and may cause allergic reactions in latex sensitive individuals. Trumenba® does not contain latex
   - Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
   - For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245
**Note:** available data are not sufficient to assess the effects of MenB on persons who are pregnant or nursing. MenB should be used during pregnancy or nursing only if benefit clearly outweighs risk, and is not covered under this standing order. Patients must obtain a written order from a privileged provider for this situation.

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at [www.immunize.org/vis](http://www.immunize.org/vis).

4. Provide vaccine as follows:
Follow dosing schedule in table below. Administer 0.5mL intramuscularly in the preferred site (anterolateral thigh for infants and toddlers or in the deltoid for children and adolescents). The alternate site (anterolateral thigh muscle or deltoid muscle) may be used if the preferred site is inadequate. Choose needle gauge and length appropriate to administration route and the patient’s age and/or body mass according to the chart below.

<table>
<thead>
<tr>
<th>Needle Length and Injection Site of IM Injections for Children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use a 22 – 25 gauge needle. Choose needle gauge and length appropriate to administration route and the patient’s age and body mass.</td>
</tr>
<tr>
<td><strong>Age Group</strong></td>
</tr>
<tr>
<td>Children (3-10 years)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Children (11-18 years)</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration [https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html](https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html).

†If skin is stretched tightly and subcutaneous tissues are not bunched
*Preferred site

### Vaccine Dose Schedule

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Dose</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bexsero* (MenB-4c, GlaxoSmithKline)</td>
<td>0.5mL</td>
<td>Two doses, 4 weeks apart†,‡</td>
</tr>
<tr>
<td>Trumenba* (MenB-FHbp, Pfizer)</td>
<td>0.5mL</td>
<td>Two doses at 0 and 6 months§,‖</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Three doses at 0, 1–2, and 6 months§,Ⅳ</td>
</tr>
</tbody>
</table>

*The two brands of MenB vaccine are not interchangeable: the series must be started and completed with the same brand of vaccine
†The 2-dose schedules of either Bexsero or Trumenba may be used in healthy adolescents
‡Either the 2-dose schedule of Bexsero or the 3-dose schedule of Trumenba should be given to persons at increased risk for meningococcal serogroup B disease
§If Dose #2 of the 2-dose Trumenba series is administered earlier than 6 months after Dose #1, a third dose should be administered at least 4 months after Dose #2.
Note: ACIP recommends:
• For persons aged ≥10 years with complement deficiency, complement inhibitor use, asplenia, or who are microbiologists:
  o Booster dose 1 year following completion of a MenB primary series followed by booster doses every 2-3 years as long as increased risk remains
• For persons aged ≥10 years determined by public health officials to be at increased risk during an outbreak:
  o One-time booster dose if it has been ≥1 year since completion of a MenB primary series

5. Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

7. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

8. This policy and procedure shall remain in effect for all patients of the _______________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

__________________________________________
Medical Director's Signature

____________________________
Date
**Standing Orders for Administering Pneumococcal Conjugate (PCV13) Vaccine (Pediatric)**

**Purpose:** To reduce morbidity and mortality from pneumococcal disease by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other healthcare professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure:**
1. Identify persons 2 months – 17 years of age in need of vaccination with pneumococcal conjugate vaccine (PCV13) based on the following criteria:
   - Age 2 - 59 months of age and generally healthy
   - Age 2 – 17 years of age with any of the following underlying conditions (see Table 1):
     - Candidate for or recipient of cochlear implant; cerebrospinal fluid leak
     - Sickle cell disease, hemoglobinopathies, functional or anatomic asplenia (e.g., splenic dysfunction, splenectomy)
     - Immunocompromising condition (e.g., congenital immunodeficiency, HIV infection, hematologic cancers, malignant neoplasms)
     - Immunosuppressive therapy (e.g., chemotherapy agents, antimetabolites, biologics, high-dose corticosteroids, radiation therapy)
     - Chronic renal failure or nephrotic syndrome; organ or bone marrow transplantation

2. Screen all patients for contraindications and precautions to PCV13:

   **Contraindications:**
   - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of PCV13 vaccine or to a vaccine component
   - For information on vaccine components, refer to the manufacturer’s package insert or go to [http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf](http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf)

   **Precautions:**
   - Moderate or severe acute illness with or without fever
   - Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
   - For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245
3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccine as follows:
   Follow dosing schedule in Table 2. Administer 0.5mL of PCV13 vaccine intramuscularly in the preferred site (anterolateral thigh for infants and toddlers or in the deltoid for children and adolescents). The alternate site (anterolateral thigh muscle or deltoid muscle) may be used if the preferred site is inadequate.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants (1-12 months)</td>
<td>1 inch</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>Toddlers (1-2 years)</td>
<td>1-1.25 inch</td>
<td>Anterolateral thigh*</td>
</tr>
<tr>
<td></td>
<td>5/8† – 1 inch</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Children (3-10 years)</td>
<td>5/8† inch-1 inch</td>
<td>Deltoid muscle of arm*</td>
</tr>
<tr>
<td></td>
<td>1-1.25 inches</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>Children (11-18 years)</td>
<td>5/8† – 1 inch</td>
<td>Deltoid muscle of arm*</td>
</tr>
<tr>
<td></td>
<td>1-1.5 inches</td>
<td>Anterolateral thigh</td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html.

†If skin is stretched tightly and subcutaneous tissues are not bunched
*Preferred site

Do not give PCV13 and PPSV23 at the same visit
Complete all doses of PCV13 before administering PPSV23 (if indicated)

Note: In persons with anatomic or functional asplenia and/or HIV infection, MenACWY-D (Menactra®) and PCV13 (Prevnar13®) should not be administered simultaneously. PCV13 should be administered first and MenACWY-D should be administered 4 weeks later

Note: Routine use of PCV13 is not recommended for healthy children ≥ 5 years

5. Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.
6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

7. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

8. This policy and procedure shall remain in effect for all patients of the ______________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

__________________________________  __________________________
Medical Director’s Signature          Date
Table 1. Underlying Medical Conditions that are Indications for Pneumococcal Vaccination

<table>
<thead>
<tr>
<th>Risk Group</th>
<th>Underlying Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Immunocompetent children and teens with risk condition(s)</td>
<td>• chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure)</td>
</tr>
<tr>
<td></td>
<td>• chronic lung disease (asthma excluded unless treated with high-dose corticosteroids)</td>
</tr>
<tr>
<td></td>
<td>• diabetes mellitus; cerebrospinal fluid leak; cochlear implant</td>
</tr>
<tr>
<td>2. Children and teens with functional or anatomic asplenia</td>
<td>• sickle cell disease and other hemoglobinopathies</td>
</tr>
<tr>
<td></td>
<td>• congenital or acquired asplenia, or splenic dysfunction</td>
</tr>
<tr>
<td>3. Children and teens with immunocompromising condition(s)</td>
<td>• HIV infection</td>
</tr>
<tr>
<td></td>
<td>• chronic renal failure, nephrotic syndrome</td>
</tr>
<tr>
<td></td>
<td>• diseases associated with treatment with immunosuppressive drugs or radiation therapy (e.g., malignant neoplasms, leukemias, lymphomas, and Hodgkin’s disease; solid organ transplantation)</td>
</tr>
<tr>
<td></td>
<td>• congenital immunodeficiency (includes B- [humoral] or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, or C4 deficiency; and phagocytic disorders [excluding chronic granulomatous disease])</td>
</tr>
</tbody>
</table>

Adapted from https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5911a1.htm

Table 2. Recommended Schedule for Administering Pneumococcal Conjugate Vaccine (PCV)

<table>
<thead>
<tr>
<th>Patient’s age now</th>
<th>Previous doses of PCV7 and/or PCV13</th>
<th>Recommended PCV13 Schedule (For minimum interval guidance for catch-up vaccination, see * below)</th>
<th>Total doses needed</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 through 6 months</td>
<td>0 doses</td>
<td>3 doses, 8 weeks* apart; 4th dose at age 12–15 months</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>1 dose</td>
<td>2 doses, 8 weeks* apart; 4th dose at age 12–15 months</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>2 doses</td>
<td>1 dose, 8 weeks* after the most recent dose; 4th dose at age 12–15 months</td>
<td>4</td>
</tr>
<tr>
<td>7 through 11 months</td>
<td>0 doses</td>
<td>2 doses, 8 weeks* apart; 3rd dose at age 12–15 months</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>1 or 2 doses before age 7 months</td>
<td>2 doses: 1 dose at age 7–11 months and a 2nd dose at age 12–15 months, at least 8* weeks after the most recent dose</td>
<td>3 or 4</td>
</tr>
<tr>
<td></td>
<td>1 dose at age 7-11 months</td>
<td>2 doses: 1 dose at age 7–11 months and a 2nd dose at age 12–15 months, at least 8* weeks after the most recent dose</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>2 doses at age 7-11 months</td>
<td>1 dose at age 12–15 months</td>
<td>3</td>
</tr>
<tr>
<td>12 through 23 months</td>
<td>0 doses</td>
<td>2 doses, at least 8 weeks apart</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>1 dose before age 12 months</td>
<td>2 doses, at least 8 weeks apart</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>2 or 3 doses before age 12 months</td>
<td>1 dose, at least 8 weeks after the most recent dose</td>
<td>3 or 4</td>
</tr>
<tr>
<td></td>
<td>1 dose at or after age 12 months</td>
<td>1 dose, at least 8 weeks after the most recent dose</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>2 doses at or after age 12 months</td>
<td>0 additional doses</td>
<td>2</td>
</tr>
<tr>
<td>24 through 59 months (healthy children)</td>
<td>0 doses or any incomplete schedule</td>
<td>1 dose, at least 8 weeks after the most recent dose</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>4 doses of PCV7 or other age-appropriate complete PCV7 schedule</td>
<td>1 dose, at least 8 weeks after the most recent dose</td>
<td>1</td>
</tr>
<tr>
<td>24 through 71 months in Risk Group 1, 2, or 3 (see specific conditions in Table 1 above)</td>
<td>Unvaccinated or any incomplete schedule of less than 3 doses</td>
<td>2 doses: 1st dose at least 8 weeks after the most recent dose, and a 2nd dose at least 8 weeks later</td>
<td>3 or 4</td>
</tr>
<tr>
<td></td>
<td>Any incomplete schedule of 3 doses, or any age-appropriate complete PCV7 schedule</td>
<td>1 dose, at least 8 weeks after the most recent dose</td>
<td>4</td>
</tr>
<tr>
<td>6 through 17 years in Risk Group 2 or 3 (see specific conditions in Table 1 above); with CSF leak, or cochlear implant</td>
<td>No history of PCV13 (regardless of previous PCV7 or PPSV23 receipt)</td>
<td>1 dose, at least 8 weeks after the most recent dose</td>
<td>1</td>
</tr>
</tbody>
</table>

*Minimum interval between doses – Adapted from Immunization Action Coalition: www.immunize.org/catg.d/p2016.pdf - Item #P2016 (10/18)

For patients younger than 12 months of age: 4 weeks.
For patients 12 months of age and older: 8 weeks.
Standing Orders for Administering Pneumococcal Polysaccharide (PPSV23) Vaccine (Pediatric)

**Purpose:** To reduce morbidity and mortality from pneumococcal disease by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure:**
1. Identify persons 2 – 18 years of age in need of vaccination with pneumococcal polysaccharide vaccine (PPSV23) based on the following criteria:
   - No or unknown history of prior receipt of PPSV23 and any of the following underlying conditions (see table below):
     - Chronic cardiovascular disease (particularly cyanotic congenital heart disease and cardiac failure)
     - Chronic pulmonary disease (asthma is excluded unless treated with high-dose corticosteroid therapy)
     - Diabetes mellitus
     - Chronic liver disease (cirrhosis), or alcoholism (patients 6 - 18 years of age only)
     - Candidate for or recipient of cochlear implant; cerebrospinal fluid leak
     - Sickle cell disease, hemoglobinopathies, anatomic or functional asplenia (splenectomy, splenic dysfunction)
     - Immunocompromising condition (e.g., congenital immunodeficiency, HIV infection, hematologic cancers, malignant neoplasms)
     - Immunosuppressive therapy (e.g., antineoplastic agents, antimetabolites, biologics, high-dose corticosteroids, radiation therapy)
     - Chronic renal failure or nephrotic syndrome; organ or bone marrow transplantation
     - Environments or settings with increased risk (e.g., long-term care facility)
2. Screen all patients for contraindications and precautions to PPSV23:
   - **Contraindications:**
     - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of PPSV23 vaccine or to a vaccine component
     - For information on vaccine components, refer to the manufacturer’s package insert or go to http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf
   - **Precautions:**
     - Moderate or severe acute illness with or without fever
     - Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccine as follows:
   - Follow dosing schedule as below. Administer 0.5mL of PPSV23 vaccine intramuscularly in the preferred site (anterolateral thigh for infants and toddlers or in the deltoid for children and adolescents). The alternate site (anterolateral thigh muscle or deltoid muscle) may be used if the preferred site is inadequate.

### Needle Length and Injection Site of IM Injections for Children

Use a 22 – 25 gauge needle. Choose needle gauge and length appropriate to administration route and the patient’s age and body mass.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toddlers (1-2 years)</td>
<td>1-1.25 inch</td>
<td>Anterolateral thigh*</td>
</tr>
<tr>
<td></td>
<td>5/8† – 1 inch</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Children (3-10 years)</td>
<td>5/8† inch- 1 inch</td>
<td>Deltoid muscle of arm*</td>
</tr>
<tr>
<td></td>
<td>1-1.25 inches</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>Children (11-18 years)</td>
<td>5/8† – 1 inch</td>
<td>Deltoid muscle of arm*</td>
</tr>
<tr>
<td></td>
<td>1-1.5 inches</td>
<td>Anterolateral thigh</td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html.

†If skin is stretched tightly and subcutaneous tissues are not bunched
*Preferred site

<table>
<thead>
<tr>
<th>Underlying Condition</th>
<th>Primary PPSV23 Series</th>
<th>PPSV23 Booster</th>
</tr>
</thead>
<tbody>
<tr>
<td>• chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure)</td>
<td>1 dose ≥8 weeks after the last dose of PCV13</td>
<td>Not recommended</td>
</tr>
<tr>
<td>• chronic lung disease (asthma excluded unless treated with high-dose corticosteroids)</td>
<td>1 dose ≥8 weeks after the last dose of PCV13</td>
<td>1 dose ≥5 years after the first dose of PPSV23</td>
</tr>
<tr>
<td>• alcoholism, chronic liver disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• diabetes mellitus; cerebrospinal fluid leak; cochlear implant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• sickle cell disease and other hemoglobinopathies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• congenital or acquired asplenia, or splenic dysfunction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• HIV infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• chronic renal failure, nephrotic syndrome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• diseases commonly treated with immunosuppressive drugs or radiation therapy (e.g., malignant neoplasms, leukemias, lymphomas, and Hodgkin’s disease; solid organ transplantation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• congenital immunodeficiency (includes B- [humoral] or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, or C4 deficiency; and phagocytic disorders [excluding chronic granulomatous disease])</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adapted from Immunization Action Coalition: www.immunize.org
Do not give PCV13 and PPSV23 at the same visit
Complete all doses of PCV13 before administering PPSV23

5. Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

7. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

8. This policy and procedure shall remain in effect for all patients of the ______________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

________________________________________  ____________________
Medical Director's Signature                     Date
Standing Orders for Administering Rotavirus Vaccine (Pediatric)

**Purpose:** To reduce morbidity and mortality from disease caused by rotavirus by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure:**
1. Identify persons 2 – 8 months of age in need of vaccination against rotavirus based on the following criteria:
   - Lacking documentation of at least 2 doses of rotavirus vaccine (RV) at the appropriate ages/intervals
   - Age 2 - 3 months (14 weeks/6 days) who have not **started** a series of rotavirus vaccine
   - Age 8 months/0 days or younger who have not **completed** a series of rotavirus vaccine

2. Screen all patients for contraindications and precautions to rotavirus vaccine:
   **Contraindications:**
   - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of RV or to a vaccine component
   - History of intussusception
   - Severe combined immunodeficiency (SCID)
   - Uncorrected congenital gastrointestinal tract malformation (such as Meckel’s diverticulum)
   - The tip caps of prefilled oral applicators of Rotarix® contain natural rubber latex and may cause allergic reactions in latex sensitive individuals. The plastic dosing tube and cap of RotaTeq® do not contain latex
   - For information on vaccine components, refer to the manufacturer’s package insert or go to [http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf](http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf)

   **Precautions:**
   - Moderate or severe acute illness with or without fever (including diarrhea and vomiting)
   - Altered immunocompetence (e.g., HIV/AIDS, cancer or malignant neoplasms, immunosuppressive therapy, etc.)
   - Chronic gastrointestinal disease
   - For Rotarix® only, spina bifida or bladder extrophy
   - For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245
3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccine as follows:
   - The RV consists of a 2-dose (ROTARIX® 1mL at 2 and 4 months of age) or 3-dose (RotaTeq® 2mL at 2, 4, and 6 months of age) series
   - Note that ROTARIX® must be reconstituted before use
   - Administer the RV orally:
     - Gently squeeze the liquid into the patient’s mouth toward the inner cheek until dosing tube is empty (a residual drop may remain in the tip of the tube)
     - If for any reason an incomplete dose is administered (e.g., infant spits or regurgitates the vaccine), a replacement dose is not recommended. The infant should continue to receive any remaining doses in the recommended series

5. Provide subsequent doses of RV to complete each patient’s schedule. For patients who did not receive RV at the ages specified in #4, give one dose at the earliest opportunity and then schedule subsequent doses according to the following:
   - Give the first dose no later than 14 weeks and 6 days of age
   - Minimum interval between doses is 4 weeks
   - Maximum age for the final dose is 8 months and 0 days
   - If any dose in the series is RotaTeq or unknown, complete a 3-dose series

6. Document all immunizations administered in the patient’s electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

7. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

8. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

9. This policy and procedure shall remain in effect for all patients of the __________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

__________________________________  _________________________________
Medical Director   Date
Standing Order for Administering Tetanus, Diphtheria and Pertussis Vaccines (Pediatric)

**Purpose:** To reduce morbidity and mortality from tetanus, diphtheria and pertussis disease by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure**
1. Identify patients 7-18 years of age in need of vaccination against tetanus, diphtheria, and pertussis based on the following criteria:
   - Lack of documentation of at least 4 doses of diphtheria and tetanus toxoids and pertussis vaccine (DTaP), with at least one dose given after age 4 years and with the most recent dose given a minimum of 4 calendar months after the preceding dose
   - Lack of documentation of at least 3 doses of diphtheria and tetanus toxoid-containing vaccine (e.g., DT, Tdap, Td)
   - Lack of documentation of a pertussis-containing vaccine given at age 10 years or older
   - Currently pregnant (preferably between 27 and 36 weeks gestation) and no documentation of Tdap given during the current pregnancy
   - Completion of a 3-dose primary series of diphtheria and tetanus toxoid-containing vaccine (DTaP, DT, Tdap, Td) with receipt of the last dose being 10 years ago or longer

2. Screen all patients for contraindications and precautions to Td / Tdap vaccine:
   **Contraindications:**
   - History of a serious reaction (e.g., anaphylaxis) after a previous dose of a tetanus or diphtheria toxoid-containing vaccine or to a vaccine component
   - For information on vaccine components, refer to the manufacturer’s package insert or go to [https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf](https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf)
   - A history of encephalopathy (e.g. coma, decreased level of consciousness, prolonged seizures) within 7 days following DTP/DTaP/Tdap not attributable to another identifiable cause

   **Precautions:**
   - History of Guillain-Barré syndrome within 6 weeks of a previous dose of tetanus toxoid-containing vaccine
   - History of an Arthus-type hypersensitivity reaction after a previous dose of tetanus or diphtheria toxoid-containing vaccine: defer vaccination until at least 10 years have elapsed since the last tetanus toxoid-containing vaccine
   - Progressive or unstable neurologic disorder, uncontrolled seizures or progressive encephalopathy: defer vaccination until a treatment regimen has been established and the condition has stabilized (Tdap only)
• Moderate or severe acute illness with or without fever
• Tip caps of prefilled syringes of Adacel®† and Boostrix® contain natural rubber latex and may cause allergic reactions in latex-sensitive individuals († tip caps of some lots of Adacel® prefilled syringes contain latex while others do not - please refer to package insert)
• Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
• For questions or concerns, consider consulting the DHA Immunization Healthcare Division at 877-438-8222, Option 1 or DSN 761-4245

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccination as follows:
• The routine schedule for Tdap vaccination in pediatric patients is one dose at age 11-12 years, followed by a booster (either Td or Tdap) every 10 years
• Pregnant patients should receive 1 dose of Tdap during each pregnancy, regardless of number of years since prior DTaP, Tdap, DT, DTP or Td vaccination. Tdap should be administered at 27–36 weeks’ gestation, preferably during the earlier part of this period (to maximize the maternal antibody response/passive antibody transfer to the infant), although it may be administered at any time during pregnancy
• Administer 0.5mL intramuscularly in the preferred site (deltoid for children and adolescents). The alternate site (anterolateral thigh muscle) may be used if the preferred site is inadequate.

<table>
<thead>
<tr>
<th>IM Injection Needle Length and Site (Pediatrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use a 22 – 25 gauge needle. Choose needle gauge and length appropriate to administration route and the patient’s age and body mass.</td>
</tr>
<tr>
<td>Age Group</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Children (3-10 years)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Adolescents (11-18 years)</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

†If skin is stretched tightly and subcutaneous tissues are not bunched
*Preferred site
Adapted from https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html
5. For persons who did not receive DTaP, DT, Td, or Tdap at the recommended ages/intervals, provide catch-up dose(s) according to the tables below. Previous doses must meet minimum age and minimum interval requirements.

<table>
<thead>
<tr>
<th>IF current age is</th>
<th>AND # of previous doses of DTaP, DT, Td, or Tdap is</th>
<th>AND</th>
<th>AND</th>
<th>AND</th>
<th>THEN</th>
<th>Next dose due</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unknown or 0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Give Dose 1 (Tdap) today</td>
<td>Give Dose 2 (Td or Tdap) at least 4 weeks after Dose 1</td>
</tr>
<tr>
<td>1</td>
<td>Dose 1 given &lt;12 months of age</td>
<td></td>
<td></td>
<td></td>
<td>Give Dose 2 (Td or Tdap) today</td>
<td>Give Dose 3 (Td or Tdap) at least 6 months after Dose 2</td>
</tr>
<tr>
<td></td>
<td>It has been at least 4 weeks since Dose 1</td>
<td></td>
<td>Dose 1 was Tdap</td>
<td>Give Dose 2 (Td or Tdap) today</td>
<td>Give Dose 3 (Td or Tdap) at least 6 months after Dose 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dose 1 given ≥12 months of age</td>
<td></td>
<td>Dose 1 was not Tdap</td>
<td>Give Dose 2 (Td or Tdap) today</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 – 9 years*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Give Dose 2 (Td or Tdap) today</td>
<td>Give Dose 3 (Td or Tdap) at least 6 months after Dose 2</td>
</tr>
<tr>
<td>2</td>
<td>Dose 1 given &lt;12 months of age</td>
<td></td>
<td></td>
<td></td>
<td>Give Dose 3 (Td or Tdap) today</td>
<td>Give Dose 3 (Td or Tdap) today</td>
</tr>
<tr>
<td></td>
<td>It has been at least 4 weeks since Dose 2</td>
<td></td>
<td>Dose 2 was Tdap*</td>
<td>Give Dose 3 (Td or Tdap) today</td>
<td>Give Dose 3 (Td or Tdap) today</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dose 1 given ≥12 months of age</td>
<td></td>
<td>No dose was Tdap</td>
<td>Give Dose 3 (Td or Tdap) today</td>
<td>Give Tdap at 11-12 years of age*†</td>
<td></td>
</tr>
<tr>
<td></td>
<td>It has been at least 6 months since Dose 2</td>
<td></td>
<td>Any dose was Tdap*</td>
<td>Give Dose 3 (Td or Tdap) today</td>
<td>Give Tdap at 11-12 years of age*†</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dose 1 given ≥12 months of age</td>
<td></td>
<td>No dose was Tdap</td>
<td>Give Dose 3 (Td or Tdap) today</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Dose 1 given &lt;12 months of age</td>
<td></td>
<td></td>
<td></td>
<td>Give Dose 4 (Td or Tdap) today</td>
<td>Give Tdap at 11-12 years of age*†</td>
</tr>
<tr>
<td></td>
<td>It has been at least 6 months since Dose 3</td>
<td></td>
<td>Any dose was Tdap*</td>
<td>Give Dose 4 (Td or Tdap) today</td>
<td>Give Tdap at 11-12 years of age*†</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dose 1 given ≥12 months of age</td>
<td></td>
<td>No dose was Tdap</td>
<td>Give Dose 4 (Td or Tdap) today</td>
<td>Give Tdap at 11-12 years of age*†</td>
<td></td>
</tr>
<tr>
<td></td>
<td>No dose was Tdap</td>
<td></td>
<td>Any dose was Tdap</td>
<td>Give Dose 4 (Td or Tdap) today</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Dose of DTaP or Tdap given after 4th birthday</td>
<td></td>
<td></td>
<td></td>
<td>Give a dose of Tdap today</td>
<td>Give Tdap at 11-12 years of age*†</td>
</tr>
<tr>
<td></td>
<td>Dose of DTaP or Tdap given after 4th birthday</td>
<td></td>
<td></td>
<td></td>
<td>Give a dose of Tdap today</td>
<td></td>
</tr>
<tr>
<td></td>
<td>No DTaP or Tdap given after 4th birthday</td>
<td></td>
<td></td>
<td></td>
<td>Give a dose of Tdap today</td>
<td></td>
</tr>
</tbody>
</table>

* For persons 7-9 years of age who receive a dose of Tdap, the routine adolescent Tdap dose should still be administered at 11-12 years of age
† Tdap may be administered regardless of the interval since the last tetanus- and diphtheria-toxoid-containing vaccine
Adapted from [https://www.cdc.gov/vaccines/schedules/downloads/child/job-aids/tdap-1.pdf](https://www.cdc.gov/vaccines/schedules/downloads/child/job-aids/tdap-1.pdf)
### Immunization Schedule for DTaP, DT, Td, or Tdap

**IF current age is**

<table>
<thead>
<tr>
<th>AND # of previous doses of DTaP, DT, Td, or Tdap is</th>
<th>AND</th>
<th>AND</th>
<th>AND</th>
<th>THEN</th>
<th>Next dose due</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unknown or 0</td>
<td></td>
<td></td>
<td></td>
<td>Give Dose 1 (Tdap) today</td>
<td>Give Dose 2 (Td or Tdap) at least 4 weeks after Dose 1</td>
</tr>
<tr>
<td>Dose 1 given &lt;12 months of age</td>
<td></td>
<td></td>
<td></td>
<td>Give Dose 2 (Td or Tdap) today</td>
<td>Give Dose 3 (Td or Tdap) at least 4 weeks after Dose 2</td>
</tr>
<tr>
<td>Dose 1 given ≥12 months of age</td>
<td></td>
<td></td>
<td></td>
<td>Give Dose 3 (Td or Tdap) today</td>
<td>Give Dose 4 (Td or Tdap) at least 6 months after Dose 3</td>
</tr>
</tbody>
</table>

**10 – 18 years**

<table>
<thead>
<tr>
<th>AND # of previous doses of DTaP, DT, Td, or Tdap is</th>
<th>AND</th>
<th>AND</th>
<th>AND</th>
<th>THEN</th>
<th>Next dose due</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose 1 given &lt;12 months of age</td>
<td></td>
<td></td>
<td></td>
<td>Give Dose 3 (Td or Tdap) today</td>
<td>Give Td or Tdap 10 years after Dose 3</td>
</tr>
<tr>
<td>Dose 1 given ≥12 months of age</td>
<td></td>
<td></td>
<td></td>
<td>Give Dose 4 (Td or Tdap) today</td>
<td>Give Td or Tdap 10 years after Dose 3</td>
</tr>
</tbody>
</table>
| Dose 1 given <12 months of age                      |     |     |     | Give Td or Tdap 10 years after Dose 3 | No dose was Tdap±
| Dose 1 given ≥12 months of age                      |     |     |     | Give Td or Tdap 10 years after Dose 3 | No dose today |

* Given at 10 years of age or older
† If the previous Tdap dose(s) was administered before the 10th birthday, then a dose of Tdap is recommended now
‡ Or Tdap administered at 9 years of age or younger
§ The preferred age at administration for this dose is 11-12 years. However, if Tdap is administered at 10 years of age, the Tdap dose may count as the adolescent Tdap dose

Adapted from https://www.cdc.gov/vaccines/schedules/downloads/child/job-aids/tdap-2.pdf

---

6. Document all immunizations administered in the patient’s electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

7. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.
8. Adverse Events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

9. This policy and procedure shall remain in effect for all patients of the ___________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

________________________________________________________________________
Medical Director’s Signature   Date
Standing Orders for Administering Typhoid Vaccine (Pediatric)

**Purpose:** To reduce morbidity and mortality from disease caused by *Salmonella enterica* serotypes Typhi and Paratyphi by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure:**
1. Identify persons 2 – 17 years of age in need of vaccination against typhoid fever based on the following criteria:
   - Anticipated travel to areas where there is a recognized risk for exposure to *S. typhi*
   - Persons with intimate exposure (e.g., household contact) to a documented *S. typhi* chronic carrier
   - Laboratory workers routinely exposed to specimens of *S. typhi*, or who work in laboratory environments where these specimens are routinely handled

2. Screen all patients for contraindications and precautions to typhoid vaccine:
   **Contraindications:**
   - Oral typhoid vaccine should not be given to immunocompromised persons
   - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of typhoid vaccine or to a vaccine component
   - For information on vaccine components, refer to the manufacturer’s package insert or go to [http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf](http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf)

   **Precautions:**
   - Oral typhoid vaccine should not be given within 3 days (before or after) of an antimicrobial agent
   - Moderate or severe acute illness with or without fever
   - Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
   - For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

**Note:** available data are not sufficient to assess the effects of typhoid vaccine on persons who are pregnant or nursing. Typhoid vaccine should be used during pregnancy or nursing only if benefit clearly outweighs risk; if indicated, inactivated vaccine (ViCPS) may be considered. This is not covered under this standing order; patients must obtain a written order from a privileged provider for this situation.
3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccine as follows:
Follow dosing schedules in table below. Patients should complete the Vivotif® regimen ≥1 week prior to exposure; Typhim VI® should be completed 2 weeks prior to exposure. Vivotif® is given orally; Typhim VI® is given intramuscularly in the preferred site (anterolateral thigh for infants and toddlers or in the deltoid for children and adolescents). The alternate site (anterolateral thigh muscle or deltoid muscle) may be used if the preferred site is inadequate.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toddlers (1-2 years)</td>
<td>1-1.25 inch</td>
<td>Anterolateral thigh*</td>
</tr>
<tr>
<td></td>
<td>5/8† – 1 inch</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Children (3-10 years)</td>
<td>5/8† inch- 1 inch</td>
<td>Deltoid muscle of arm*</td>
</tr>
<tr>
<td></td>
<td>1-1.25 inches</td>
<td>Anterolateral thigh</td>
</tr>
<tr>
<td>Children (11-18 years)</td>
<td>5/8† – 1 inch</td>
<td>Deltoid muscle of arm*</td>
</tr>
<tr>
<td></td>
<td>1-1.5 inches</td>
<td>Anterolateral thigh</td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html.
†If skin is stretched tightly and subcutaneous tissues are not bunched
*Preferred site

5. Document all immunizations administered in the patient’s electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.
6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

7. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

8. This policy and procedure shall remain in effect for all patients of the ______________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

_________________________________       ___________________________________
Medical Director's Signature                Date
Standing Orders for Administering Varicella (Chickenpox) Vaccine (Pediatric)

**Purpose:** To reduce morbidity and mortality from varicella disease by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other healthcare professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure:**
1. Identify all persons 12 months to 17 years of age in need of varicella vaccination (VAR) based on the following criteria:
   - Lack of acceptable evidence of varicella immunity (e.g., documentation of 2 doses of VAR vaccine at the appropriate age/interval, positive serologic testing, or diagnosis/verification of a history of varicella or herpes zoster by a healthcare provider)

2. Screen all patients for contraindications and precautions to VAR vaccine:
   - **Contraindications:**
     - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of VAR vaccine or to a vaccine component (to include gelatin and neomycin)
     - For information on vaccine components, refer to the manufacturer’s package insert or go to [http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf](http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf)
     - Pregnancy (or may become pregnant in the next 30 days)
     - Immunosuppression (e.g., HIV/AIDS, cancer or malignant neoplasms)
     - High-dose immunosuppressive therapy (e.g., two weeks or more of daily receipt of 20 mg or more [or 2mg/kg body weight or more] of prednisone or equivalent)
     - HIV-infected persons with CD4+ T-lymphocyte percentages <15% and total CD4 cell count <200/mm³
     - Family history of congenital or hereditary immunodeficiency in 1st degree relatives (e.g., parents and siblings) unless the immune competence of the potential vaccine recipient has been clinically substantiated or verified by a laboratory

   **Precautions:**
   - Moderate or severe acute illness with or without fever
   - Recent (≤11 months) receipt of an antibody-containing blood product
   - Need for tuberculosis (TB) screening by skin testing or interferon-gamma release assay (IGRA) testing. To prevent potential interference between varicella vaccine

Note: Do not give combination MMRV (ProQuad®) to a patient with primary or acquired immunodeficiency, including immunosuppression associated with AIDS or other clinical manifestations of HIV infections, cellular immunodeficiencies, hypogammaglobulinemia, or dysgammaglobulinemia.
and TB testing (possibly causing false-negative TB results), TB testing may be performed before varicella vaccination, on the same day as varicella vaccination (preferred), or postponed for at least 4 weeks after varicella vaccination

- Use of aspirin or aspirin-containing products
- Recent receipt of specific antivirals (i.e., acyclovir, famciclovir, or valcylovir) 24 hours before vaccination; avoid use of these antiviral drugs for 14 days after vaccination
- Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
- For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccine as follows:
The VAR vaccine (VARIVAX®) consists of a 2-dose series at 12-15 months and 4-6 years of age. Administer 0.5mL of VAR vaccine subcutaneously in the preferred site (fatty tissue over the anterolateral thigh muscle for infants and toddlers or the fatty tissue over the triceps for children and adolescents). The alternate site (fatty tissue over anterolateral thigh muscle or triceps) may be used if the preferred site is inadequate. Use a 23–25 gauge 5/8” needle.

5. For persons who did not receive VAR at the ages specified in #4:
   - Give one dose at the earliest opportunity
   - Schedule the second dose (if needed): the minimum interval is 3 months for patients 12 months - 12 years of age; 4 weeks for patients >13 years of age

6. Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

7. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

8. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.
9. This policy and procedure shall remain in effect for all patients of the
_________________________________ until rescinded and/or upon a change in
the Medical Director, whichever is earlier.

_________________________________  ________________________________
Medical Director's Signature       Date
Standing Order for Administering Yellow Fever Vaccine (Pediatric)

**Purpose:** To reduce morbidity and mortality from yellow fever disease by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure**

1. Identify all persons 9 months – 17 years of age in need of vaccination against yellow fever virus (YF) based on the following criteria:
   - Vaccination is required for Service members and beneficiaries as indicated per Combatant Command (CCMD) force health protection requirements

2. Screen all patients for contraindications and precautions to the yellow fever vaccine

**Contraindications:**

- A history of a serious allergic reaction (e.g., anaphylaxis) after a previous dose of YF vaccine or to a vaccine component (to include egg, chicken, or gelatin)
- Immunosuppression (e.g., HIV/AIDS [including those with a CD4 T lymphocyte count <200/mm³ or <15% of total lymphocytes for children < 6 years], cancer or malignant neoplasms, immunosuppressive therapy, etc.)

**Precautions:**

- Moderate or severe acute illness with or without fever
- Asymptomatic HIV infections with a CD4 count of 200-499/mm³ (or 15-24% of total lymphocytes for children aged <6 years)
- Pregnancy (or may become pregnant in the next 30 days). The safety of YF vaccine has not been studied in any large trials. YF vaccine should be given to a pregnant woman only if clearly needed
- Nursing: because of the potential for serious adverse reactions in nursing infants from YF vaccine, a decision should be made whether to discontinue nursing or not to administer the vaccine, taking into account the importance of the vaccine to the mother
• Need for tuberculosis (TB) screening by skin testing or interferon-gamma release assay (IGRA) testing. To prevent potential interference between yellow fever vaccine and TB testing (possibly causing false-negative TB results), TB testing may be performed before yellow fever vaccination, on the same day as yellow fever vaccination (preferred), or postponed for at least 4 weeks after yellow fever vaccination.

• Asymptomatic HIV infection with CD4 T lymphocyte values 200-499 mm$^3$ (or 15-24% of total lymphocytes for children aged <6 years).

• Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope.

• For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245.

Note: Yellow fever vaccine may be administered as young as 6 months of age in some circumstances. However, that is not covered under this standing order: patients must obtain a written order from a privileged provider for this situation. Providers considering vaccinating an infant 6-8 months of age are encouraged to contact DHA-IHD at (877) 438-8222, Option 1 prior to doing so.

3. Provide all persons (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the person’s medical record, the publication date of the VIS and the date it was given to the person (or parent/legal representative). Provide non-English speaking persons with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccine as follows:
   • YF vaccine (YF-Vax®) consists of a 1-dose series. Administer 0.5mL subcutaneously in the preferred site (fatty tissue over the anterolateral thigh muscle for infants and toddlers or the fatty tissue over the triceps for children and adolescents). The alternate site (fatty tissue over anterolateral thigh muscle or triceps) may be used if the preferred site is inadequate. Use a 23–25 gauge 5/8” needle.
   • Boosters are not routinely recommended for most travelers. Per the World Health Organization (WHO) and ACIP, a single primary dose of YF vaccine provides long-lasting protection and is adequate for most travelers. However, providers may consider administering a booster dose of YF vaccine for travelers who received their last dose ≥10 years ago if they are going to higher risk settings based on season, location, activities and duration of travel.
   • AFRICOM, SOCOM, and SOUTHCOM do not require booster doses for force health protection requirements.
   • Women who were pregnant when they received their initial dose of YF vaccine should receive 1 additional dose before they are next at risk for YF.
   • Persons who received a hematopoietic stem cell transplant after a dose of YF vaccine should be revaccinated before they are next at risk for YF (as long as they are sufficiently immunocompetent).
Persons infected with HIV when they received their last dose of YF vaccine should receive a dose every 10 years if they continue to be at risk for YF as long as they are sufficiently immunocompetent (CD4 T lymphocyte values ≥ 500/mm³ or >25% of total lymphocytes for children <6 years).

Laboratory workers who routinely handle wild-type yellow fever virus should have yellow fever virus-specific neutralizing antibody titers measured at least every 10 years to determine the need for additional doses of YF vaccine.

Note: Booster doses are not covered under this standing order. Patients must obtain a written order from a privileged provider familiar with appropriate indications for YF vaccine booster doses in this situation.

Note: If possible, it is recommended to separate MMR and yellow fever vaccines by at least 30 days due to limited data suggesting a decreased immune response to most antigens when co-administered.

5. The vaccine powder must be reconstituted immediately before use with the diluent supplied. Allow the reconstituted vaccine to sit for 1-2 minutes and then carefully swirl mixture until uniform suspension is achieved. Avoid vigorous shaking as this tends to cause foaming of the suspension. Once reconstituted, the vaccine should be maintained at 2°C–8°C and should be used or discarded within 1 hour. YF vaccine should be administered at least 10 days before travel.

6. Document all immunizations administered in the patient’s electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

7. International health regulation requires persons who receive YF vaccine to provide proof of vaccination on an International Certificate of Vaccination of Prophylaxis (ICVP). The CDC 731 form fulfills this requirement for vaccines received in the US, which must have a certified uniform stamp. A certificate of vaccination is considered valid 10 days after vaccination and for the life of the patient.

8. International health regulation requires additional documentation from persons with contraindications to receipt of YF vaccine before travel to yellow-fever endemic areas.

9. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as appropriate equipment and medications.

10. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

11. This policy and procedure shall remain in effect for all patients of the __________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

Medical Director’s Signature __________________________ Date ________________

Reviewed by DHA-IHD June 2020
Adult Standing Orders

Anthrax Vaccine
Hepatitis A Vaccine
Hepatitis B Vaccine
Hepatitis A/Hepatitis B Combination Vaccine
*Haemophilus influenzae* type b Vaccine
Human Papillomavirus Vaccine
Inactivated Polio Vaccine
Japanese Encephalitis Vaccine
Meningococcal ACWY Vaccine
Meningococcal Group B Vaccine
Measles Mumps Rubella Vaccine
Pneumococcal (PCV13 & PPSV23) Vaccine
Pneumococcal Vaccine Timing Chart- For Adults
Pre-Exposure Rabies Vaccine
Tetanus Diphtheria and Pertussis Vaccine
Typhoid Vaccine
Varicella (Chickenpox) Vaccine
Yellow Fever Vaccine
Zoster Vaccine
**Standing Order for Administering Anthrax Vaccine (Adult)**

**Purpose:** To reduce morbidity and mortality from anthrax by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure:**

1. Identify all persons 18 - 65 years of age in need of vaccination against anthrax based on the following criteria:
   - Required for individuals as indicated per Combatant Command (CCMD) force health protection requirements
   - Voluntary for individuals who have received at least one previous dose
   - Occupational exposure to *Bacillus anthracis* in the laboratory

2. Screen all patients for contraindications and precautions to the anthrax vaccine (AVA):
   - **Contraindications:**
     - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of AVA or to a vaccine component
     - For information on vaccine components, refer to the manufacturer’s package insert or go to [http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf](http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf)
     - Pregnancy: defer vaccination until completion of pregnancy
     - History of anthrax disease
   - **Precautions:**
     - Moderate or severe acute illness with or without fever
     - Breastfeeding
     - The vials of BioThrax® contain natural rubber latex and may cause allergic reactions in latex sensitive individuals
     - Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
     - For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal [Vaccine Information Statement (VIS)](http://www.immunize.org/vis) and the DoD brochure titled “What You Need to Know About Anthrax Vaccine.” You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at [www.immunize.org/vis](http://www.immunize.org/vis).
4. Provide vaccine as follows
   - AVA (BioThrax®) consists of a 3-dose priming series at 0, 1, and 6 months, with booster doses at 12 and 18 months and annually thereafter.
   - Administer 0.5mL intramuscularly in the deltoid muscle for adults

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men and Women (&lt;130 lbs)</td>
<td>1 inch†</td>
<td>Deltoid Muscle of Arm</td>
</tr>
<tr>
<td>Men and Women (130-152 lbs)</td>
<td>1 inch</td>
<td></td>
</tr>
<tr>
<td>Men (152-260 lbs)</td>
<td>1-1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (152-200 lbs)</td>
<td>1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Men (&gt; 260 lbs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women (&gt;200 lbs)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration
https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html
† Some experts recommend a 5/8 inch needle for men and women who weigh <130 lbs, skin must be stretched tightly (do not bunch subcutaneous tissue).

5. Observe a minimum interval of 4 weeks between the 1st and 2nd dose; 150 days between the 2nd and 3rd dose; and at least 180 days between the 3rd, 4th, and 5th doses. DO NOT compress the minimum interval between doses. Do not restart the primary series for any reason; resume the series with administration of the next dose.

6. Refer women who were inadvertently vaccinated while pregnant to the BioThrax (Anthrax) Vaccine in Pregnancy Registry via email at nhrc-VaccineRegistry@med.navy.mil or by calling (619) 553-9255.

7. Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

8. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

9. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

10. This policy and procedure shall remain in effect for all patients of the __________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

Medical Director's Signature __________________________ Date __________________________
Standing Orders for Administering Hepatitis A Vaccine (Adult)

**Purpose:** To reduce morbidity and mortality from hepatitis A virus infection by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure:**
1. Identify all persons ≥19 years of age in need of vaccination against hepatitis A virus (HAV) based on the following criteria:
   - Has not completed a hepatitis A vaccine (HepA) series (persons aged >40 years are at increased risk)
   - Anticipated international travel; see CDC Traveler’s Health for updates
   - Pregnant and non-pregnant persons identified to be at risk for an infection or severe outcome from HAV:
     - altered immunocompetence (e.g., congenital, drug-induced, or acquired, such as HIV)
     - use of injection or non-injection illegal drugs
     - occupational risk (i.e., in a HAV research lab or with primates)
     - close contact with an international adoptee during the first 60 days after the arrival of the adoptee in the United States
     - males who have sex with other males (MSM)
     - incarceration or homelessness
     - chronic liver disease (e.g., hepatitis B or C, cirrhosis, fatty or alcoholic liver disease, autoimmune hepatitis, or ALT/AST levels persistently greater than twice the upper limit of normal)
   - In settings providing services for at-risk persons as defined above, such as group homes and nonresidential day care facilities for developmentally disabled persons
   - At-risk persons (as defined above) during a hepatitis A outbreak
   - Unvaccinated persons possibly exposed to HAV within the last two weeks
   - Any other adult who wants to be protected from HAV

2. Screen all patients for contraindications and precautions to hepatitis A vaccine:
   **Contraindications:**
   - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of HepA or to a vaccine component (to include neomycin)
   - For information on vaccine components, refer to the manufacturer’s package insert or go to http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf
Precautions:
- Moderate or severe acute illness with or without fever
- The tip caps of the prefilled syringes of HAVRIX® and VAQTA®, and the vials of VAQTA®, contain natural rubber latex and may cause allergic reactions in latex sensitive individuals. The vials of HAVRIX® do not contain latex
- Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
- For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccine as follows:
   HepA consists of a 2-dose series (HAVRIX®: 0, 6-12 months; VAQTA®: 0, 6-18 months). Administer 1mL intramuscularly in the deltoid muscle for adults.

   **Note: persons 12 months – 18 years of age receive a 0.5mL dose; persons 19 years of age and older receive a 1mL dose. Please see the appropriate standing order for administration of HepA to pediatric patients for details**

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men and Women (&lt;130 lbs)</td>
<td>1 inch†</td>
<td>Deltoid Muscle of Arm</td>
</tr>
<tr>
<td>Men and Women (130-152 lbs)</td>
<td>1 inch</td>
<td></td>
</tr>
<tr>
<td>Men (152-260 lbs)</td>
<td>1-1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (152-200 lbs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men (&gt; 260 lbs)</td>
<td>1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (&gt;200 lbs)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

Needle Length and Injection Site of IM Injections for Adults

Use a 22 – 25 gauge needle. Choose needle gauge and length appropriate to administration route and the patient’s age and body mass.

† Some experts recommend a 5/8 inch needle for men and women who weigh <130 lbs, skin must be stretched tightly (do not bunch subcutaneous tissue)
5. Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

7. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

8. This policy and procedure shall remain in effect for all patients of the ______________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

_________________________________________  _________________________
Medical Director's Signature                Date
Standing Orders for Administering Hepatitis B Vaccine (Adult)

**Purpose:** To reduce morbidity and mortality from hepatitis B virus infection by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure:**

1. Identify persons ≥18 years of age in need of vaccination against hepatitis B virus (HBV) based on the following criteria:
   - Have not received at least 3 doses of hepatitis B vaccine (HepB) at the appropriate ages/intervals
   - Anticipated travel to a country with intermediate or high endemicity for HBV: see CDC Traveler’s Health site (Yellow Book) for updates
   - End stage renal disease, hemodialysis; HIV infection; or chronic liver disease, diabetes mellitus (Note: for those age 60 and over with diabetes, at the discretion of the provider)
   - Diagnosis of HIV infection
   - Current or recent use of injectable street drugs
   - Persons at risk for infection by sexual exposure, seeking evaluation or treatment for sexually transmitted infection, sexually active and not in a monogamous relationship, male who has sex with males, sex partner or household member of a person chronically infected with hepatitis B
   - Diagnosis of chronic liver disease, including hepatitis C
   - Persons with occupational risk (e.g., healthcare workers)
   - Residents and staff of facilities for developmentally disabled persons
   - Any other adult who wants to be protected from HBV

2. Screen all patients for contraindications and precautions to HepB: **Contraindications:**
   - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of HepB or to a vaccine component (to include yeast)
   - For information on vaccine components, refer to the manufacturer’s package insert or go to http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf

**Precautions:**

- Pregnancy: Heplisav-B should not be given to pregnant patients (see below)
- Moderate or severe acute illness with or without fever
- The tip caps of the prefilled syringes of Engerix-B® and Recombivax HB®, and the vials of Recombivax HB®, contain natural latex rubber and may cause allergic reactions in latex sensitive individuals. The vials of Engerix-B® do not contain latex
• Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope.

• For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccine as follows:
   Follow dosing schedules in tables below. Administer the appropriate product-specific dose intramuscularly in the deltoid muscle for adults.

<table>
<thead>
<tr>
<th>Needle Length and Injection Site of IM Injections for Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use a 22 – 25 gauge needle. Choose needle gauge and length appropriate to administration route and the patient’s age and body mass.</td>
</tr>
<tr>
<td>Age Group</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Men and Women (&lt;130 lbs)</td>
</tr>
<tr>
<td>Men and Women (130-152 lbs)</td>
</tr>
<tr>
<td>Men (152-260 lbs)</td>
</tr>
<tr>
<td>Women (152-200 lbs)</td>
</tr>
<tr>
<td>Men (&gt; 260 lbs)</td>
</tr>
<tr>
<td>Women (&gt;200 lbs)</td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration
https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html
† Some experts recommend a 5/8 inch needle for men and women who weigh <130 lbs, skin must be stretched tightly (do not bunch subcutaneous tissue)

<table>
<thead>
<tr>
<th>Type of Vaccine</th>
<th>Age Group</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heplisav-B®</td>
<td>18 yrs &amp; older</td>
<td>0.5 mL</td>
</tr>
<tr>
<td>Pediatric formulation of Engerix-B® or Recombivax HB®</td>
<td>19 yrs &amp; younger</td>
<td>0.5 mL</td>
</tr>
<tr>
<td>Adult formulation of Engerix-B® or Recombivax HB®</td>
<td>20 yrs &amp; older</td>
<td>1.0 mL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>History of Previous Vaccination</th>
<th>For patients whose previous brand of vaccine is known, continue with the same brand. If brand is unknown or not available, continue with a 3-dose schedule as indicated in the right-hand column</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heplisav-B</td>
<td>Engerix-B or Recombivax HB</td>
</tr>
<tr>
<td>None or unknown</td>
<td>2-dose series at 0 and 1 month</td>
</tr>
<tr>
<td>1 dose</td>
<td>Dose #2 at least 4 wks after dose #1; dose #3 ≥8 wks after dose #2 AND ≥16 wks after dose #1</td>
</tr>
<tr>
<td>2 doses</td>
<td>Dose #3 ≥8 wks after dose #2 AND ≥16 wks after dose #1</td>
</tr>
</tbody>
</table>
Note: safety data on administration during pregnancy are not available for Heplisav-B. Providers should vaccinate pregnant persons with a HepB vaccine from a different manufacturer

Note: revaccination may be recommended for certain populations, including:
- Hemodialysis patients
- Other immunocompromised persons
  Patients must obtain a written order from a privileged provider for these situations

5. Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

7. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

8. This policy and procedure shall remain in effect for all patients of the __________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

______________________________  ______________________
Medical Director's Signature     Date
Standing Order for Administering Hepatitis A / Hepatitis B Combination Vaccine (Adult)

Purpose: To reduce morbidity and mortality from hepatitis A and hepatitis B disease by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

Policy: Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

Procedure
1. Identify all persons ≥18 years of age in need of vaccination against both hepatitis A and hepatitis B based on the following criteria:
   - Lacking documentation of at least 2 doses of hepatitis A vaccine (HepA) and lacking a completed series (2 or 3 doses depending on product) of hepatitis B vaccine (HepB) at the appropriate ages/intervals
   - Anticipated travel to a country with intermediate or high endemicity for hepatitis A and B (generally all except Canada, Japan, Australia, New Zealand, and most of Western Europe; see CDC Yellow Book, TRAVAX, or other travel medicine guidelines)
   - End stage renal disease, hemodialysis; HIV infection; or chronic liver disease, diabetes mellitus (Note: for those age 60 and over with diabetes, at the discretion of the provider)
   - Diagnosis of HIV infection
   - Current or recent use of injectable street drugs
   - Persons at risk for infection by sexual exposure, seeking evaluation or treatment for sexually transmitted infection, sexually active and not in a monogamous relationship, male who has sex with males, sex partner or household member of a person chronically infected with hepatitis B
   - Diagnosis of chronic liver disease, including hepatitis C
   - Persons with occupational risk (e.g., healthcare workers)
   - Residents and staff of facilities for developmentally disabled persons
   - Any other adult who wants to be protected from hepatitis A and B

   Note: if patient has completed either the hepatitis A vaccination series or the hepatitis B vaccination series DO NOT give TWINRIX®: see the applicable monovalent standing order for information

2. Screen all patients for contraindications and precautions to TWINRIX® vaccine:
   Contraindications:
   - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of any hepatitis A or B-containing vaccine, or to any component of the vaccine (including neomycin and yeast)
   - For information on vaccine components, refer to the manufacturer's package insert or go to http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf
Precautions:

- Moderate or moderate or severe acute illness with or without fever
- The tip caps of the prefilled syringes of Twinrix® contain natural rubber latex that may cause allergic reactions in latex sensitive individuals
- Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
- For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must provide both the HepA and HepB VISs as there is no VIS for TWINRIX®. You must document, in the patient’s medical record, the publication date of the VISs and the date they were given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccine as follows:
   - The combination HepA/HepB vaccine (TWINRIX®) consists of a 3-dose series at 0, 1, and 6 months. Administer 1mL intramuscularly in the deltoid muscle for adults.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men and Women (&lt;130 lbs)</td>
<td>1 inch†</td>
<td>Deltoid Muscle of Arm</td>
</tr>
<tr>
<td>Men and Women (130-152 lbs)</td>
<td>1 inch</td>
<td></td>
</tr>
<tr>
<td>Men (152-260 lbs)</td>
<td>1-1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (152-200 lbs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men (&gt; 260 lbs)</td>
<td>1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (&gt;200 lbs)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration [https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html](https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html)

† Some experts recommend a 5/8 inch needle for men and women who weigh <130 lbs, skin must be stretched tightly (do not bunch subcutaneous tissue)

5. Provide subsequent doses of TWINRIX® vaccine to complete each patient’s 3-dose series by observing a minimum interval of 1 month between the 1st and 2nd dose, and 5 months between the 2nd and 3rd dose.
Note: TWINRIX® is also FDA-approved for accelerated dosing (0, 7days, 21-30 days, and 12 months) for impending travel in less than 28 days. This is not recommended by ACIP for routine dosing, and is not covered under these standing orders. Patients must obtain a written order from a privileged provider for this situation.

Note: Interchangeability of TWINRIX® and single antigen Hepatitis A and B vaccines:
- A dose of TWINRIX® contains a standard adult dose of hepatitis B vaccine and a pediatric dose of hepatitis A vaccine. A dose of TWINRIX® can be substituted for any dose of the hepatitis B series but not for any dose of the hepatitis A series.
- Any combination of 3 doses of adult hepatitis B or 3 doses of TWINRIX® is a complete series of hepatitis B vaccine.
- One dose of TWINRIX® and 2 doses of adult hepatitis A is a complete series of hepatitis A vaccine.
- Two doses of TWINRIX® and 1 dose of adult hepatitis A is a complete series of hepatitis A vaccine.

6. Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

7. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

8. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

9. This policy and procedure shall remain in effect for all patients of the ____________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

_________________________________________  ____________________________
Medical Director's Signature              Date
Standing Orders for Administering *Haemophilus influenzae* type b Vaccine (Adult)

**Purpose:** To reduce morbidity and mortality from *Haemophilus influenzae* type b disease by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure:**
1. Identify persons ≥18 years of age in need of vaccination against *Haemophilus influenzae* type b based on the following criteria:
   - Diagnosis of anatomic or functional asplenia (including sickle cell disease) and no documented history of Hib vaccination
   - Patients undergoing elective splenectomy and no documented history of Hib vaccination
   - Recipient of a hematopoietic stem cell transplant

2. Screen all patients for contraindications and precautions to Hib:
   **Contraindications:**
   - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of Hib or to one of its components. For information on vaccine components, refer to the manufacturer’s package insert or go to [http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf](http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf)

   **Precautions:**
   - Moderate or severe acute illness with or without fever
   - The vial stoppers for PedvaxHIB® and the DTaP-IPV-Hib and ActHIB vaccine components of Pentacel® contain natural rubber latex and may cause allergic reactions in latex sensitive individuals
   - Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
   - For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal **Vaccine Information Statement (VIS).** You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at [www.immunize.org/vis](http://www.immunize.org/vis).
4. Provide vaccine as follows:
Follow dosing schedules in table below. Administer 0.5 mL intramuscularly in the deltoid muscle for adults.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men and Women (&lt;130 lbs)</td>
<td>1 inch†</td>
<td>Deltoid Muscle of Arm</td>
</tr>
<tr>
<td>Men and Women (130-152 lbs)</td>
<td>1 inch</td>
<td></td>
</tr>
<tr>
<td>Men (152-260 lbs)</td>
<td>1-1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (152-200 lbs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men (&gt; 260 lbs)</td>
<td>1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (&gt;200 lbs)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration
https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html
† Some experts recommend a 5/8 inch needle for men and women who weigh <130 lbs, skin must be stretched tightly (do not bunch subcutaneous tissue)

<table>
<thead>
<tr>
<th>Medical Indication</th>
<th>Dosing Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Functional or anatomic asplenia</td>
<td>Give 1 dose</td>
</tr>
<tr>
<td>Elective splenectomy</td>
<td>Give 1 dose, preferably at least 14 days before procedure</td>
</tr>
<tr>
<td>Hematopoietic stem cell transplant</td>
<td>Give 3 doses (at least 4 weeks apart) beginning 6–12 months after transplant, regardless of Hib vaccination history</td>
</tr>
</tbody>
</table>

5. Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

7. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

8. This policy and procedure shall remain in effect for all patients of the __________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

______________________________  __________________________
Medical Director’s Signature     Date

Reviewed by DHA-IHD June 2020
Standing Orders for Administering Human Papillomavirus Vaccine (Adult)

**Purpose:** To reduce morbidity and mortality from human papillomavirus (HPV) infection by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure**

1. Identify all persons 18 – 45 years of age who have not completed the HPV vaccination series.

2. Screen all patients for contraindications and precautions to HPV vaccine:
   - **Contraindications:**
     - A history of a severe allergic reaction (e.g., anaphylaxis) after a previous dose of HPV vaccine or to one of its components (including yeast)
     - Pregnancy: delay vaccination until after completion of pregnancy
   - **Precautions:**
     - Moderate or severe acute illness with or without fever
     - Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
     - For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at [www.immunize.org/vis](http://www.immunize.org/vis).

4. Provide vaccine as follows:
   - Routine vaccination is recommended at 11-12 years of age, but can start at 9 years of age if appropriate. The HPV vaccine (GARDASIL 9®) consists of a 2 or 3 dose series depending on age at time of initial vaccination:
     - **Age 9-14 years at initial vaccination:** a 2-dose series at 0 and 6-12 months (minimum interval 5 months; repeat dose if given too soon)
- **Age 15-26 years at initial vaccination (or ages 9-26 with impaired immunity):** a 3-dose series at 0, 2, and 6 months (observe a minimum interval of 4 weeks between the 1st and 2nd doses, 12 weeks between the 2nd and 3rd doses, and at least 5 months between the 1st and 3rd dose: repeat dose if administered too soon)
  - Administer 0.5mL of HPV vaccine intramuscularly in the deltoid muscle for adults

### Needle Length and Injection Site of IM Injections for Adults

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men and Women (&lt;130 lbs)</td>
<td>1 inch†</td>
<td>Deltoid Muscle of Arm</td>
</tr>
<tr>
<td>Men and Women (130-152 lbs)</td>
<td>1 inch</td>
<td></td>
</tr>
<tr>
<td>Men (152-260 lbs)</td>
<td>1-1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (152-200 lbs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men (&gt; 260 lbs)</td>
<td>1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (&gt;200 lbs)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration [https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html](https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html)

† Some experts recommend a 5/8 inch needle for men and women who weigh <130 lbs, skin must be stretched tightly (do not bunch subcutaneous tissue)

5. For persons 18–26 years of age who did not receive HPV vaccine at the ages specified in #4:
   - Administer one dose at the earliest opportunity and then schedule subsequent doses as needed to complete the age-appropriate schedule
   - Minimum intervals are specified in #4

6. For persons 27–45 years of age who have not completed the HPV vaccine series:
   - Catch-up HPV vaccination is not recommended for all adults aged >26 years. Instead, shared clinical decision-making regarding HPV vaccination is recommended for some adults who are not adequately vaccinated
   - Patients should discuss this issue with a privileged provider before vaccination. If HPV vaccine is indicated, provide doses as specified in #5 after receiving a written order from the patient’s provider. This standing order does not cover vaccination of persons 27-45 years of age due to the requirement for shared clinical decision making between the provider and the patient

7. Document all immunizations administered in the patient’s electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.
8. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

9. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

10. This policy and procedure shall remain in effect for all patients of the ____________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

________________________________  ________________________
Medical Director’s Signature                Date
Standing Orders for Administering Inactivated Polio Vaccine (Adult)

**Purpose:** To reduce morbidity and mortality from poliomyelitis by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure:**
1. Identify persons ≥18 years of age in need of vaccination against poliovirus based on the following criteria:
   - Routine poliovirus vaccination of adults in the United States is not necessary. Most adults have a minimal risk for exposure to polioviruses and are immune as a result of childhood vaccination. Vaccination is recommended for certain adults who are at greater risk for exposure to polioviruses than the general population, including the following:
     - basic trainees and other accessions personnel*
     - military personnel outside of accessions settings**
     - travelers to areas or countries where polio is epidemic or endemic
     - members of communities or specific population groups with disease caused by wild polioviruses
     - laboratory workers who handle specimens that might contain polioviruses
     - healthcare workers who have close contact with patients who might be excreting wild polioviruses
     - unvaccinated adults

   *Note: *Receipt of the primary series of IPV may be assumed unless there is a reason to believe otherwise (e.g., childhood spent in a developing country, childhood immunizations not received, etc.)

   **Due to the high level of childhood immunization against the disease, do not screen immunization records for polio immunity after Initial Entry Training except during an outbreak or for clinical purposes

2. Screen all patients for contraindications and precautions to inactivated polio vaccine (IPV):
   **Contraindications:**
   - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of IPV or to a vaccine component (to include neomycin, streptomycin, or polymyxin B)
   - For information on vaccine components, refer to the manufacturer’s package insert or go to http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf
Precautions:
- Moderate or severe acute illness with or without fever
- Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
- For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide IPV (IPOL®) as follows:
- Basic trainees and other accessions personnel: 1 dose
- Individuals traveling OCONUS for > 4 weeks: 1 dose within 12 months of DEPARTURE FROM a polio-affected area (check with latest Force Health Protection guidelines or see CDC Traveler’s Health for updates)
- Unvaccinated adults: a 3-dose series (0, 1-2 and 6-12 months)
- Administer 0.5mL intramuscularly in the deltoid muscle for adults

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men and Women (&lt;130 lbs)</td>
<td>1 inch†</td>
<td>Deltoid Muscle of Arm</td>
</tr>
<tr>
<td>Men and Women (130-152 lbs)</td>
<td>1 inch</td>
<td></td>
</tr>
<tr>
<td>Men (152-260 lbs)</td>
<td>1-1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (152-200 lbs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men (&gt; 260 lbs)</td>
<td>1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (&gt;200 lbs)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

† Some experts recommend a 5/8 inch needle for men and women who weigh <130 lbs, skin must be stretched tightly (do not bunch subcutaneous tissue)

5. If three doses of IPV cannot be administered within the recommended intervals before protection is needed, the following alternatives are recommended:
- If >8 weeks before protection is needed: 3 doses at least 4 weeks apart
- If 4 – 8 weeks before protection is needed: 2 doses at least 4 weeks apart
- If <4 weeks before protection is needed: 1 dose
6. Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

7. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

8. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

9. This policy and procedure shall remain in effect for all patients of the __________________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

_________________________________________  ________________________________
Medical Director’s Signature                Date
Standing Order for Administering Japanese Encephalitis Vaccine (Adult)

**Purpose:** To reduce the morbidity and mortality from Japanese encephalitis (JE) by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure:**
1. Identify all persons ≥18 years of age in need of vaccination against JE based on the following criteria:
   - Vaccination is required for service members and beneficiaries as indicated per Combatant Command (CCMD) force health protection requirements
   - Travelers who plan to spend 1 month or longer in endemic areas (per CDC Yellow Book, TRAVAX, or other travel medicine guidelines) during JE transmission season (including long-term travelers and recurrent travelers based in urban areas but likely to visit endemic or rural or agricultural areas)
   - Short-term (<1 month) travelers to endemic areas during JE transmission season if they plan to travel outside of an urban area and will have increased risk for JE exposure
   - Travelers to an area with ongoing JE outbreak
   - Travelers to endemic area who are uncertain of specific destinations, activities, or duration of travel

2. Screen all persons for contraindications and precautions to the JE vaccine (JE-VC):
   - **Contraindications:**
     - A history of a serious allergic reaction (e.g., anaphylaxis) after a previous dose of JE-VC or to a vaccine component (to include protamine sulfate.) Ask diabetic patients about allergic reactions to their insulin (which may also contain protamine sulfate)
     - For information on vaccine components, refer to the manufacturer’s package insert or go to http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf
   - **Precautions:**
     - Pregnancy: vaccination is generally deferred during pregnancy, though pregnant women traveling to high-risk areas may receive JE-VC if benefit outweighs risk
     - Moderate or severe acute illness with or without fever
     - Syncope (fainting) can occur in association with administration of injectable vaccines Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
     - For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245
Note: although JE-VC vaccination during pregnancy may be warranted, this is an off-label use of the vaccine and is not covered under these standing orders. Patients must obtain a written order from a privileged provider for this situation

3. Provide all persons (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the person’s medical record, the publication date of the VIS and the date it was given to the person (or parent/legal representative). Provide non-English speaking persons with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis

4. Provide vaccine as follows:
   - Follow dosing schedule as below
   - JE-VC (IXIARO®) consists of a 2-dose primary series and a single booster for continued risk
   - Primary series should be completed ≥1 week before travel. Administer 0.5mL intramuscularly in the deltoid muscle for adults.

<table>
<thead>
<tr>
<th>AGE</th>
<th>DOSE</th>
<th>ROUTE</th>
<th>SCHEDULE</th>
<th>BOOSTER†</th>
</tr>
</thead>
<tbody>
<tr>
<td>18–65 y</td>
<td>0.5 mL</td>
<td>IM</td>
<td>0, 7-28 days</td>
<td>≥1 y after primary series</td>
</tr>
<tr>
<td>&gt;65 y</td>
<td>0.5 mL</td>
<td>IM</td>
<td>0, 28 days</td>
<td>≥1 y after primary series</td>
</tr>
</tbody>
</table>

   † If potential for JEV exposure continues

   Needle Length and Injection Site of IM Injections for Adults

   Use a 22 – 25 gauge needle. Choose needle gauge and length appropriate to administration route and the patient’s age and body mass.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men and Women (&lt;130 lbs)</td>
<td>1 inch†</td>
<td>Deltoid Muscle of Arm</td>
</tr>
<tr>
<td>Men and Women (130-152 lbs)</td>
<td>1 inch</td>
<td></td>
</tr>
<tr>
<td>Men (152-260 lbs)</td>
<td>1-1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (152-200 lbs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men (&gt; 260 lbs)</td>
<td>1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (&gt;200 lbs)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

   Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration
   https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html
   † Some experts recommend a 5/8 inch needle for men and women who weigh <130 lbs, skin must be stretched tightly (do not bunch subcutaneous tissue)

5. Document all immunizations administered in the patient’s electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.
6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as appropriate equipment and medications.

7. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

8. This policy and procedure shall remain in effect for all patients of the ______________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

______________________________________________  __________________________
Medical Director's Signature                              Date
Standing Order for Administering Measles-Mumps-Rubella Vaccine (Adult)

Purpose: To reduce morbidity and mortality from measles, mumps, and rubella virus infection by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

Policy: Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

Procedure:
1. Identify all persons ≥18 years of age in need of vaccination against measles, mumps, and rubella (MMR) based on the following criteria:
   - Lack of acceptable evidence of measles, mumps, and rubella immunity (e.g., documentation of 2 doses of MMR vaccine at the appropriate age/interval, positive serologic testing, or born before 1957*)
   - History of two previous doses of MMR and identified by public health as being at increased risk during a mumps outbreak
*Does not apply to healthcare workers

2. Screen all patients for contraindications and precautions to MMR vaccine: Contraindications:
   - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of MMR vaccine or to a vaccine component (to include gelatin and neomycin)
   - For information on vaccine components, refer to the manufacturer’s package insert or go to http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf
   - Pregnancy (or may become pregnant in the next 30 days)
   - Immunosuppression (e.g., cancer or malignant neoplasms, immunosuppressive therapy [to include prolonged high-dose steroid therapy], etc.)
   - HIV infection in children or teens who are severely immunosuppressed as determined by a CD4+ T-lymphocyte count of <200 cells per microliter (or less than 15%)
   - A family history of congenital or hereditary immunodeficiency in first-degree relatives unless immune competence of the potential vaccine recipient has been clinically verified by a laboratory
   - Patients with any concerns about possible immunosuppression (from medical conditions or medications) should be referred to a privileged provider before administration of any live-virus vaccine (such as MMR)

Precautions:
   - Moderate or severe acute illness with or without fever
   - Recent (≤11 months) receipt of an antibody-containing blood product
   - History of thrombocytopenia or thrombocytopenic purpura
   - To prevent potential interference between MMR vaccine and TB testing (skin testing or interferon-gamma release assay [IGRA] testing), possibly causing false-negative results, TB testing should be performed before, on the same day (preferred), or postponed for at least 4 weeks after MMR vaccination
• Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope

• For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccine as follows:
   • MMR vaccine (M-M-R II®) consists of a 2-dose series at 0 and 28 days. Administer 0.5mL subcutaneously in the fatty tissue over the triceps for adults. Use a 23–25 gauge 5/8” needle. If indicated, give dose #2 at least 4 weeks after dose #1.

5. Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

7. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

8. This policy and procedure shall remain in effect for all patients of the ___________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

_________________________________________  __________________________
Medical Director’s Signature                        Date
Standing Orders for Administering Meningococcal ACWY Vaccine (Adult)

Purpose: To reduce morbidity and mortality from meningococcal disease caused by *Neisseria meningitides* serogroups A, C, Y, and W-135 by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

Policy: Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

Procedure
1. Identify persons ≥18 years of age in need of vaccination against meningococcal disease based on any of the following criteria:
   - Diagnosis of persistent complement component deficiency (an immune system disorder which may also be caused by Soliris [eculizumab]), or diagnosis of anatomic or functional asplenia (including sickle-cell disease)
   - Diagnosis of HIV infection
   - Microbiologists who are exposed routinely to *N. meningitidis*
   - Persons with anticipated travel to a country where meningococcal disease is hyperendemic or epidemic (e.g., the “meningitis belt” of sub-Saharan Africa), particularly if contact with the local population will be prolonged (refer to current CDC Yellow Book, TRAVAX, or other travel medicine guidelines)
   - First-year college students 19 - 21 years of age living in a residence hall who were never vaccinated, or who were last vaccinated before 16 years of age
   - Persons who are part of an outbreak attributable to a vaccine serogroup
   - Military recruits

2. Screen all patients for contraindications and precautions to meningococcal vaccine:
   **Contraindication:**
   - A history of a serious allergic reaction (e.g., anaphylaxis) after a previous dose of meningococcal vaccine or to a vaccine component
   **Precaution:**
   - Moderate or severe acute illness with or without fever
   - Pregnancy should not preclude vaccination, if indicated: consult the patient’s PCM for an appropriate order
   - Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
   - For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245
3. Provide all patients (or parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (or parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at [www.immunize.org/vis](http://www.immunize.org/vis).

4. Provide vaccine as follows:
   - Follow dosing schedules in table below
   - Administer 0.5 mL intramuscularly in the deltoid muscle for adults

<table>
<thead>
<tr>
<th>Needle Length and Injection Site of IM Injections for Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use a 22 – 25 gauge needle. Choose needle gauge and length appropriate to administration route and the patient’s age and body mass.</td>
</tr>
<tr>
<td>Age Group</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Men and Women (&lt;130 lbs)</td>
</tr>
<tr>
<td>Men and Women (130-152 lbs)</td>
</tr>
<tr>
<td>Men (152-260 lbs)</td>
</tr>
<tr>
<td>Women (152-200 lbs)</td>
</tr>
<tr>
<td>Men (&gt; 260 lbs)</td>
</tr>
<tr>
<td>Women (&gt;200 lbs)</td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration [https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html](https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html)

† Some experts recommend a 5/8 inch needle for men and women who weigh <130 lbs, skin must be stretched tightly (do not bunch subcutaneous tissue)

<table>
<thead>
<tr>
<th>Routine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Military Recruits</td>
</tr>
<tr>
<td>1st year college students, 19-21 years of age, living in residence halls</td>
</tr>
<tr>
<td>If no history of prior vaccination with MenACWY, give 1 dose</td>
</tr>
<tr>
<td>If history of 1 dose of MenACWY given before 16 years of age, give dose #2; if no previous history of MenACWY, give single dose now</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Travelers to, or residents of, countries where meningococcal disease is epidemic, during an outbreak, or occupational exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults 18 years and older</td>
</tr>
<tr>
<td>Give 1 dose of either MenACWY vaccine</td>
</tr>
<tr>
<td>Boost every 5 years</td>
</tr>
<tr>
<td>Persons with complement component deficiencies or with HIV infection or functional/anatomic asplenia (including sickle cell disease)</td>
</tr>
<tr>
<td>Adults 18 years and older</td>
</tr>
<tr>
<td>Give 2 doses of either MenACWY vaccine 8 weeks apart</td>
</tr>
<tr>
<td>Boost every 5 years</td>
</tr>
</tbody>
</table>

**Note:** While MenACWY Package Inserts state the vaccine is indicated only through 55 years of age, the ACIP recommends meningococcal vaccine for individuals 56 years of age or older at increased risk for meningococcal disease. Either Menactra or Menveo may be used. This represents the current standard of care and is permissible under this standing order.
Note: While MenACWY Package Inserts recommend a single booster vaccination, the ACIP recommends a booster dose every 5 years for high-risk patients, as well as a booster dose for international travelers visiting sub-Saharan Africa (if the last dose was administered 5 or more years previously). This represents the current standard of care and is permissible under this standing order.

Note: In persons with anatomic or functional asplenia and/or HIV infection, MenACWY-D, (Menactra®) and pneumococcal conjugate vaccine (PCV13, (Prevnar13) should not be administered simultaneously PCV13 should be administered first and MenACWY-D should be administered 4 weeks later.

5. Document all immunizations administered in the patient’s electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as appropriate equipment and medications.

7. Adverse Events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can only be submitted to VAERS online. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

8. This policy and procedure shall remain in effect for all patients of the ______________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

______________________________  ________________________________
Medical Director’s Signature    Date
Standing Orders for Administering Meningococcal Group B Vaccine (Adult)

Purpose: To reduce morbidity and mortality from serogroup B meningococcal disease by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

Policy: Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

Procedure:
1. Identify persons 18 – 25 years of age in need of vaccination against serogroup B meningococcal disease based on the following criteria:
   - Persons 18 – 25 years of age with:
     - Diagnosis of persistent complement component deficiency (e.g., deficiencies in C3, C5-9, factor D, factor H, or properdin)
     - Anatomic or functional asplenia
     - Taking eculizumab (Soliris®) or ravulizumab (Ultomiris®)
     - Laboratory staff routinely exposed to Neisseria meningitides
     - Increased risk due to serogroup B meningococcal disease outbreak
   - Persons 18 – 23 years of age not at increased risk who want protection against serogroup B meningococcal disease*

   *Note: the decision to vaccinate persons not at increased risk should be based on shared clinical decision-making: these patients should speak with a privileged provider before vaccination

2. Screen all patients for contraindications and precautions to serogroup B meningococcal vaccine (MenB):
   - Contraindications:
     - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of MenB or to a vaccine component (to include kanamycin)
     - For information on vaccine components, refer to the manufacturer's package insert or go to http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf
   - Precautions:
     - Moderate or severe acute illness with or without fever
     - The tip caps of the prefilled syringes of Bexsero® contain natural rubber latex and may cause allergic reactions in latex sensitive individuals. Trumenba® does not contain latex
     - Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
     - For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245
Note: available data are not sufficient to assess the effects of MenB on persons who are pregnant or nursing. MenB should be used during pregnancy or nursing only if benefit clearly outweighs risk, and is not covered under this standing order. Patients must obtain a written order from a privileged provider for this situation.

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccine as follows:
   - Follow dosing schedule in table below
   - Administer 0.5mL intramuscularly in the deltoid muscle for adults

<table>
<thead>
<tr>
<th>Needle Length and Injection Site of IM Injections for Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use a 22 – 25 gauge needle. Choose needle gauge and length appropriate to administration route and the patient’s age and body mass.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men and Women (&lt;130 lbs)</td>
<td>1 inch†</td>
<td>Deltoid Muscle of Arm</td>
</tr>
<tr>
<td>Men and Women (130-152 lbs)</td>
<td>1 inch</td>
<td></td>
</tr>
<tr>
<td>Men (152-260 lbs)</td>
<td>1-1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (152-200 lbs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men (&gt; 260 lbs)</td>
<td>1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (&gt;200 lbs)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html

† Some experts recommend a 5/8 inch needle for men and women who weigh <130 lbs, skin must be stretched tightly (do not bunch subcutaneous tissue)

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Dose</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bexsero¹ (MenB-4c, GlaxoSmithKline)</td>
<td>0.5mL</td>
<td>Two doses, 4 weeks apart²³</td>
</tr>
<tr>
<td>Trumenba¹ (MenB-FHbp, Pfizer)</td>
<td>0.5mL</td>
<td>Two doses at 0 and 6 months²⁴</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Three doses at 0, 1–2, and 6 months³</td>
</tr>
</tbody>
</table>

¹ The two brands of MenB vaccine are not interchangeable: the series must be started and completed with the same brand of vaccine
² The 2-dose schedules of either Bexsero or Trumenba may be used in healthy persons
³ Either the 2-dose schedule of Bexsero or the 3-dose schedule of Trumenba should be given to persons at increased risk for meningococcal serogroup B disease
⁴ If Dose #2 of the 2-dose Trumenba series is administered earlier than 6 months after Dose #1, a third dose should be administered at least 4 months after Dose #2.

**Note: ACIP recommends:**
- For persons aged ≥10 years with complement deficiency, complement inhibitor use, asplenia, or who are laboratory staff:
  - Booster dose 1 year following completion of a MenB primary series followed by booster doses every 2-3 years as long as increased risk remains
• For persons aged ≥10 years determined by public health officials to be at increased risk during an outbreak:
  o One-time booster dose if it has been ≥1 year since completion of a MenB primary series

These recommendations are off-label uses of the vaccine and are not covered under these standing orders. Patients must obtain a written order from a privileged provider for these situations

5. Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

7. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

8. This policy and procedure shall remain in effect for all patients of the _________________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

__________________________________________  __________________________
Medical Director’s Signature                   Date
Standing Order for Administering Pneumococcal Vaccines (Adult)

Purpose: To reduce morbidity and mortality from pneumococcal disease by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

Policy: Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

Procedure:

1. Identify persons in need of vaccination with pneumococcal conjugate vaccine (PCV13) based on the following criteria:
   - Age 19-64 years with no or unknown history of prior receipt of PCV13 and any of the following underlying conditions (see Table 1):
     - Candidate for or recipient of cochlear implant; cerebrospinal fluid leak
     - Sickle cell disease, hemoglobinopathies, functional or anatomic asplenia (e.g., splenic dysfunction, splenectomy)
     - Immunocompromising condition (e.g., congenital immunodeficiency, HIV infection, hematologic cancers, malignant neoplasms)
     - Immunosuppressive therapy (e.g., chemotherapy, antimetabolites, biologics, high-dose corticosteroids, radiation therapy, etc.)
     - Chronic renal failure or nephrotic syndrome; organ or bone marrow transplantation

2. Identify persons in need of vaccination with pneumococcal polysaccharide vaccine (PPSV23) based on the following criteria:
   - Age 65 years or older with no or unknown history of prior receipt of PPSV23
   - Age 65 years or older and received PPSV23 before age 65 years
   - Age 19 - 64 years with no or unknown history of prior receipt of PPSV23 and any of the following underlying conditions (see Table 1):
     - Any of the conditions in #1
     - Chronic cardiovascular disease (particularly cyanotic congenital heart disease and cardiac failure)
     - Chronic pulmonary disease (asthma is excluded unless treated with high-dose corticosteroid therapy)
     - Diabetes mellitus
     - Chronic liver disease (cirrhosis), or alcoholism (patients 6 - 18 years of age only)
     - Candidate for or recipient of cochlear implant; cerebrospinal fluid leak
     - Sickle cell disease, hemoglobinopathies, anatomic or functional asplenia (splenectomy, splenic dysfunction)
     - Immunocompromising condition (e.g., congenital immunodeficiency, HIV infection, hematologic cancers, malignant neoplasms)
     - Immunosuppressive therapy (e.g., antineoplastic agents, antimetabolites, biologics, high-dose corticosteroids, radiation therapy)
o Chronic renal failure or nephrotic syndrome; organ or bone marrow transplantation
o Environments or settings with increased risk (e.g., long-term care facility)

Table 1. Risk-based Vaccination for Adults age 19 years and older

<table>
<thead>
<tr>
<th>Category of underlying medical condition or other risk factor</th>
<th>Recommended vaccines are marked “x” below</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PCV13: 1 dose¹</td>
</tr>
<tr>
<td>Non-immunocompromising</td>
<td></td>
</tr>
<tr>
<td>Chronic heart disease⁴, chronic lung disease⁵</td>
<td>x</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>x</td>
</tr>
<tr>
<td>Chronic liver disease, cirrhosis</td>
<td>x</td>
</tr>
<tr>
<td>Cigarette smoking</td>
<td>x</td>
</tr>
<tr>
<td>Alcoholism</td>
<td>x</td>
</tr>
<tr>
<td>Cochlear implant, cerebrospinal fluid (CSF) leak</td>
<td>x</td>
</tr>
<tr>
<td>Immunocompromising</td>
<td></td>
</tr>
<tr>
<td>Sickle cell disease, other hemoglobinopathy</td>
<td>x</td>
</tr>
<tr>
<td>Congenital or acquired asplenia</td>
<td>x</td>
</tr>
<tr>
<td>Congenital or acquired immunodeficiency⁶, HIV</td>
<td>x</td>
</tr>
<tr>
<td>Chronic renal failure, nephrotic syndrome</td>
<td>x</td>
</tr>
<tr>
<td>Leukemia, lymphoma</td>
<td>x</td>
</tr>
<tr>
<td>Generalized malignancy, Hodgkin disease</td>
<td>x</td>
</tr>
<tr>
<td>Iatrogenic immunosuppression⁷</td>
<td>x</td>
</tr>
<tr>
<td>Solid organ transplant, multiple myeloma</td>
<td>x</td>
</tr>
</tbody>
</table>

Footnotes
1. PCV13 is recommended as a one-time dose among persons in a risk group not previously vaccinated with PCV13.
2. Administer PPSV23 unless PCV13 is also needed. In that case, give PCV13 first followed by PPSV23 at least 8 weeks later. If PPSV23 was previously given, administer PCV13 at least 1 year after PPSV23.
3. Give a second PPSV 23 at least 5 years after the first PPSV23 and at least 8 weeks after PCV13. However, for adults age 65 years and older, give only one dose of PPSV23.
4. Chronic heart disease includes congestive heart failure and cardiomyopathies; excludes hypertension.
5. Chronic lung disease includes chronic obstructive pulmonary disease, emphysema, and asthma.
6. Congenital or acquired immunodeficiency includes B-(humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease).
7. Iatrogenic immunosuppression includes diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids, and radiation therapy.

Do not give PCV13 and PPSV23 at the same visit

3. Screen all patients for contraindications and precautions to PCV13 or PPSV23 vaccine:

Contraindications:
- A history of a serious reaction (e.g., anaphylaxis) after a previous dose of PCV13 or PPSV23 vaccine, or to a vaccine component. Yeast is now acknowledged as a component of PCV13.
- For information on vaccine components, refer to the manufacturer’s package insert or go to http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf

Precautions:
- Moderate or severe acute illness with or without fever
- Syncope (fainting) can occur in association with administration of injectable vaccines.
Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope for questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1.

4. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

5. Provide vaccines as follows:
   - Follow the dosing schedules in Tables 2 & 3
   - Administer 0.5mL of the appropriate pneumococcal vaccine: both PCV13 and PPSV23 may be given intramuscularly (IM) in the deltoid muscle for adults

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men and Women (&lt;130 lbs)</td>
<td>1 inch†</td>
<td>Deltoid Muscle of Arm</td>
</tr>
<tr>
<td>Men and Women (130-152 lbs)</td>
<td>1 inch</td>
<td></td>
</tr>
<tr>
<td>Men (152-260 lbs)</td>
<td>1-1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (152-200 lbs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men (&gt; 260 lbs)</td>
<td>1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (&gt;200 lbs)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html

† Some experts recommend a 5/8 inch needle for men and women who weigh <130 lbs, skin must be stretched tightly (do not bunch subcutaneous tissue)

Note: As of November 2019, PCV13 vaccine is no longer routinely recommended for all persons > 65 years. The decision to vaccinate should be based upon shared clinical decision making, and is not covered under these standing orders. Patients must obtain a written order from a privileged provider for this situation.

Note: In persons with anatomic or functional asplenia and/or HIV infection, MenACWY-D, (Menactra®) and pneumococcal conjugate vaccine (PCV13 (Prevnar13) should not be administered simultaneously PCV13 should be administered first and MenACWY-D should be administered 4 weeks later.
### Table 2. Routine Vaccination for all Adults ages 65 years and older

<table>
<thead>
<tr>
<th>Age of patient</th>
<th>Vaccine(s) indicated</th>
<th>History of prior vaccination</th>
<th>Schedule for administration of PCV13 &amp; PPSV23</th>
</tr>
</thead>
<tbody>
<tr>
<td>65 yrs or older</td>
<td>PPSV23 PCV13 can be considered for a 1-time dose based on shared clinical decision-making (SCDM)</td>
<td>None or unknown</td>
<td>Administer PPSV23. If PCV13 is also needed based on SCDM, give PCV13 first followed by PPSV23 1 year later</td>
</tr>
<tr>
<td></td>
<td>PPSV23 when younger than age 65 years; 0 or unknown PCV13</td>
<td></td>
<td>Administer another PPSV23 after at least 5 years after previous PCV13. If PCV13 is also needed based on SCDM, administer PCV13 first, followed by PPSV23 1 year later</td>
</tr>
<tr>
<td></td>
<td>PPSV23 when younger than age 65 years; PCV13</td>
<td></td>
<td>Administer another PPSV23 at least 5 years after previous dose of PCV13 and at least 1 year after previous dose of PCV13</td>
</tr>
<tr>
<td></td>
<td>PPSV23 when age 65 years or older; 0 or unknown PCV13</td>
<td></td>
<td>Administer PCV13, if needed based on SCDM, at least 1 year after PPSV23</td>
</tr>
<tr>
<td></td>
<td>0 or unknown PPSV23; PCV13</td>
<td></td>
<td>Administer PPSV23 at least 1 year after PCV13</td>
</tr>
</tbody>
</table>

### Table 3. Risk-based Vaccination schedule for Adults ages 19 years and older

<table>
<thead>
<tr>
<th>Age of patient</th>
<th>Vaccine(s) indicated</th>
<th>History of prior vaccination</th>
<th>Schedule for administration of PCV13 &amp; PPSV23</th>
</tr>
</thead>
<tbody>
<tr>
<td>19–64 years</td>
<td>For medical conditions and other risk factors for which only PPSV23 is indicated (see Table 1)</td>
<td>1 dose PPSV23 None or unknown</td>
<td>Administer PPSV23</td>
</tr>
<tr>
<td></td>
<td>For non-immunocompromising medical conditions for which both PCV13 and PPSV23 are indicated (see Table 1)</td>
<td>1 dose PCV13 and 1 dose PPSV23 0 or unknown</td>
<td>Administer PCV13 followed in 8 weeks by PPSV23</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0 or unknown PPSV23; 1 dose PCV13</td>
<td>Administer PPSV23 at least 8 weeks after PCV13</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 dose PPSV23; 0 or unknown PCV13</td>
<td>Administer PCV13 at least 1 year after PPSV23</td>
</tr>
<tr>
<td></td>
<td>For immunocompromising medical conditions for which both PCV13 and PPSV23 are indicated (see Table 1)</td>
<td>1 dose PCV13 and 2 doses PPSV23 0 or unknown PCV13</td>
<td>Administer PCV13 followed in 8 weeks by PPSV23 #1. Administer PPSV23 #2 at least 5 years after PPSV23 #1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 dose PPSV23; 0 or unknown PCV13</td>
<td>Administer PCV13 at least 1 year after PPSV23 #1. Administer PPSV23 #2 at least 5 years after PPSV23 #1 and at least 8 weeks after PCV13</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0 or unknown PPSV23; 1 dose PCV13</td>
<td>Administer PPSV23 #1 at least 8 weeks after PCV13. Administer PPSV23 #2 at least 5 years after PPSV23 #1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 dose PPSV23; 1 dose PCV13</td>
<td>Administer PPSV23 #2 at least 5 years after PPSV23 #1 and at least 8 weeks after PCV13</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 doses PPSV23; 0 or unknown PCV13</td>
<td>Administer PCV13 at least 1 year after PPSV23 #2</td>
</tr>
<tr>
<td>Age Group</td>
<td>Immunization Schedule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>65 years and older</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 dose PPSV23</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None or unknown PPSV23</td>
<td>Administer PPSV23. If PCV13 is also needed based on SCDM, administer PCV13 first, followed by PPSV23 at least 1 year later.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 dose PPSV23 given before age 65</td>
<td>Administer PPSV23 at least 5 years after previous PPSV23. If PCV13 is needed based on SCDM, administer PCV13 first at least 1 year after previous PPSV23; give PPSV23 at least 1 year after PCV13.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For non-immunocompromising medical conditions for which both PCV13 and PPSV23 are indicated (see Table 1):

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Immunization Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 dose PPSV23 and 1 dose PCV13</td>
<td></td>
</tr>
<tr>
<td>0 or unknown PPSV23; 0 or unknown PCV13</td>
<td>Administer PCV13 followed in at least 8 weeks by PPSV23.</td>
</tr>
<tr>
<td>1 dose PPSV23 before age 65; 0 or unknown PCV13</td>
<td>Administer PCV13 at least 1 year after previous PPSV23; administer PCV13 #2 at least 8 weeks after PCV13 and 5 years after previous PPSV23.</td>
</tr>
<tr>
<td>0 or unknown PPSV23; 1 dose PCV13</td>
<td>Administer PPSV23 at least 8 weeks after PCV13.</td>
</tr>
<tr>
<td>1 dose PPSV23 at/after 65; 0 or unknown PCV13</td>
<td>Administer PCV13 at least 1 year after PPSV23.</td>
</tr>
</tbody>
</table>

For immunocompromising medical conditions for which both PCV13 and PPSV23 are indicated (see Table 1):

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Immunization Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 dose PPSV23 and 1 dose PCV13</td>
<td></td>
</tr>
<tr>
<td>0 or unknown PPSV23; 0 or unknown PCV13</td>
<td>Administer PCV13 followed in 8 weeks by PPSV23.</td>
</tr>
<tr>
<td>0 or unknown PPSV23; 1 dose PCV13</td>
<td>Administer PPSV23 at least 8 weeks after PCV13.</td>
</tr>
<tr>
<td>1 or 2 doses PPSV23 before age 65; 0 or unknown PCV13</td>
<td>Administer PCV13 at least 1 year after prior PPSV23; administer PCV13 at least 5 years after prior PPSV23 and at least 8 weeks after PCV13.</td>
</tr>
<tr>
<td>1 dose PPSV23 at/after 65; 0 or unknown PCV13</td>
<td>Administer PCV13 at least 1 year after PPSV23.</td>
</tr>
</tbody>
</table>

All tables adapted with permission from www.immunize.org/catg.d/p3075.pdf • Item #P3075 (2/20)

6. Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

7. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

8. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

9. This policy and procedure shall remain in effect for all patients of the __________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

Medical Director’s Signature __________________________ Date __________________________
Pneumococcal Vaccine Timing for Adults

Make sure your patients are up to date with pneumococcal vaccination.

Two pneumococcal vaccines are recommended for adults:
- 13-valent pneumococcal conjugate vaccine (PCV13, Prevnar13®)
- 23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumovax®23)

PCV13 and PPSV23 should not be administered during the same office visit.

When both are indicated, PCV13 should be given before PPSV23 whenever possible.

If either vaccine is inadvertently given earlier than the recommended window, do not repeat the dose.

One dose of PCV13 is recommended for adults:
- 19 years or older with certain medical conditions and who have not previously received PCV13. See Table 1 for specific guidance.
- Adults 65 years or older can discuss and decide, with their clinician, to receive PCV13 if they have not previously received a dose (shared clinical decision-making).

One dose of PPSV23 is recommended for adults:
- 65 years or older, regardless of previous history of vaccination with pneumococcal vaccines.
  - Once a dose of PPSV23 is given at age 65 years or older, no additional doses of PPSV23 should be administered.
- 19 through 64 years with certain medical conditions.
  - A second dose may be indicated depending on the medical condition. See Table 1 for specific guidance.

Adults 65 years or older without an immunocompromising condition, CSF* leak, or cochlear implant

For those who have not received any pneumococcal vaccines, or those with unknown vaccination history

If patient and provider decide PCV13 is not to be given:
- Administer 1 dose of PPSV23.

If patient and provider decide PCV13 is to be given:

PCV13 (at ≥ 65 years)  

At least 1 year apart  

PPSV23 (at ≥ 65 years)

- Administer 1 dose of PCV13.
- Administer 1 dose of PPSV23 at least 1 year later.

For those who have previously received 1 dose of PPSV23 at ≥ 65 years and no doses of PCV13

If patient and provider decide PCV13 is not to be given:
- Series complete. No additional doses indicated.

If patient and provider decide PCV13 is to be given:

PPSV23 (at ≥ 65 years)  

At least 1 year apart  

PCV13 (at ≥ 65 years)

- Administer 1 dose of PCV13 at least 1 year after the dose of PPSV23 for all adults, regardless of medical conditions.

*Cerebrospinal fluid leak

www.cdc.gov/pneumococcal/vaccination.html
Pneumococcal vaccine timing for adults with certain medical conditions

### Indicated to receive 1 dose of PPSV23 at 19 through 64 years with no history of pneumococcal vaccination or unknown history

<table>
<thead>
<tr>
<th>PPSV23 (at 19–64 years)</th>
<th>At least 1 year apart</th>
<th>PPSV23 (at ≥ 65 years)</th>
</tr>
</thead>
</table>

If the patient and provider decide (through shared clinical decision-making) PCV13 is **not** to be given at age 65 years or older:

- Administer 1 dose of PPSV23 at 19 through 64 years.
- Administer 1 final dose of PPSV23 at 65 years or older. This dose should be given at least 5 years after the most recent dose of PPSV23.

**Includes adults with:** chronic heart, lung, or liver disease • diabetes mellitus • alcoholism • Also includes adults who smoke cigarettes

### Indicated to receive 1 dose of PCV13 at ≥ 19 years and 1 or 2 doses of PPSV23 at 19 through 64 years

<table>
<thead>
<tr>
<th>PCV13 (at ≥ 19–64 years)</th>
<th>At least 8 weeks apart</th>
<th>PPSV23 (at 19–64 years)</th>
<th>At least 5 years apart</th>
<th>PPSV23 (at 19–64 years)</th>
<th>At least 5 years apart</th>
<th>PPSV23 (at ≥ 65 years)</th>
</tr>
</thead>
</table>

For those who have **not** received any pneumococcal vaccines, or those with unknown vaccination history:

- Administer 1 dose of PCV13.
- Administer 1 dose of PPSV23 at least 8 weeks later.
- Administer a second dose of PPSV23 at least 5 years after the previous dose (*note: a second dose is not indicated for those with CSF leaks or cochlear implants*).
- Administer 1 final dose of PPSV23 at 65 years or older. This dose should be given at least 5 years after the most recent dose of PPSV23.

**Includes adults with:**

- cerebrospinal fluid (CSF) leaks*
- cochlear implants*
- sickle cell disease or other hemoglobinopathies
- congenital or acquired asplenia
- congenital or acquired immunodeficiencies
- HIV infection
- chronic renal failure
- nephrotic syndrome
- leukemia
- lymphoma
- Hodgkin disease
- generalized malignancy
- iatrogenic immunosuppression
- solid organ transplant
- multiple myeloma

*Note: a second dose is not indicated for those with CSF leaks or cochlear implants.*
Table 1. Medical conditions or other indications for administration of PCV13 and PPSV23 for adults

<table>
<thead>
<tr>
<th>Medical indication</th>
<th>Underlying medical condition</th>
<th>PCV13 for ≥ 19 years</th>
<th>PPSV23* for 19 through 64 years</th>
<th>PCV13 at ≥ 65 years</th>
<th>PPSV23 at ≥ 65 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>None of the below</td>
<td>Recommended</td>
<td>Recommended Revaccination</td>
<td>Recommended</td>
<td>If PCV13 has been given, then give PPSV23 ≥1 year after PCV13</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Based on shared clinical decision-making</td>
<td></td>
</tr>
<tr>
<td>Immunocompetent persons</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcoholism</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic heart disease†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic liver disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic lung disease§</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cigarette smoking</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cochlear implants</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSF leaks</td>
<td></td>
<td>✓</td>
<td>≥ 8 weeks after PCV13</td>
<td></td>
<td>≥ 8 weeks after PCV13</td>
</tr>
<tr>
<td>Persons with functional or anatomic asplenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congenital or acquired asplenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sickle cell disease/other hemoglobinopathies</td>
<td></td>
<td>✓</td>
<td>≥ 8 weeks after PCV13</td>
<td>≥ 5 years after first dose PPSV23</td>
<td>≥ 8 weeks after PCV13</td>
</tr>
<tr>
<td>Immunocompromised persons</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic renal failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congenital or acquired immunodeficiencies¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Generalized malignancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV infection</td>
<td></td>
<td>✓</td>
<td>≥ 8 weeks after PCV13</td>
<td>≥ 5 years after first dose PPSV23</td>
<td>≥ 8 weeks after PCV13</td>
</tr>
<tr>
<td>Hodgkin disease</td>
<td></td>
<td>✓</td>
<td>≥ 8 weeks after PCV13</td>
<td>≥ 5 years after first dose PPSV23</td>
<td>≥ 8 weeks after PCV13</td>
</tr>
<tr>
<td>Iatrogenic immunosuppression²</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td></td>
<td>✓</td>
<td>≥ 8 weeks after PCV13</td>
<td>≥ 5 years after first dose PPSV23</td>
<td>≥ 8 weeks after PCV13</td>
</tr>
<tr>
<td>Lymphoma</td>
<td></td>
<td>✓</td>
<td>≥ 8 weeks after PCV13</td>
<td>≥ 5 years after first dose PPSV23</td>
<td>≥ 8 weeks after PCV13</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td></td>
<td>✓</td>
<td>≥ 8 weeks after PCV13</td>
<td>≥ 5 years after first dose PPSV23</td>
<td>≥ 8 weeks after PCV13</td>
</tr>
<tr>
<td>Nephrotic syndrome</td>
<td></td>
<td>✓</td>
<td>≥ 8 weeks after PCV13</td>
<td>≥ 5 years after first dose PPSV23</td>
<td>≥ 8 weeks after PCV13</td>
</tr>
<tr>
<td>Solid organ transplant</td>
<td></td>
<td>✓</td>
<td>≥ 8 weeks after PCV13</td>
<td>≥ 5 years after first dose PPSV23</td>
<td>≥ 8 weeks after PCV13</td>
</tr>
</tbody>
</table>

*This PPSV23 column only refers to adults 19 through 64 years of age. All adults 65 years of age or older should receive one dose of PPSV23 5 or more years after any prior dose of PPSV23, regardless of previous history of vaccination with pneumococcal vaccine. No additional doses of PPSV23 should be administered following the dose administered at 65 years of age or older.‡Diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy

†Including congestive heart failure and cardiomyopathies

§Including chronic obstructive pulmonary disease, emphysema, and asthma

¹Includes B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease)

²Diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy

NCIRDig410 | 03/16/20

Centers for Disease Control and Prevention
Additional scenarios: completing the pneumococcal vaccination series for adults recommended to receive PCV13 ≥ 19 years

- For those who have already received 1 or more doses of PPSV23, or those with unclear documentation of the type of pneumococcal vaccine received:
  - Administer 1 dose of PCV13 at least 1 year after the most recent pneumococcal vaccine dose.
  - Administer a second dose of PPSV23 at least 8 weeks after PCV13 and at least 5 years after the previous dose of PPSV23 (note: a second dose is not indicated for those with CSF leaks or cochlear implants).
  - Administer 1 final dose of PPSV23 at 65 years or older. This dose should be given at least 5 years after the most recent dose of PPSV23.
- For those who have already received 1 dose of PCV13, do not administer an additional dose at 65 years or older.
Standing Order for Administering Pre-Exposure Rabies Vaccine (Adult)

Purpose: To reduce morbidity and mortality from disease caused by Rhabdoviridae Genus Lyssavirus by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

Policy: Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

Procedure
1. Identify individuals (all ages from birth to adult) in need of the pre-exposure prophylaxis rabies vaccine based on the following criteria:
   - Travelers spending a month or longer in an endemic area (especially rural)
   - Frequent risk persons such as veterinarians and their staff, animal handlers, rabies researchers, laboratory staff, spelunkers, or animal control and wildlife officers in areas where rabies is enzootic/epizootic
   - Individuals in need of a booster dose for ongoing protection (e.g., when a rabies titer is non-protective)

Note: This standing order does not cover post-exposure cases, which are a medical urgency. Rabies is associated with the highest case fatality rate of any infectious disease. All patients with a suspected rabid bite or non-bite exposure should seek immediate medical care. Patients should be referred to the local Emergency Department to begin post-exposure treatment and prophylaxis and public health surveillance.

2. Screen all patients for contraindications and precautions to rabies vaccine:
   Contraindications:
   - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of rabies vaccine or to a vaccine component (to include neomycin)
   - For information on vaccine components, refer to the manufacturer’s package insert or go to http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf
   - Immunosuppression (e.g., HIV/AIDS, cancer or malignant neoplasms, immunosuppressive therapy, etc.): patients should postpone pre-exposure vaccinations and consider avoiding activities for which rabies pre-exposure prophylaxis is indicated

Precautions:
   - Moderate or severe acute illness with or without fever
   - Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
   - For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245
3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccine as follows:
   - Rabies vaccine (Imovax®, RabAvert®) for pre-exposure prophylaxis consists of a 3-dose series at 0, 7, and 21-28 days
   - Administer 1mL intramuscularly in the deltoid muscle for adults

<table>
<thead>
<tr>
<th>Needle Length and Injection Site of IM Injections for Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use a 22 – 25 gauge needle. Choose needle gauge and length appropriate to administration route and the patient's age and body mass.</td>
</tr>
<tr>
<td>Age Group</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Men and Women (&lt;130 lbs)</td>
</tr>
<tr>
<td>Men and Women (130-152 lbs)</td>
</tr>
<tr>
<td>Men (152-260 lbs)</td>
</tr>
<tr>
<td>Women (152-200 lbs)</td>
</tr>
<tr>
<td>Men (&gt; 260 lbs)</td>
</tr>
<tr>
<td>Women (&gt;200 lbs)</td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration
https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html
† Some experts recommend a 5/8 inch needle for men and women who weigh <130 lbs, skin must be stretched tightly (do not bunch subcutaneous tissue)

5. Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

7. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

8. This policy and procedure shall remain in effect for all patients of the __________________________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

__________________________________________  ________________________
Medical Director's Signature                  Date

123 Reviewed by DHA-IHD June 2020
Standing Order for Administering Tetanus, Diphtheria and Pertussis Vaccines (Adult)

Purpose: To reduce morbidity and mortality from tetanus, diphtheria and pertussis disease by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

Policy: Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

Procedure
1. Identify patients ≥18 years of age in need of vaccination against tetanus, diphtheria, and pertussis based on the following criteria:
   - Lack of documentation of completion of a diphtheria, tetanus and pertussis toxoid-containing vaccine (DTaP) series
   - Lack of documentation of receiving a routine dose of diphtheria, tetanus and pertussis toxoid-containing vaccine (Tdap) at age 10 years or older
   - Pregnant women who have not received a dose of Tdap during their current pregnancy
   - Recent deep and dirty wound (e.g., contaminated with dirt, feces, saliva) and no record of having received a tetanus toxoid-containing vaccine in the previous 5 years

2. Screen all patients for contraindications and precautions to Td / Tdap vaccine:
   Contraindications:
   - History of a serious reaction (e.g., anaphylaxis) after a previous dose of a tetanus or diphtheria toxoid-containing vaccine or to a vaccine component
   - For information on vaccine components, refer to the manufacturer’s package insert or go to https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf
   - A history of encephalopathy (e.g. coma, decreased level of consciousness, prolonged seizures) within 7 days following DTP/DTaP/Tdap not attributable to another identifiable cause

   Precautions:
   - History of Guillain-Barré syndrome within 6 weeks of a previous dose of tetanus toxoid-containing vaccine
   - History of an Arthus-type hypersensitivity reaction after a previous dose of tetanus or diphtheria toxoid-containing vaccine: defer vaccination until at least 10 years have elapsed since the last tetanus toxoid-containing vaccine
   - Progressive or unstable neurologic disorder, uncontrolled seizures or progressive encephalopathy: defer vaccination until a treatment regimen has been established and the condition has stabilized (Tdap only)
   - Moderate or severe acute illness with or without fever
   - The tip caps of the prefilled syringes of Adacel®† and Boostrix® contain natural rubber latex and may cause allergic reactions in latex sensitive individuals († the tip caps of
some lots of Adacel® prefilled syringes contain latex while others do not – please refer to package insert.

- Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope.
- For questions or concerns, consider consulting the DHA Immunization Healthcare Division at 877-438-8222, Option 1 or DSN 761-4245

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccination as follows:
   - See dosing as below. The routine schedule for Td or Tdap vaccination in adults with no lifetime history of receiving any diphtheria, tetanus, and/or pertussis-containing vaccine is to administer a 3-dose series at 0, 1, and 6–12 month intervals. One of the primary doses should be Tdap (preferably the first dose), followed by a booster (either Td or Tdap) every 10 years.
   - Pregnant women should receive 1 dose of Tdap during each pregnancy, regardless of number of years since prior DTaP, DT, Td or Tdap vaccination. Tdap should be administered at 27–36 weeks’ gestation, preferably during the earlier part of this period (to maximize the maternal antibody response/passive antibody transfer to the infant), although it may be administered at any time during pregnancy.
   - Administer 0.5mL of Td or Tdap vaccine intramuscularly in the deltoid muscle for adults.

<table>
<thead>
<tr>
<th>History of previous DTP, DTaP, Td, or Tdap</th>
<th>Dose and schedule for administration of Td and Tdap**</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 documented doses, or none known</td>
<td>Give Tdap as dose #1. Give dose #2 (Td or Tdap) at least 4 weeks later, and dose #3 (Td or Tdap) 6–12 months after dose #2.</td>
</tr>
<tr>
<td>1 previous dose (not Tdap)</td>
<td>Give Tdap as dose #2 at least 4 weeks after dose #1.</td>
</tr>
<tr>
<td>1 previous dose (Tdap)</td>
<td>Give Td or Tdap as dose #2 at least 4 weeks after dose #1.</td>
</tr>
<tr>
<td>2 previous doses (none Tdap)</td>
<td>Give Tdap as dose #3 at least 6 months after dose #2.</td>
</tr>
<tr>
<td>2 previous doses (including 1 Tdap)</td>
<td>Give dose #3 (Td or Tdap) at least 6 months after dose #2.</td>
</tr>
<tr>
<td>3 or more previous doses (none Tdap)</td>
<td>Give Tdap as soon as possible (you do not need to wait 10 years from previous dose).</td>
</tr>
<tr>
<td>3 or more previous doses (including 1 Tdap)</td>
<td>Give Td or Tdap booster every 10 years unless patient needs prophylaxis for wound management sooner.</td>
</tr>
</tbody>
</table>

Adapted from Immunization Action Coalition: www.immunize.org/catg.d/p3078.pdf • Item #P3078 (3/20)
Needle Length and Injection Site of IM Injections for Adults

Use a 22 – 25 gauge needle. Choose needle gauge and length appropriate to administration route and the patient’s age and body mass.

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men and Women (&lt;130 lbs)</td>
<td>1 inch†</td>
<td>Deltoid Muscle of Arm</td>
</tr>
<tr>
<td>Men and Women (130-152 lbs)</td>
<td>1 inch</td>
<td></td>
</tr>
<tr>
<td>Men (152-260 lbs)</td>
<td>1-1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (152-200 lbs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men (&gt; 260 lbs)</td>
<td>1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (&gt;200 lbs)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration [https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html](https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html)

† Some experts recommend a 5/8 inch needle for men and women who weigh <130 lbs: skin must be stretched tightly (do not bunch subcutaneous tissue)

5. Document all immunizations administered in the patient’s electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

7. Adverse Events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at [https://vaers.hhs.gov](https://vaers.hhs.gov).

8. This policy and procedure shall remain in effect for all patients of the __________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

Medical Director’s Signature __________________________ Date __________________________
Standing Order for Administering Typhoid Vaccine (Adult)

**Purpose:** To reduce morbidity and mortality from disease caused by *Salmonella enterica* serotypes Typhi and Paratyphi by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure:**

1. Identify persons ≥18 years of age in need of vaccination against typhoid fever based on the following criteria:
   - Anticipated travel to areas where there is a recognized risk for exposure to *S. typhi*
   - Persons with intimate exposure (e.g., household contact) to a documented *S. typhi* chronic carrier
   - Laboratory workers routinely exposed to specimens of *S. typhi*, or who work in laboratory environments where these specimens are routinely handled

2. Screen all patients for contraindications and precautions to typhoid vaccine:

   **Contraindications:**
   - Oral typhoid vaccine should not be given to immunocompromised persons
   - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of typhoid vaccine or to a vaccine component
   - For information on vaccine components, refer to the manufacturer’s package insert or go to [http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf](http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf)

   **Precautions:**
   - Oral typhoid vaccine should not be given within 3 days (before or after) of an antimicrobial agent
   - Moderate or severe acute illness with or without fever
   - Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
   - For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

**Note:** available data are not sufficient to assess the effects of typhoid vaccine on persons who are pregnant or nursing. Typhoid vaccine should be used during pregnancy or nursing only if benefit clearly outweighs risk; if indicated, inactivated vaccine (ViCPS) may be considered. This is not covered under this standing order; patients must obtain a written order from a privileged provider for this situation.
3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccine as follows:
   - Follow dosing schedules in table below
   - Patients should complete the Vivotif® regimen ≥1 week prior to exposure; Typhim Vi® should be completed 2 weeks prior to exposure. Vivotif is given orally; Typhim is given intramuscularly in the deltoid muscle for adults

<table>
<thead>
<tr>
<th>Needle Length and Injection Site of IM Injections for Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use a 22 – 25 gauge needle. Choose needle gauge and length appropriate to administration route and the patient’s age and body mass.</td>
</tr>
<tr>
<td>Age Group</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Men and Women (&lt;130 lbs)</td>
</tr>
<tr>
<td>Men and Women (130-152 lbs)</td>
</tr>
<tr>
<td>Men (152-260 lbs)</td>
</tr>
<tr>
<td>Women (152-200 lbs)</td>
</tr>
<tr>
<td>Men (&gt; 260 lbs)</td>
</tr>
<tr>
<td>Women (&gt;200 lbs)</td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html
† Some experts recommend a 5/8 inch needle for men and women who weigh <130 lbs, skin must be stretched tightly (do not bunch subcutaneous tissue)

<table>
<thead>
<tr>
<th>Dosing Schedule for Typhoid Vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccination</td>
</tr>
<tr>
<td>-------------</td>
</tr>
<tr>
<td>Oral, Live, Attenuated Ty21a Vaccine (Vivotif)†</td>
</tr>
<tr>
<td>Primary series</td>
</tr>
<tr>
<td>Booster</td>
</tr>
<tr>
<td>Vi Capsular Polysaccharide Vaccine (Typhim Vi)</td>
</tr>
<tr>
<td>Primary series</td>
</tr>
<tr>
<td>Booster</td>
</tr>
</tbody>
</table>

†The vaccine must be kept refrigerated (35.6 - 46.4°F, 2 - 8°C)
§ Administer with cool liquid no warmer than 98.6°F (37°C)

5. Document all immunizations administered in the patient’s electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.
6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

7. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at [https://vaers.hhs.gov](https://vaers.hhs.gov).

8. This policy and procedure shall remain in effect for all patients of the ____________________________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

_________________________________  ______________________________
Medical Director’s Signature                     Date
Standing Order for Administering Varicella (Chickenpox) Vaccine (Adult)

Purpose: To reduce morbidity and mortality from varicella disease by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

Policy: Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

Procedure:
1. Identify all persons ≥18 years of age in need of varicella vaccination (VAR) based on the following criteria:
   - Lack of acceptable evidence of varicella immunity (e.g., documentation of 2 doses of VAR vaccine at the appropriate age/interval, positive serologic testing, born before 1980*, or diagnosis/verification of a history of varicella or herpes zoster by a healthcare provider)
   - Household and close contacts of immunocompromised persons
   * Does not apply to healthcare personnel

2. Screen all patients for contraindications and precautions to VAR:
   **Contraindications:**
   - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of VAR or to a vaccine component (to include gelatin and neomycin)
   - For information on vaccine components, refer to the manufacturer’s package insert or go to http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf
   - Pregnancy (or may become pregnant in the next 30 days)
   - Immunosuppression (e.g., HIV/AIDS, cancer or malignant neoplasms, immunosuppressive therapy, etc.)
   - HIV-infected persons with CD4+ T-lymphocyte <200cells/µL
   - Family history of congenital or hereditary immunodeficiency in 1st degree relatives (e.g., parents and siblings) unless the immune competence of the potential vaccine recipient has been clinically substantiated or verified by a laboratory

   **Precautions:**
   - Moderate or severe acute illness with or without fever
   - Recent (≤11 months) receipt of an antibody-containing blood product
   - Need for tuberculosis (TB) screening by skin testing or interferon-gamma release assay (IGRA) testing. To prevent potential interference between varicella vaccine and TB testing (possibly causing false-negative TB results), TB testing may be performed before varicella vaccination, on the same day as varicella vaccination (preferred), or postponed for at least 4 weeks after varicella vaccination
   - History of receipt of specific antivirals (i.e., acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination; avoid use of these antiviral drugs for 14 days after vaccination
   - Use of aspirin or aspirin-containing products
• Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope.
• For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccine as follows:
   • VAR (VARIVAX®) consists of a 2-dose series at 0 and 4 weeks (for persons ≥13 years of age)
   • Administer 0.5mL subcutaneously in the preferred site (fatty tissue over the triceps for adults). Use a 23–25 gauge 5/8” needle

5. Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

7. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

8. This policy and procedure shall remain in effect for all patients of the ________________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

_________________________________________    ________________________________
Medical Director’s Signature                     Date
Standing Order for Administering Yellow Fever Vaccine (Adult)

**Purpose:** To reduce morbidity and mortality from yellow fever disease by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

**Procedure**

1. Identify all adults ≥18 years of age in need of vaccination against yellow fever virus (YF) based on the following criteria:
   - Vaccination is required for Service members and beneficiaries as indicated per Combatant Command (CCMD) force health protection requirements

2. Screen all patients for contraindications and precautions to the yellow fever vaccine

**Contraindications:**

- A history of a serious allergic reaction (e.g., anaphylaxis) after a previous dose of YF vaccine or to a vaccine component (to include egg, chicken, or gelatin)
- Immunosuppression (e.g., HIV/AIDS [including those with a CD4 T lymphocyte count <200/mm³ (or <15% of total lymphocytes for children < 6 years), cancer or malignant neoplasms, immunosuppressive therapy, etc.) is a contraindication to receiving the yellow fever vaccine

**Precautions:**

- Moderate or severe acute illness with or without fever
- Adults ≥60 years of age (rate of serious adverse reactions is increased)
- Pregnancy (or may become pregnant in the next 30 days). The safety of YF vaccine has not been studied in any large trials. YF vaccine should be given to a pregnant woman only if clearly needed
- Nursing: because of the potential for serious adverse reactions in nursing infants from YF vaccine, a decision should be made whether to discontinue nursing or not to administer the vaccine, taking into account the importance of the vaccine to the mother
- Need for tuberculosis (TB) screening by skin testing or interferon-gamma release assay (IGRA) testing. To prevent potential interference between yellow fever vaccine and TB testing (possibly causing false-negative TB results), TB testing may be performed before yellow fever vaccination, on the same day as yellow fever vaccination (preferred), or postponed for at least 4 weeks after yellow fever vaccination.
- Asymptomatic HIV infection with CD4 T lymphocyte values 200-499 mm$^3$ (or 15-24% of total lymphocytes for children aged <6 years).
- Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope.
- For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245.

3. Provide all persons (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the person’s medical record, the publication date of the VIS and the date it was given to the person (or parent/legal representative). Provide non-English speaking persons with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.

4. Provide vaccine as follows:
   - YF vaccine (YF-Vax®) consists of a 1-dose series. Administer 0.5mL subcutaneously in the preferred site (fatty tissue over the triceps muscle for adults). Use a 23–25 gauge 5/8” needle.
   - Boosters are not routinely recommended for most travelers. Per the World Health Organization (WHO) and ACIP, a single primary dose of YF vaccine provides long-lasting protection and is adequate for most travelers. However, providers may consider administering a booster dose of YF vaccine for travelers who received their last dose ≥10 years ago if they are going to higher risk settings based on season, location, activities and duration of travel.
   - AFRICOM, SOCOM, and SOUTHCOM do not require booster doses for force health protection requirements.
   - Women who were pregnant when they received their initial dose of YF vaccine should receive 1 additional dose before they are next at risk for YF.
   - Persons who received a hematopoietic stem cell transplant after a dose of YF vaccine should be revaccinated before they are next at risk for YF (as long as they are sufficiently immunocompetent).
   - Persons infected with HIV when they received their last dose of YF vaccine should receive a dose every 10 years if they continue to be at risk for YF as long as they are sufficiently immunocompetent (CD4 T lymphocyte values ≥500/ mm$^3$ or ≥25% of total lymphocytes for children <6 years).
   - Laboratory workers who routinely handle wild-type yellow fever virus should have yellow fever virus-specific neutralizing antibody titers measured at least every 10 years to determine the need for additional doses of YF vaccine.
5. The vaccine powder must be reconstituted immediately before use with the diluent supplied. Allow the reconstituted vaccine to sit for 1-2 minutes and then carefully swirl mixture until uniform suspension is achieved. Avoid vigorous shaking as this tends to cause foaming of the suspension. Once reconstituted, the vaccine should be maintained at 2°C–8°C and should be used or discarded within 1 hour. YF vaccine should be administered at least 10 days before travel.

6. Document all immunizations administered in the patient’s electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

7. International health regulation requires persons who receive YF vaccine to provide proof of vaccination on an International Certificate of Vaccination of Prophylaxis (ICVP). The CDC 731 form fulfills this requirement for vaccines received in the US, which must have a certified uniform stamp. A certificate of vaccination is considered valid 10 days after vaccination and for the life of the patient.

8. International health regulation requires additional documentation from persons with contraindications to receipt of YF vaccine before travel to yellow-fever endemic areas.

9. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as appropriate equipment and medications.

10. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

11. This policy and procedure shall remain in effect for all patients of the ________________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

________________________________________  ________________________
Medical Director’s Signature                     Date

Reviewed by DHA-IHD June 2020
Standing Order for Administering Zoster Vaccine (Adult)

Purpose: To reduce morbidity and mortality from herpes zoster (shingles) disease by vaccinating all persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

Policy: Under these standing orders, eligible nurses and other health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

Procedure
1. Identify adults ≥50 years of age in need of vaccination against shingles.

   Note: SHINGRIX® (RZV) is preferred over ZOSTAVAX® (ZVL). ACIP recommends patients previously vaccinated with ZVL receive RZV, observing a minimum interval of ≥8 weeks between ZVL and RZV doses

2. Screen all patients for contraindications and precautions to RZV

   Contraindications:
   - A history of a serious reaction (e.g., anaphylaxis) after a previous dose of RZV or to a vaccine component (to include Quillaja saponaria [QS-21] or monophosphoryl A)
   - For information on vaccine components, refer to the manufacturer’s package insert or go to http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf

   Precautions:
   - An acute episode of herpes zoster: RZV is not a treatment for herpes zoster or post-herpetic neuralgia
   - Pregnancy and breastfeeding: no available data. Consider delaying vaccination with RZV in such circumstances
   - Moderate or severe acute illness with or without fever
   - Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid a falling injury (e.g. 15 minute observation after administration) and to restore cerebral perfusion following syncope
   - For questions or concerns, consider consulting the DHA Immunization Healthcare Division at (877) 438-8222, Option 1 or DSN 761-4245

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). You must document, in the patient’s medical record, the publication date of the VIS and the date it was given to the patient (parent/legal representative). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred; these can be found at www.immunize.org/vis.
4. Provide vaccine as follows:
   - RZV (SHINGRIX®) consists of a 2-dose series at 0 and 2-6 months. Administer 0.5mL intramuscularly in the deltoid muscle for adults

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men and Women (&lt;130 lbs)</td>
<td>1 inch†</td>
<td>Deltoid Muscle of Arm</td>
</tr>
<tr>
<td>Men and Women (130-152 lbs)</td>
<td>1 inch</td>
<td></td>
</tr>
<tr>
<td>Men (152-260 lbs)</td>
<td>1-1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (152-200 lbs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men (&gt; 260 lbs)</td>
<td>1.5 inches</td>
<td></td>
</tr>
<tr>
<td>Women (&gt;200 lbs)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adapted from General Best Practice Guidelines for Immunization: Vaccine Administration
https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html
† Some experts recommend a 5/8 inch needle for men and women who weigh <130 lbs, skin must be stretched tightly (do not bunch subcutaneous tissue)

*Note: In the event of an invalid dose, RZV should be administered 28 days after the invalid dose to reduce the burden of adverse reactions which occur with this vaccine*

5. Document all immunizations administered in the patient’s electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.

6. Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.

7. Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS). Reports can be submitted to VAERS online, by fax, or by mail. Additional information about VAERS is available by telephone (800-822-7967) or online at https://vaers.hhs.gov.

8. This policy and procedure shall remain in effect for all patients of the _________________________________ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

Medical Director’s Signature ________________________________ Date ____________________________
Immunization Resources

Administering Vaccines: Dose, Route, Site, and Needle Size
How to Administer Intramuscular and Subcutaneous Vaccine Injections
Medical Management of Vaccine Reactions in Adult Patients
Medical Management of Vaccine Reactions in Children and Teens
Recommended and Minimum Ages and Intervals between Doses
Routine Screening Form - Pediatric
Routine Screening Form – Adult
Offsite Vaccination Clinic Checklist – Best Practices
Recommended Immunization Schedules for Persons Aged 0 through 18 years
Recommended Adult Immunization Schedule
Administering Vaccines to Adults: Dose, Route, Site, and Needle Size

## Vaccine Dose Route

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Dose</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthrax (AVA)</td>
<td>0.5mL</td>
<td>IM</td>
</tr>
<tr>
<td>Hepatitis A (HepA)</td>
<td>≤18 yrs: 0.5mL; ≥19 yrs: 1mL</td>
<td>IM</td>
</tr>
<tr>
<td>Hepatitis B (HepB)</td>
<td>Engerix-B, Recombivax HB ≤20 yrs: 1mL; ≥19 yrs: 0.5mL</td>
<td>IM</td>
</tr>
<tr>
<td>HepA and HepB (HepA/B)</td>
<td>≥18 yrs: 1mL</td>
<td>IM</td>
</tr>
<tr>
<td>Human papillomavirus (HPV)</td>
<td>0.5mL</td>
<td>IM</td>
</tr>
<tr>
<td>Influenza, live attenuated (LAIV)</td>
<td>0.2mL (0.1mL in each nostril)</td>
<td>NAS</td>
</tr>
<tr>
<td>Influenza, inactivated (IIV) and recombinant (RIV)</td>
<td>0.5mL</td>
<td>IM</td>
</tr>
<tr>
<td>Japanese encephalitis (JE-VC)</td>
<td>0.5mL</td>
<td>IM</td>
</tr>
<tr>
<td>Measles, Mumps, Rubella (MMR)</td>
<td>0.5mL</td>
<td>SC</td>
</tr>
<tr>
<td>Meningococcal serogroups A, C, W, Y (MCV4)</td>
<td>0.5mL</td>
<td>IM</td>
</tr>
<tr>
<td>Meningococcal serogroup B (MenB)</td>
<td>0.5mL</td>
<td>IM</td>
</tr>
<tr>
<td>Rabies (RAB)</td>
<td>0.5mL</td>
<td>IM</td>
</tr>
<tr>
<td>Smallpox (SPV)</td>
<td>15 jabs</td>
<td>PC</td>
</tr>
<tr>
<td>Tetanus, Diphtheria (Td); with Pertussis (Tdap)</td>
<td>0.5mL</td>
<td>IM</td>
</tr>
<tr>
<td>Typhoid (ViCPS)</td>
<td>0.5mL</td>
<td>IM</td>
</tr>
<tr>
<td>Varicella (VAR)</td>
<td>0.5mL</td>
<td>SC</td>
</tr>
<tr>
<td>Yellow Fever (YF-Vax)</td>
<td>0.5mL</td>
<td>SC</td>
</tr>
</tbody>
</table>

### Injection Site and Needle Size

**Subcutaneous (SC) injection** – Use a 23–25 gauge, 5/8” needle. Inject in fatty tissue over triceps.

**Intramuscular (IM) injection** – Use a 22–25 gauge needle. Inject in deltoid muscle of arm. Choose the needle length as indicated below:

<table>
<thead>
<tr>
<th>Gender/Weight</th>
<th>Needle Length</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female or male less than 130 lbs</td>
<td>5/8”–1”</td>
</tr>
<tr>
<td>Female or male 130–152 lbs</td>
<td>1”</td>
</tr>
<tr>
<td>Female 153–200 lbs</td>
<td>1–1 1/2”</td>
</tr>
<tr>
<td>Male 153–260 lbs</td>
<td>1 1/2”</td>
</tr>
<tr>
<td>Female 200+ lbs</td>
<td>1 1/2”</td>
</tr>
<tr>
<td>Male 260+ lbs</td>
<td>1 1/2”</td>
</tr>
</tbody>
</table>

* A 5/8” needle may be used for patients weighing less than 130 lbs (<60 kg) for IM injection in the deltoid muscle. ONLY if the subcutaneous tissue is not bunched AND the injection is made at a 90-degree angle.

**Note:** Always refer to the package insert included with each biologic for complete vaccine administration information. CDC’s Advisory Committee on Immunization Practices (ACIP) recommendations for the particular vaccine should be reviewed as well:

https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html.

**Adapted from Immunization Action Coalition:**
www.immunize.org/catg.d/p2020a.pdf • Item #P2020a (1/18)
www.immunize.org/catg.d/p3084.pdf • Item #P3084 (10/18)

**Reviewed by DHA Immunization Healthcare Division 6/1/2019**
How to Administer Intramuscular and Subcutaneous Vaccine Injections to Adults

Intramuscular (IM) Injections

Administer these vaccines via IM route
- *Haemophilus influenzae* type b (Hib)
- Hepatitis A (HepA)
- Hepatitis B (HepB)
- Human papillomavirus (HPV)
- Influenza vaccine, injectable (IIV)
- Influenza vaccine, recombinant (RIV3; RIV4)
- Meningococcal conjugate (MenACWY)
- Meningococcal serogroup B (MenB)
- Pneumococcal conjugate (PCV13)
- Pneumococcal polysaccharide (PPSV23) – may also be given Subcut
- Polio (IPV) – may also be given Subcut
- Tetanus, diphtheria (Td), or with pertussis (Tdap)
- Zoster, recombinant (RZV; Shingrix)

Injection site
Give in the central and thickest portion of the deltoid muscle – above the level of the armpit and approximately 2–3 fingerbreadths (~2") below the acromion process. See the diagram. To avoid causing an injury, do not inject too high (near the acromion process) or too low.

Needle size
22–25 gauge, 1–1½" needle (see note at right)

Needle insertion
- Use a needle long enough to reach deep into the muscle.
- Insert the needle at a 90° angle to the skin with a quick thrust.
- Separate two injections given in the same deltoid muscle by a minimum of 1".

Subcutaneous (Subcut) Injections

Administer these vaccines via Subcut route
- Measles, mumps, rubella (MMR)
- Pneumococcal polysaccharide (PPSV23) – may also be given IM
- Polio (IPV) – may also be given IM
- Varicella (Var; chickenpox)
- Zoster, live (ZVL; Zostavax)

Injection site
Give in fatty tissue over the triceps. See the diagram.

Needle size
23–25 gauge, 5/8" needle

Needle insertion
- Pinch up on the tissue to prevent injection into the muscle. Insert the needle at a 45° angle to the skin.
- Separate two injections given in the same area of fatty tissue by a minimum of 1".

Note: A ⅝" needle is sufficient in adults weighing less than 130 lbs (<60 kg) for IM injection in the deltoid muscle only if the subcutaneous tissue is not bunched and the injection is made at a 90° angle; a 1" needle is sufficient in adults weighing 130–152 lbs (60–70 kg); a 1–1½" needle is recommended in women weighing 153–200 lbs (70–90 kg) and men weighing 153–260 lbs (70–118 kg); a 1½" needle is recommended in women weighing more than 200 lbs (91 kg) or men weighing more than 260 lbs (more than 118 kg).
Medical Management of Vaccine Reactions in Adults in a Community Setting

Administering any medication, including vaccines, has the potential to cause an adverse reaction. To minimize the likelihood of an adverse event, screen patients for vaccine contraindications and precautions prior to vaccination (see “Screening Checklist for Contraindications to Vaccines for Adults” at www.immunize.org/catg.d/p4065.pdf). When adverse reactions do occur, they can vary from minor (e.g., soreness, itching) to the rare and serious (e.g., anaphylaxis). Be prepared.

Vaccine providers should know how to recognize allergic reactions, including anaphylaxis. Have a plan in place and supplies available to provide appropriate medical care should such an event occur.

<table>
<thead>
<tr>
<th>REACTION</th>
<th>SIGNS AND SYMPTOMS</th>
<th>MANAGEMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Localized</td>
<td>Soreness, redness, itching, or swelling at the injection site</td>
<td>Apply a cold compress to the injection site. Consider giving an analgesic (pain reliever) or antipruritic (anti-itch) medication.</td>
</tr>
<tr>
<td></td>
<td>Slight bleeding</td>
<td>Apply pressure and an adhesive compress over the injection site.</td>
</tr>
<tr>
<td></td>
<td>Continuous bleeding</td>
<td>Place thick layer of gauze pads over site and maintain direct and firm pressure; raise the bleeding injection site (e.g., arm) above the level of the patient’s heart.</td>
</tr>
<tr>
<td>Psychological fright, presyncope, and syncope (fainting)</td>
<td>Fright before injection is given</td>
<td>Have patient sit or lie down for the vaccination.</td>
</tr>
<tr>
<td></td>
<td>Patient feels “faint” (e.g., light-headed, dizzy, weak, nauseated, or has visual disturbance)</td>
<td>Have patient lie flat. Loosen any tight clothing and maintain open airway. Apply cool, damp cloth to patient’s face and neck. Keep them under close observation until full recovery.</td>
</tr>
<tr>
<td>Fall, without loss of consciousness</td>
<td></td>
<td>Examine the patient to determine if injury is present before attempting to move the patient. Place patient flat on back with feet elevated.</td>
</tr>
<tr>
<td>Loss of consciousness</td>
<td></td>
<td>Check to determine if injury is present before attempting to move the patient. Place patient flat on back with feet elevated. Call 911 if patient does not recover immediately.</td>
</tr>
<tr>
<td>Anaphylaxis</td>
<td>Skin and mucosal symptoms such as generalized hives, itching, or flushing; swelling of lips, face, throat, or eyes. Respiratory symptoms such as nasal congestion, change in voice, sensation of throat closing, stridor, shortness of breath, wheeze, or cough. Gastrointestinal symptoms such as nausea, vomiting, diarrhea, cramping abdominal pain. Cardiovascular symptoms such as collapse, dizziness, tachycardia, hypotension.</td>
<td>See the emergency medical protocol on the next page for detailed steps to follow in treating anaphylaxis.</td>
</tr>
</tbody>
</table>

continued on next page
Suggested Medications for Managing Anaphylaxis in a Community Immunization Clinic Setting

**FIRST-LINE medication**
- **Epinephrine**: 1.0 mg/mL aqueous solution (1:1000 dilution) in prefilled autoinjector or prefilled syringe (0.3 mg), prepackaged syringes, vials, or ampules. At least three epinephrine doses should be available onsite.
- **Diphenhydramine**: (e.g., Benadryl) oral, 12.5 mg/5 mL liquid, 25 or 50 mg tablets

**OPTIONAL medications: H1 antihistamines**
- These relieve itching and hives only; they DO NOT relieve upper or lower airway obstruction, hypotension, or shock.
- **Alcohol wipes**
- **Tourniquet**

**Additional emergency supplies you may need**
- **Syringes** (1 and 3 cc) and needles (22 and 25 g, 1”, 1½”, and 2”) if needed for epinephrine
- **Blood pressure measuring device with adult-sized and extra-large cuffs**
- **Tongue depressors**
- **Light with extra batteries** (for examination of the mouth and throat)
- **A timing device**, such as wristwatch, for checking pulse
- **Cell phone or access to onsite phone**

**For remote areas without EMS support**
- **Adult airways** (various sizes)
- **Adult-sized pocket mask with one-way valve**
- **Oxygen** (if available)

**Emergency medical protocol for management of anaphylactic reactions in adults in a community setting**

1. If itching and swelling are confined to the injection site where the vaccination was given, observe patient closely for the development of generalized symptoms.
2. If symptoms are generalized, activate the emergency medical system (EMS; e.g., call 911) and notify the patient’s physician. This should be done by a second person, while the primary healthcare professional assesses the airway, breathing, circulation, and level of consciousness of the patient. Vital signs should be monitored continuously.

3. **DRUG DOSING INFORMATION:** The first-line and most important therapy in anaphylaxis is epinephrine. There are NO absolute contraindications to epinephrine in the setting of anaphylaxis.

   a. **First-line treatment: EPINEPHRINE** is the first-line treatment for anaphylaxis, and there is no known equivalent substitute. Use epinephrine in a 1.0 mg/mL aqueous solution (1:1000 dilution). Administer a 0.3 mg dose IM using a premeasured or prefilled syringe or an autoinjector in the mid-outer thigh. If using another epinephrine formulation, the recommended dose is 0.01 mg/kg, ranging for adults from 0.3 mg to maximum dose of 0.5 mg. Administer IM, preferably in the mid-outer thigh. Epinephrine dose may be repeated 2 additional times every 5–15 minutes (or sooner as needed) while waiting for EMS to arrive.

   b. **Optional treatment: H1 antihistamines** relieve itching and urticaria (hives). These medications DO NOT relieve upper or lower airway obstruction, hypotension, or shock. Consider giving diphenhydramine (e.g., Benadryl) for relief of itching and hives. Administer orally 1–2 mg/kg every 4–6 hours, up to a maximum single dose of 100 mg.

4. Monitor the patient closely until EMS arrives. Perform cardiopulmonary resuscitation (CPR), if necessary, and maintain airway. Keep patient in recumbent position (flat on back) unless he or she is having breathing difficulty. If breathing is difficult, patient’s head may be elevated, provided blood pressure is adequate to prevent loss of consciousness. If blood pressure is low, elevate legs. Monitor blood pressure and pulse every 5 minutes.

5. Record the patient’s reaction (e.g., hives, anaphylaxis) to the vaccine, all vital signs, medications administered to the patient, including the time, dosage, response, and the name of the medical personnel who administered the medication, and other relevant clinical information.


**REFERENCES**

- Campbell RL, Kelso JM. Anaphylaxis: Emergency treatment. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. November 2018.

---

**Immunization Action Coalition** • Saint Paul, Minnesota • 651-647-9009 • www.immunize.org • www.vaccineinformation.org
Medical Management of Vaccine Reactions in Children and Teens in a Community Setting

Administering any medication, including vaccines, has the potential to cause an adverse reaction. To minimize the likelihood of an adverse event, screen patients for vaccine contraindications and precautions prior to vaccination (see “Screening Checklist for Contraindications to Vaccines for Children and Teens” at www.immunize.org/catg.d/p4060.pdf). When adverse reactions do occur, they can vary from minor (e.g., soreness, itching) to the rare and serious (e.g., anaphylaxis). Be prepared.

Vaccine providers should know how to recognize allergic reactions, including anaphylaxis. Have a plan in place and supplies available to provide appropriate medical care should such an event occur.

The table below describes steps to take if an adverse reaction occurs following vaccination.

<table>
<thead>
<tr>
<th>REACTION</th>
<th>SIGNS AND SYMPTOMS</th>
<th>MANAGEMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Localized</td>
<td>Soreness, redness, itching, or swelling at the injection site</td>
<td>Apply a cold compress to the injection site. Consider giving an analgesic (pain reliever) or antipruritic (anti-itch) medication.</td>
</tr>
<tr>
<td></td>
<td>Slight bleeding</td>
<td>Apply pressure and an adhesive compress over the injection site.</td>
</tr>
<tr>
<td></td>
<td>Continuous bleeding</td>
<td>Place thick layer of gauze pads over site and maintain direct and firm pressure; raise the bleeding injection site (e.g., arm) above the level of the patient’s heart.</td>
</tr>
<tr>
<td>Psychological fright and syncope (fainting)</td>
<td>Fright before injection is given</td>
<td>Have patient sit or lie down for the vaccination.</td>
</tr>
<tr>
<td></td>
<td>Paleness, sweating, coldness of the hands and feet, nausea, light-headedness, dizziness, weakness, or visual disturbances</td>
<td>Have patient lie flat. Loosen any tight clothing and maintain open airway. Apply cool, damp cloth to patient’s face and neck. Keep them under close observation until full recovery.</td>
</tr>
<tr>
<td></td>
<td>Fall, without loss of consciousness</td>
<td>Examine the patient to determine if injury is present before attempting to move the patient. Place patient flat on back with feet elevated.</td>
</tr>
<tr>
<td></td>
<td>Loss of consciousness</td>
<td>Check to determine if injury is present before attempting to move the patient. Place patient flat on back with feet elevated. Call 911 if patient does not recover immediately.</td>
</tr>
<tr>
<td>Anaphylaxis</td>
<td>Skin and mucosal symptoms such as generalized hives, itching, or flushing; swelling of lips, face, throat, or eyes.</td>
<td>See the emergency medical protocol on the next page for detailed steps to follow in treating anaphylaxis. Respiratory symptoms such as nasal congestion, change in voice, sensation of throat closing, stridor, shortness of breath, wheeze, or cough. Gastrointestinal symptoms such as nausea, vomiting, diarrhea, cramping abdominal pain. Cardiovascular symptoms such as collapse, dizziness, tachycardia, hypotension.</td>
</tr>
</tbody>
</table>

CONTINUED ON NEXT PAGE
**Emergency medical protocol for management of anaphylactic reactions in children and teens in a community setting**

1. If itching and swelling are confined to the injection site where the vaccination was given, observe patient closely for the development of generalized symptoms.

2. If symptoms are generalized, activate the emergency medical system (EMS; e.g., call 911) and notify the patient’s physician. This should be done by a second person, while the primary healthcare professional assesses the airway, breathing, circulation, and level of consciousness of the patient. Vital signs should be monitored continuously.

3. **Drug dosing information:** The first-line and most important therapy in anaphylaxis is epinephrine. There are NO absolute contraindications to epinephrine in the setting of anaphylaxis.

   a. **First-line treatment: Epinephrine is the first-line treatment for anaphylaxis, and there is no known equivalent substitute.** Use epinephrine in a 1.0 mg/mL aqueous solution (1:1000 dilution). See page 3 to determine correct dose to be used based on child’s weight. If using an autoinjector or pre-filled syringe, administer a dose of 0.1 mg, 0.15 mg, or 0.3 mg IM (as appropriate for the patient’s weight) into the anterolateral thigh. If using another epinephrine format, the recommended dose is 0.01 mg/kg per dose, up to a maximum single dose of 0.5 mg. Administer IM, preferably in the anterolateral thigh. Epinephrine dose may be repeated every 5–15 minutes (or sooner as needed) while waiting for EMS to arrive.

   b. **Optional treatment: H1 antihistamines** relieve itching and urticaria (hives). These medications DO NOT relieve upper or lower airway obstruction, hypotension, or shock. Consider giving diphenhydramine (e.g., Benadryl) or hydroxyzine (e.g., Atarax, Vistaril) for relief of itching or hives.

      - Administer diphenhydramine orally, standard dose of 1–2 mg/kg every 4–6 hours. Maximum single dose is 40 mg for children age <12 years; for children age ≥12 years, 100 mg. See dosing chart on page 3.

      - Administer hydroxyzine orally; the standard dose is 0.5–1 mg/kg/dose, up to 50–100 mg maximum per day in children and adolescents. See dosing chart on page 3.

4. Monitor the patient closely until EMS arrives. Perform cardiopulmonary resuscitation (CPR), if necessary, and maintain airway. Keep patient in recumbent position (flat on back) unless he or she is having breathing difficulty. If breathing is difficult, patient’s head may be elevated, provided blood pressure is adequate to prevent loss of consciousness. If blood pressure is low, elevate legs. Monitor blood pressure and pulse every 5 minutes.

5. Record the patient’s reaction (e.g., hives, anaphylaxis) to the vaccine, all vital signs, medications administered to the patient, including the time, dosage, response, and the name of the medical personnel who administered the medication, and other relevant clinical information.


---

**REFERENCES**


Campbell RL, Kelso JM. Anaphylaxis: Emergency treatment. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. November 2018.

For your convenience, approximate dosages based on weight and age are provided in the following charts. Please confirm that you are administering the correct dose for your patient.

<table>
<thead>
<tr>
<th>First-Line Treatment: Epinephrine</th>
<th>Epinephrine Dose</th>
</tr>
</thead>
</table>
| **Recommended dose**
| is 0.01 mg/kg body weight up to 0.5 mg maximum dose. May be repeated every 5–15 minutes (or sooner) up to 3 times while waiting for EMS to arrive. |
| **Infants and children** | **Range of weight (lb)** | **Range of weight (kg)** |
| 1–6 months | 9–19 lb | 4–8.5 kg |
| 7–36 months | 20–32 lb† | 9–14.5 kg† |
| 37–59 months | 33–39 lb | 15–17.5 kg |
| 5–7 years | 40–56 lb | 18–25.5 kg |
| 8–10 years | 57–76 lb | 26–34.5 kg |
| **Teens** | **Range of weight (lb)** | **Range of weight (kg)** |
| 11–12 years | 77–99 lb | 35–45 kg |
| 13 years & older | 100+ lb | 46+ kg |
| **Note:** If body weight is known, then dosing by weight is preferred. If weight is not known or not readily available, dosing by age is appropriate. |

<table>
<thead>
<tr>
<th>Optional Treatment: Diphenhydramine</th>
<th>Diphenhydramine dose calculations based on 1 mg/kg†</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>commonly known as Benadryl</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Recommended dose</strong> is 1–2 mg/kg body weight every 4–6 hrs†</td>
<td></td>
</tr>
<tr>
<td><strong>Infants and children</strong></td>
<td><strong>Range of weight (lb)</strong></td>
</tr>
<tr>
<td>7–36 months</td>
<td>20–32 lb</td>
</tr>
<tr>
<td>37–59 months</td>
<td>33–39 lb</td>
</tr>
<tr>
<td>5–7 years</td>
<td>40–56 lb</td>
</tr>
<tr>
<td>8–12 years</td>
<td>57–76 lb</td>
</tr>
<tr>
<td><strong>Teens</strong></td>
<td><strong>Range of weight (lb)</strong></td>
</tr>
<tr>
<td>13 years &amp; older</td>
<td>100+ lb</td>
</tr>
<tr>
<td><strong>Note:</strong> If body weight is known, then dosing by weight is preferred. If weight is not known or not readily available, dosing by age is appropriate.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Optional Treatment: Hydroxyzine</th>
<th>Hydroxyzine dose calculations based on 0.5 mg/kg†</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>commonly known as Atarax, Vistaril</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Recommended oral dose</strong> is 0.5–1 mg/kg body weight every 4–6 hrs†</td>
<td></td>
</tr>
<tr>
<td><strong>Infants and children</strong></td>
<td><strong>Range of weight (lb)</strong></td>
</tr>
<tr>
<td>7–36 months</td>
<td>20–32 lb</td>
</tr>
<tr>
<td>37–59 months</td>
<td>33–39 lb</td>
</tr>
<tr>
<td>5–7 years</td>
<td>40–56 lb</td>
</tr>
<tr>
<td>8–12 years</td>
<td>57–76 lb</td>
</tr>
<tr>
<td><strong>Teens</strong></td>
<td><strong>Range of weight (lb)</strong></td>
</tr>
<tr>
<td>11–12 years</td>
<td>77–99 lb</td>
</tr>
<tr>
<td>13 years &amp; older</td>
<td>100+ lb</td>
</tr>
<tr>
<td><strong>Note:</strong> If body weight is known, then dosing by weight is preferred. If weight is not known or not readily available, dosing by age is appropriate.</td>
<td></td>
</tr>
</tbody>
</table>

This policy and procedure shall remain in effect for all patients of the name of practice effective __________ until rescinded or until __________. Medical Director

Immunization Action Coalition • Saint Paul, Minnesota • 651-647-9009 • www.immunize.org • www.vaccineinformation.org

www.immunize.org/catg.d/p3082a.pdf • Item #P3082a (7/19)
<table>
<thead>
<tr>
<th>Vaccine and dose number</th>
<th>Recommended age for this dose</th>
<th>Minimum age for this dose</th>
<th>Recommended interval to next dose</th>
<th>Minimum interval to next dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphtheria-tetanus-acellular pertussis (DTaP)-1&lt;sup&gt;5&lt;/sup&gt;</td>
<td>2 months</td>
<td>6 weeks</td>
<td>8 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td>DTaP-2</td>
<td>4 months</td>
<td>10 weeks</td>
<td>8 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td>DTaP-3</td>
<td>6 months</td>
<td>14 weeks</td>
<td>6-12 months&lt;sup&gt;6&lt;/sup&gt;</td>
<td>6 months&lt;sup&gt;6&lt;/sup&gt;</td>
</tr>
<tr>
<td>DTaP-4</td>
<td>15-18 months</td>
<td>15 months&lt;sup&gt;6&lt;/sup&gt;</td>
<td>3 years</td>
<td>6 months</td>
</tr>
<tr>
<td>DTaP-5&lt;sup&gt;7&lt;/sup&gt;</td>
<td>4-6 years</td>
<td>4 years</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Haemophilus influenzae type b (Hib)-1&lt;sup&gt;8&lt;/sup&gt;</td>
<td>2 months</td>
<td>6 weeks</td>
<td>8 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td>Hib-2</td>
<td>4 months</td>
<td>10 weeks</td>
<td>8 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td>Hib-3&lt;sup&gt;9&lt;/sup&gt;</td>
<td>6 months</td>
<td>14 weeks</td>
<td>6-9 months</td>
<td>8 weeks</td>
</tr>
<tr>
<td>Hib-4</td>
<td>12-15 months</td>
<td>12 months</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Hepatitis A (HepA)-1&lt;sup&gt;5&lt;/sup&gt;</td>
<td>12-23 months</td>
<td>12 months</td>
<td>6-18 months</td>
<td>6 months</td>
</tr>
<tr>
<td>HepA-2</td>
<td>≥18 months</td>
<td>18 months</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Hepatitis B (HepB)-1&lt;sup&gt;10&lt;/sup&gt;</td>
<td>Birth</td>
<td>Birth</td>
<td>4 weeks-4 months</td>
<td>4 weeks</td>
</tr>
<tr>
<td>HepB-2</td>
<td>1-2 months</td>
<td>4 weeks</td>
<td>8 weeks-17 months</td>
<td>8 weeks</td>
</tr>
<tr>
<td>HepB-3&lt;sup&gt;11&lt;/sup&gt;</td>
<td>6-18 months</td>
<td>24 weeks</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Herpes zoster Live (ZVL)&lt;sup&gt;12&lt;/sup&gt;</td>
<td>≥60 years</td>
<td>60 years&lt;sup&gt;13&lt;/sup&gt;</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Herpes zoster Recombinant (RZV)-1</td>
<td>≥50 years</td>
<td>50 years&lt;sup&gt;14&lt;/sup&gt;</td>
<td>2-6 months</td>
<td>4 weeks</td>
</tr>
<tr>
<td>RZV-2</td>
<td>≥50 years (+2-6 months)</td>
<td>50 years</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Human papillomavirus (HPV) – Two-Dose Series&lt;sup&gt;16&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV-1</td>
<td>11-12 years</td>
<td>9 years</td>
<td>6 months</td>
<td>5 months</td>
</tr>
<tr>
<td>HPV-2</td>
<td>11-12 years (+ 6 months)</td>
<td>9 years (+ 5 months)&lt;sup&gt;16&lt;/sup&gt;</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Human papillomavirus (HPV) – Three-Dose Series</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV-1&lt;sup&gt;17&lt;/sup&gt;</td>
<td>11-12 years</td>
<td>9 years</td>
<td>1-2 months</td>
<td>4 weeks</td>
</tr>
<tr>
<td>HPV-2</td>
<td>11-12 years (+ 1-2 months)</td>
<td>9 years (+ 4 weeks)</td>
<td>4 months</td>
<td>12 weeks&lt;sup&gt;15&lt;/sup&gt;</td>
</tr>
<tr>
<td>HPV-3&lt;sup&gt;17&lt;/sup&gt;</td>
<td>11-12 years (+ 6 months)</td>
<td>9 years (+5 months)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Influenza, inactivated (IIV)&lt;sup&gt;18&lt;/sup&gt;</td>
<td>≥6 months</td>
<td>6 months&lt;sup&gt;19&lt;/sup&gt;</td>
<td>4 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td>Influenza, live attenuated (LAIV)&lt;sup&gt;18&lt;/sup&gt;</td>
<td>2-49 years</td>
<td>2 years</td>
<td>4 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td>Measles-mumps-rubella (MMR)-1&lt;sup&gt;20&lt;/sup&gt;</td>
<td>12-15 months</td>
<td>12 months</td>
<td>3-5 years</td>
<td>4 weeks</td>
</tr>
<tr>
<td>MMR-2&lt;sup&gt;20&lt;/sup&gt;</td>
<td>4-6 years</td>
<td>13 months</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Meningococcal conjugate (MenACWY)-1&lt;sup&gt;21&lt;/sup&gt;</td>
<td>11-12 years</td>
<td>2 months&lt;sup&gt;22&lt;/sup&gt;</td>
<td>4-5 years</td>
<td>8 weeks</td>
</tr>
<tr>
<td>MenACWY-2</td>
<td>16 years</td>
<td>11 years (+ 8 weeks)&lt;sup&gt;23&lt;/sup&gt;</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Meningococcal B (Healthy Adolescents)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MenB-1</td>
<td>16-23 years</td>
<td>16 years</td>
<td>Bexsero: 4 weeks</td>
<td>Trumenba: 6 months&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>MenB-2</td>
<td>16-23 years (+1 month)</td>
<td>16 years (+1 month)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Meningococcal B (Persons at Increased Risk)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MenB-1</td>
<td>≥10 years</td>
<td>10 years</td>
<td>Bexsero: 4 weeks</td>
<td>Trumenba: 1-2 months&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>MenB-2</td>
<td>≥10 years (+1 month)</td>
<td>10 years (+1 month)</td>
<td>Bexsero: N/A</td>
<td>Trumenba: 4-5 months&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>MenB-3&lt;sup&gt;24&lt;/sup&gt;</td>
<td>≥10 years (+6 months)&lt;sup&gt;3&lt;/sup&gt;</td>
<td>10 years (+6 months)&lt;sup&gt;3&lt;/sup&gt;</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Pneumococcal conjugate (PCV13)-1&lt;sup&gt;8&lt;/sup&gt;</td>
<td>2 months</td>
<td>6 weeks</td>
<td>8 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td>PCV-2</td>
<td>4 months</td>
<td>10 weeks</td>
<td>8 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td>PCV-3</td>
<td>6 months</td>
<td>14 weeks</td>
<td>6 months</td>
<td>8 weeks</td>
</tr>
<tr>
<td>PCV-4</td>
<td>12-15 months</td>
<td>12 months</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>
### Pneumococcal polysaccharide (PPSV)-1

<table>
<thead>
<tr>
<th>Age Group</th>
<th>2 years</th>
<th>5 years</th>
<th>5 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poliovirus, Inactivated (IPV)-1</td>
<td>2 months</td>
<td>6 weeks</td>
<td>8 weeks</td>
</tr>
<tr>
<td>IPV-2</td>
<td>4 months</td>
<td>10 weeks</td>
<td>8 weeks-14 months</td>
</tr>
<tr>
<td>IPV-3</td>
<td>6-18 months</td>
<td>14 weeks</td>
<td>3-5 years</td>
</tr>
<tr>
<td>IPV-4</td>
<td>4-6 years</td>
<td>4 years</td>
<td>—</td>
</tr>
</tbody>
</table>

### Poliovirus, Inactivated (IPV)

<table>
<thead>
<tr>
<th>Age Group</th>
<th>2 months</th>
<th>6 weeks</th>
<th>8 weeks</th>
<th>4 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPV-2</td>
<td>4 months</td>
<td>10 weeks</td>
<td>8 weeks-14 months</td>
<td>4 weeks</td>
</tr>
<tr>
<td>IPV-3</td>
<td>6-18 months</td>
<td>14 weeks</td>
<td>3-5 years</td>
<td>6 months</td>
</tr>
<tr>
<td>IPV-4</td>
<td>4-6 years</td>
<td>4 years</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

### Rotavirus (RV)-1

<table>
<thead>
<tr>
<th>Age Group</th>
<th>2 months</th>
<th>6 weeks</th>
<th>8 weeks</th>
<th>4 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>RV-2</td>
<td>4 months</td>
<td>10 weeks</td>
<td>8 weeks</td>
<td>4 weeks</td>
</tr>
<tr>
<td>RV-3</td>
<td>6 months</td>
<td>14 weeks</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

### Tetanus-diphtheria (Td)

<table>
<thead>
<tr>
<th>Age Group</th>
<th>11-12 years</th>
<th>7 years</th>
<th>10 years</th>
<th>5 years</th>
</tr>
</thead>
</table>

### Tetanus-diphtheria-acellular pertussis (Tdap)

<table>
<thead>
<tr>
<th>Age Group</th>
<th>≥11 years</th>
<th>7 years</th>
<th>—</th>
<th>—</th>
</tr>
</thead>
</table>

### Varicella (Var)

<table>
<thead>
<tr>
<th>Age Group</th>
<th>12-15 months</th>
<th>12 months</th>
<th>3-5 years</th>
<th>12 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Var-2</td>
<td>4-6 years</td>
<td>15 months</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

1. Combination vaccines are available. Use of licensed combination vaccines is generally preferred to separate injections of their equivalent component vaccines. When administering combination vaccines, the minimum age for administration is the oldest age for any of the individual components. The minimum interval between doses is equal to the greatest interval of any of the individual components.

2. Information on travel vaccines including typhoid, Japanese encephalitis, and yellow fever, is available at www.cdc.gov/travel. Information on other vaccines that are licensed in the US but not distributed, including anthrax and smallpox, is available at https://emergency.cdc.gov/bioterrorism/.

3. “Months” refers to calendar months.

4. A hyphen used to express a range (as in “12-15 months”) means “through.”

5. Combination vaccines containing a hepatitis B component (Pediarix and Twinrix) are available. These vaccines should not be administered to infants younger than 6 weeks because of the other components (i.e., Hib, DTaP, HepA, and IPV).

6. The minimum recommended interval between DTaP-3 and DTaP-4 is 6 months. However, DTaP-4 need not be repeated if administered at least 4 months after DTaP-3. This is a special grace period of 2 months, which can be used when evaluating records retrospectively. An additional 4 days should not be added to this grace period prospectively, but can be added retrospectively.

7. If a fourth dose of DTaP is given on or after the fourth birthday, a fifth dose is not needed.

8. Children receiving the first dose of Hib or PCV13 vaccine at age 7 months or older require fewer doses to complete the series.

9. If PedvaxHib is administered at ages 2 and 4 months, a dose at age 6 months is not necessary. The minimum age for the final dose is 12 months.

10. Adjuvanted Hepatitis B vaccine (Heplisav-B) can be administered to adults 18 years old and older on a two-dose schedule, the first and second doses separated by 4 weeks.

11. HepB-3 should be administered at least 8 weeks after HepB-2 and at least 16 weeks after HepB-1, and should not be administered before 24 weeks of age.

12. Herpes zoster live vaccine (Zostavax) is recommended as a single dose for persons 60 years of age and older.

13. If a dose of Zostavax is administered to someone 50-59 years of age, the dose does not need to be repeated. A 4-day grace period can be added to the absolute minimum age of 50 years when evaluating records retrospectively.

14. If the first dose of recombinant zoster vaccine (Shingrix) is administered to someone 18-49 years of age, the dose does not need to be repeated. A 4-day grace period can be added to the absolute minimum age of 18 years when evaluating records retrospectively.

15. A two-dose series of HPV vaccine is recommended for most persons who begin the series at 9 through 14 years of age. See HPV-specific recommendations for details. https://www.cdc.gov/mmwr/volumes/65/wr/pdfs/mm6549a5.pdf

16. If a patient is eligible for a 2-dose HPV series and the 2nd dose is given too early, it is an invalid dose.

**Prospectively:**
- If the 2nd dose was given less than 4 weeks after the 1st dose, give an additional dose 6-12 months after the 1st dose.
- If the 2nd dose was given more than 4 weeks but less than 5 months after the 1st dose, give an additional dose at least 12 weeks after the 2nd dose and at least 6-12 months after the 1st dose. The 4-day grace period may be used in either case.

**Retrospectively:**
- If this additional dose was given before December 16, 2016, and was given 12 weeks after the 2nd dose and 16 weeks after the 1st dose, it may be counted as valid.
- If it was given on or after December 16, 2016, and was given 12 weeks after the 2nd dose and 5 months after the 1st dose, it may be counted as valid. The 4-day grace period may be used in either case.
17 The minimum age for HPV-3 is based on the baseline minimum age for the first dose (i.e., 9 years) and the minimum interval of 5 months between the first and third dose.
- If the 3rd dose was given before December 16, 2016 and was given 12 weeks after the 2nd dose and 16 weeks after the 1st dose, it may be counted as valid.
- If the 3rd dose was given on or after December 16, 2016 and was given 12 weeks after the 2nd dose and 5 months after the 1st dose, it may be counted as valid. The 4-day grace period may be used in either case.

18 One dose of influenza vaccine per season is recommended for most people. Some children younger than 9 years of age should receive 2 doses in a single season. See current influenza recommendations for details.

19 The minimum age for inactivated influenza vaccine varies by vaccine manufacturer. See package inserts for vaccine-specific minimum ages.

20 Combination MMRV vaccine can be used for children 12 months through 12 years of age. See www.cdc.gov/mmwr/pdf/rr/rr5903.pdf for details.

21 Revaccination with meningococcal vaccine is recommended for previously vaccinated persons who remain at high risk for meningococcal disease. See www.cdc.gov/mmwr/pdf/rr/rr6202.pdf for details.

22 High-risk children can receive Menactra as young as 9 months and Menevo as young as 2 months. MenHibrix is given as a four-dose series at 2, 4, 6, and 12-18 months. It can be given as young as 6 weeks for high-risk children.

23 For routine, non-high risk adolescent vaccination, the minimum age for the booster dose is 16 years.

24 This dose is not necessary if Bexsero is correctly administered, or if Trumenba is correctly administered to healthy adolescents.

25 A second dose of PPSV23 5 years after the first dose is recommended for persons <65 years of age at highest risk for serious pneumococcal infection, and for those who are likely to have a rapid decline in pneumococcal antibody concentration. See www.cdc.gov/mmwr/PDF/rr/rr4608.pdf for details.

26 A fourth dose is not needed if the third dose was administered on or after the 4th birthday and at least 6 months after the previous dose.

27 The first dose of rotavirus must be administered no earlier than 6 weeks and no later than 14 weeks 6 days. The vaccine series should not be started for infants 15 weeks 0 days or older. Rotavirus vaccine should not be administered to children older than 8 months 0 days, regardless of the number of doses received before that age. If two doses of Rotarix are administered as age appropriate, a third dose is not necessary.

28 Only one dose of Tdap is recommended. Subsequent doses should be given as Td. For management of a tetanus-prone wound in a person who has received a primary series of a tetanus-toxoid containing vaccine, the minimum interval after a previous dose of any tetanus-containing vaccine is 5 years.

29 A special grace period of 2 months, based on expert opinion, can be applied to the minimum interval of 3 months when evaluating records retrospectively, which results in an acceptable minimum interval of 4 weeks. An additional 4 days should not be added to this grace period.

30 A special grace period of 2 months, based on expert opinion, can be applied to the minimum age of 15 months when evaluating records retrospectively, which will result in an acceptable minimum age of 13 months. An additional 4 days should not be added to this grace period.

Grace Period
Vaccine doses administered up to 4 days before the recommended age or interval are considered valid. However, local or state mandates might supersede this 4-day guideline.

Adapted from Table 3-1, ACIP General Best Practice Guidelines for Immunization. May 2019
## Routine Immunization Screening Form: Pediatric

**AUTHORITY:** 10 U.S.C. 1071-1085, Medical and Dental Care; Army Regulation 40-562, Immunizations and Chemoprophylaxis for the Prevention of Infectious Disease; DoD 6005.18, Implementation of the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule in DoD Health Care Programs.

**PURPOSE:** To determine whether your child can safely receive a routine immunization.

**ROUTINE USES:** Use and disclosure of your child's records outside of DoD may occur in accordance with the Privacy Act of 1974, as amended (5 U.S.C. 552a(b)). Collected information may be shared with entities including the Departments of Health and Human Services, Veterans Affairs, and other Federal, State, local, or foreign government agencies, or authorized private business entities. To appropriate agencies, entities, and persons when (1) the DoD suspects or has confirmed that there has been a breach of the system of records; (2) the DoD has determined that as a result of the suspected or confirmed breach there is a risk of harm to individuals, the DoD (including its information systems, programs, and operations), the Federal Government, or national security; and (3) the disclosure made to such agencies, entities, and persons is reasonably necessary to assist in connection with the DoD's efforts to respond to the suspected or confirmed breach or to prevent, minimize, or remedy such harm.

**APPLICABLE SORN:** EDHA 07, Military Health Information System (November 18, 2013, 78 FR 68076) [https://dpcrids.defense.gov/Privacy/SORNs/index/DOD-wide-SORN-Article-View/Article/570672/edha-07/](https://dpcrids.defense.gov/Privacy/SORNs/index/DOD-wide-SORN-Article-View/Article/570672/edha-07/)

**DISCLOSURE:** Voluntary. If you choose not to provide the requested information, no penalty may be imposed; however, failure to provide the information may result in delays in assessing contraindications for receiving vaccinations.

### Screening Checklist for Contraindications to Vaccines for Children and Teens

**For parents/guardians:** The following questions will help us determine which vaccines your child may be given today. If you answer “yes” to any question, it does not necessarily mean your child should not be vaccinated. It just means additional questions must be asked. If a question is not clear, please ask your healthcare provider to explain it.

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
<th>Don't Know</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Is the child sick today?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Has the child had a serious reaction after receiving a vaccination?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Does the child have allergies to medication, food, a vaccine component, or latex?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Has the child, a sibling, or a parent had a seizure; has the child had brain or other nervous system problems?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Has the child had a health problem involving heart, lung (e.g., asthma), kidney, or metabolic disease (e.g., diabetes), anemia, or other blood disorder? Is he/she on long-term aspirin therapy?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Does the child have cancer, leukemia, HIV/AIDS, or does the child or family members (parents or siblings) have an immune system problem?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. In the past 3 months, has the child taken medications that weaken his/her immune system, such as prednisone or other steroids; anticancer drugs; biologic drugs for autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, or psoriasis; or had radiation treatments?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. In the past year, has the child received a transfusion of blood or blood products, or been given immune (gamma) globulin or an antiviral drug?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. If your child is a baby, have you ever been told he/she has had intussusception?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. If the child to be vaccinated is 2 through 4 years of age, has a healthcare provider told you that the child had wheezing or asthma in the past 12 months?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Has the child had (or is a candidate for) his/her spleen removed, or do they have sickle cell anemia?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Has the child ever passed out (had vasovagal syncope) during or after a previous immunization or blood draw?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Has the child received any vaccinations in the past 4 weeks?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14. Is the child/teen pregnant or is there a chance she could become pregnant during the next month? Not Applicable</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please list any medications the child is currently taking:

---

**Form completed by:** [Name]

**Date (YYYYMMDD):** [Date]

**Form reviewed by:** [Name]

**Date (YYYYMMDD):** [Date]

**Did you bring your immunization record/card with you?** [Yes] [No]

It is important for you to have a personal record of your vaccinations. If you don’t have a personal record, ask your healthcare provider to give you one. Keep this record in a safe place and bring it with you every time you seek medical care. Make sure your healthcare provider records all your vaccinations on it. For questions or concerns regarding immunizations, providers, nurses and patients may call the DHA Immunization Healthcare Support Center 24/7 at 1-877-438-8222, Option 1.
1. Is the child sick today? [all vaccines]

There is no evidence that acute illness reduces vaccine efficacy or increases vaccine adverse events. However, as a precaution, if moderate to severe acute illness, all vaccines should be delayed until the illness has improved. Mild illnesses (such as otitis media, upper respiratory infections, and diarrhea) are NOT contraindications to vaccination. Do not withhold vaccination if a person is taking antibiotics.

2. Has the child ever had a serious reaction after receiving a vaccination? [all vaccines]

History of anaphylactic reaction (see question 3) to a previous dose of vaccine or vaccine component is a contraindication for subsequent doses. 1 History of encephalopathy within days following DTP/DTaP is a contraindication for further doses of pertussis-containing vaccine. There are other adverse events that might have occurred following vaccination that constitute contraindications. For example, if a child displays a life-threatening anaphylactic reaction, vaccines are deferred when a precaution is present. However, situations may arise when the benefit outweighs the risk (e.g., during a community pertussis outbreak).

3. Does the child have allergies to medications, foods, a vaccine component, or latex? [all vaccines]

An anaphylactic reaction to latex is a contraindication to vaccines that contain latex as a component or as part of the packaging (e.g., vial stoppers, prefilled syringe plungers or caps). If a person has anaphylaxis after eating gelatin, do not administer vaccines containing gelatin. For patients with known Alpha-gal syndrome (red meat allergy) caution should be exercised with gelatin-containing vaccines (i.e., MMR, VAR, YF-Vax), as some of these patients have demonstrated anaphylaxis with these vaccines. A local reaction to a prior vaccine dose or vaccine component, including latex, is not a contraindication to a subsequent dose or vaccine containing that component. 2 People with egg allergy of any severity can receive any recommended influenza vaccine (i.e., any IIV or RIV) that is otherwise appropriate for the patient's age. For people with a history of severe allergic reaction to egg involving any symptom other than hives (e.g., angioedema, respiratory distress), or who have used epinephrine or another emergent medical medication, the vaccine should be administered in a medical setting, such as a clinic, health department, or physician office. Vaccine administration should be supervised by a healthcare provider who is able to recognize and manage severe allergic reactions.

4. Has the child or a sibling of the parent/several have a prior record? has the child had brain or other nervous system problems? [DTaP, Td, Tdap, IIV, LAIV, MMRV]

DTaP and Tdap are contraindicated in children who have a history of encephalopathy within 7 days following DTP/DTaP. An unstable, progressive neurologic condition is a precaution to the use of D TaP and Tdap. For children with stable neurologic disorders (including seizures), an unstable condition (exception: children with a personal or family history of seizures) should not be vaccinated with MMRV, they should receive separate MMR and VAR vaccines. A history of Guillain-Barre syndrome (GBS) is a precaution for the following:

1) To Tdap: if GBS has occurred within 6 weeks of a tetanus-containing vaccine and the decision is made to continue vaccination, if no history of prior Tdap, give Tdap instead of Td.
2) Influenza vaccine (IIV or LAIV): if GBS has occurred within 6 weeks of a prior influenza vaccination, vaccinate with IIV if at high risk for severe influenza complications.

5. Has the child had a health problem involving heart, lung (e.g. asthma), kidney, or metabolic disease (e.g. diabetes), anemia, or other blood disorder? Is he/she on long-term aspirin therapy? [MMR, MMRV, LAIV]

A history of thrombocytopenia or thrombocytopenic purpura is a precaution to MMR and MMRV vaccines. The safety of LAIV in pediatric patients with these conditions has not been established. These conditions, including asthma in children 5 years of age and older, are considered precautions for LAIV use. Patients on long-term aspirin therapy should not receive LAIV: they should receive IIV instead.

6. Does the child or a family member have cancer, leukemia, HIV/AIDS, or any other immune system problem? [LAIV, MMR, MMRV, RV, YF-Vax, VAR, YF-Vax]

Live virus vaccines are usually contraindicated in immunocompromised patients; however, there are exceptions. MMR is recommended for HIV-infected children who do not have evidence of severe immunosuppression. VAR should be considered for HIV-infected children with age-specific CD4+ T-lymphocyte percentage at 15% or greater, or for children 6-18 years of age with CD4+ T-lymphocyte counts of greater than or equal to 200 cells/mL. MMR and VAR vaccines should not be given to a patient with a family history of congenital or hereditary immunodeficiency in first-degree relatives (i.e., parents, siblings) unless the immune competence of that patient has been clinically substantiated or verified by a laboratory of a hospital that child should not receive LAIV. Infants who have been diagnosed with severe combined immune deficiency (SCID) should not be given a live virus vaccine, including RV. Other forms of immunosuppression is a precaution, not a contraindication, to RV. For details, consult current ACIP recommendations.

7. In the past 3 months, has the child taken medications that weaken his/her immune system, such as prednisone or other steroids; anticancer drugs; biologic drugs for autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, or psoriasis; or had radiation treatments? [Adenovirus, MMR, MMRV, Y21a, VAR, YF-Vax]

Live virus vaccines should be postponed until after chemotherapy or long-term high-dose steroid therapy has ended. For details and length of time to postpone, consult the current ACIP statement 3 An immune modulator and immune modulator drugs (especially the antitumor necrosis factor agents adalimumab, infliximab, and etanercept) may be immunosuppressive. The use of live vaccines should be avoided in persons taking these drugs. 4 Specific vaccine schedules for stem cell transplant (bone marrow transplant) patients can be found on the NIH website. LAIV, when recommended, can be given only to healthy, non-pregnant people ages 2 through 49 years.

8. In the past year, has the child received a transfusion of blood or blood products, or been given immune (gamma) globulin (anti-rabies) vaccine? [MMR, MMRV, VAR] Certain live virus vaccines may need to be deferred, depending on several variables. Consult the most current ACIP recommendations or the current Red Book for information on intervals between receipt of antiviral drugs, immune globulin or blood products, and live virus vaccines.

9. If your child is a baby, have you ever been told he/she has had intussusception? [RV]

Infants who have a history of intussusception (i.e., the telescoping of one portion of the intestine into another) should not be given RV.

10. If the child to be vaccinated is 2 through 4 years of age, has a healthcare provider told you that the child had wheezing or asthma in the past 12 months? [LAIV]

Children ages 2 through 4 years who have had a wheezing episode within the past 12 months should not be given LAIV. Instead, these children should be given IIV.

11. Has the child had (or is a candidate for) his/her spleen removed, or do they have sickle cell anemia? [Hbo, LAIV, PCV13, PPSV23, MCV4, MenB]

Patients with anatomic or functional asplenia (i.e. sickle-cell disease) are at an increased risk of certain vaccine preventable diseases, including Haemophilus influenzae type b, meningococcal, and pneumococcal disease. LAIV is not recommended for people with anatomic or functional asplenia. Hbo, PCV13, MCV4, and MenB vaccine should be given 14 days after the last dose of PPSV23 should be administered 8 weeks after the last dose of PCV13. A second dose of PPSV23 should be administered 5 years after the first dose.

12. Has the child ever passed out (had vasovagal syncope) during or after a previous immunization or blood draw? [all vaccines]

Providers should be aware of the potential for syncope (fainting) associated with vaccination, particularly among adolescents. Appropriate measures should be taken to prevent syncope, and to readily respond to the patient who feels faint. Observe all patients for 15 minutes after vaccination for signs and symptoms that precede syncope, such as weakness, dizziness, sweatiness, and pallor. For patients prone to syncope, make sure they are either seated or lying down at the time of vaccination. (If the patient is seated during vaccination, the immunizer should be seated as well, to minimize the risk of SIRVA). If a patient becomes pre-syncope, have them lie flat or sit with head between knees for several minutes; loosen any tight clothing and maintain an open airway; apply cold damp cloths to the patient's face and neck. Observe the patient until symptoms completely resolve.

13. Has the child received any vaccinations in the past 4 weeks? [LAIV, MMR, MMRV, VAR, YF-Vax]

Patients who were given either LAIV or an injectable live virus vaccine should wait 28 days before administering another vaccine. Inactivated vaccines may be given at the same time or at any spacing interval.

14. Is the child/teen pregnant, or is there a chance she could become pregnant during the next month? [Adenovirus, HPV, IPV, MMR, MMRV, LAIV, YF-Vax, VAR, YF-Vax]

Live virus vaccines are contraindicated one month before and during pregnancy because of the theoretical risk of viral transmission to the fetus. Sexually active young women who receive a live virus vaccine should be instructed to practice careful contraception for one month following receipt. 5 On theoretical grounds, HPV and IPV should not be given during pregnancy; however, IPV may be given if risk of exposure is imminent (e.g., travel to endemic areas). Inactivated vaccine and Td are both recommended during pregnancy.

Vaccine Abbreviations:

- DTaP: diphtheria/tetanus toxoids, acellular pertussis
- DTP: diphtheria/tetanus toxoids, whole-cell pertussis
- Hbo: Haemophilus influenzae type b
- HPV: human papillomavirus
- IPV: inactivated influenza
- IPV: inactivated poliovirus
- LAIV: live attenuated influenza
- PCV13: pneumococcal conjugate (13-valent)
- RV: recombinant influenza
- SIRVA: shoulder injury related to vaccine administration
- Td: tetanus/diphtheria toxoids
- Ty21a: oral typhoid
- VAR: varicella
- YF-Vax: yellow fever

Routine Immunization Screening Form: Adult

NOTE: If cholera or smallpox vaccines are being considered, please complete their respective immunization screening forms.

AUTHORITY: 10 U.S.C. 1071-1085, Medical and Dental Care; Army Regulation 40-562, Immunizations and Chemoprophylaxis for the Prevention of Infectious Disease; DoDM 6025.18, Implementation of the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule in DoD Health Care Programs.

PURPOSE: To determine whether you can safely receive a routine immunization.

ROUTINE USES: Use and disclosure of your records outside of DoD may occur in accordance with the Privacy Act of 1974, as amended (5 U.S.C. 552a(b)). Collected information may be shared with entities including the Departments of Health and Human Services, Veterans Affairs, and other Federal, State, local, or foreign government agencies, or authorized private business entities.

To appropriate agencies, entities, and persons when (1) the DoD suspects or has confirmed that there has been a breach of the system of records; (2) the DoD has determined that as a result of the suspected or confirmed breach there is a risk of harm to individuals, the DoD (including its information systems, programs, and operations), the Federal Government, or national security; and (3) the disclosure made to such agencies, entities, and persons is reasonably necessary to assist in connection with the DoD’s efforts to respond to the suspected or confirmed breach or to prevent, minimize, or remedy such harm.

APPLICABLE SORN: EDHA 07, Military Health Information System (November 18, 2013, 78 FR 89076) https://dpdcl.defense.gov/Privacy/SORNsIndex/DODD-wide-SORN-Article-View/Article/570872/edha-07/

DISCLOSURE: Voluntary. If you choose not to provide the requested information, no penalty may be imposed; however, failure to provide the information may result in delays in assessing contraindications for receiving vaccinations.

Patient name: DOB (YYYYMMDD):

Screening Checklist for Contraindications to Vaccines for Adults

For patients: The following questions will help us determine which vaccines you may be given today. If you answer "yes" to any question, it does not necessarily mean you should not be vaccinated. It just means additional questions must be asked. If a question is not clear, please ask your healthcare provider to explain it.

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
<th>Don't Know</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Are you sick today?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Have you ever had a serious reaction after receiving a vaccination?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Do you have allergies to medication, food, a vaccine component, or latex?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Have you had a seizure or a brain or other nervous system problem?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Have you had a health problem involving heart, lung (e.g., asthma), kidney, or metabolic disease (e.g., diabetes), anemia, or other blood disorder?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Do you have cancer, leukemia, HIV/AIDS, or any other immune system problem?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. In the past 3 months, have you taken medications that weaken your immune system, such as prednisone or other steroids; anticancer drugs; biologic drugs for autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, or psoriasis; or had radiation treatments?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. In the past year, have you received a transfusion of blood or blood products, or been given immune (gamma) globulin or an antiviral drug?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Have you had (or are you a candidate for) your spleen removed, or do you have sickle cell anemia?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Have you ever passed out (had vasovagal syncope) during or after a previous immunization or blood draw?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Have you received any vaccinations in the past 4 weeks?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Are you pregnant or is there a chance you could become pregnant during the next month?</td>
<td>Not Applicable</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please list any medications you are currently taking:

Form completed by: Date (YYYYMMDD):

Form reviewed by: Date (YYYYMMDD):

Did you bring your immunization record/card with you? Yes No

It is important for you to have a personal record of your vaccinations. If you don’t have a personal record, ask your healthcare provider to give you one. Keep this record in a safe place and bring it with you every time you seek medical care. Make sure your healthcare provider records all your vaccinations on it. For questions or concerns regarding immunizations, providers, nurses and patients may call the DHA Immunization Healthcare Support Center 24/7 at 1-877-438-8222, Option 1.
1. Are you sick today? [all vaccines]

There is no evidence that acute illness reduces vaccine efficacy or increases vaccine adverse events. 

2. Have you ever had a serious reaction after receiving a vaccination? [all vaccines]

History of anaphylactic reaction (see question 3) to a previous dose of vaccine or vaccine component is a contraindication for subsequent doses. History of encephalopathy within 7 days following DTP/DTaP is a contraindication for further doses of pertussis-containing vaccine. There are other adverse events that may occur following vaccination that constitute contraindications or precautions to future doses. Under normal circumstances, vaccines are deferred when a precaution is present. However, situations may arise when the benefit outweighs the risk (e.g., during a community pertussis outbreak).

3. Do you have allergies to medications, food, a vaccine component, or latex? [all vaccines]

An anaphylactic reaction to latex is a contraindication to vaccines that contain latex as a component or as part of the packaging (e.g., vial stoppers, prefilled syringe plungers or caps). If a person has anaphylaxis after eating gelatin, do not administer vaccines containing gelatin. For patients with known Alpha-gal syndrome (red meat allergy), caution should be exercised with gelatin-containing vaccines (i.e., MMR, VAR, YF-Vax). Some of these patients have demonstrated anaphylaxis with these vaccines. A local reaction to a prior vaccine dose or vaccine component, including latex, is not a contraindication to a subsequent dose or vaccine containing that component. People with egg allergy of any severity can receive any recommended influenza vaccine (i.e., any IIV or RIV) that is otherwise appropriate for the patient’s age. For people with a history of severe allergic reaction to egg involving any symptom other than hives (e.g., angioedema, respiratory distress), or who required epinephrine or another emergency medical intervention, the vaccine should be administered in a medical setting, such as a clinic, health department, or physician’s office. Vaccine administration should be supervised by a healthcare provider who is able to recognize and manage severe allergic conditions.

4. Have you had a seizure, or had brain or other nervous system problems? [IIV, LAIV, Td, Tdap]

Tdap is contraindicated in patients who have a history of encephalopathy within 7 days following DTP/DTPa given as a child. An unstable, progressive neurologic condition is a precaution to the use of Tdap. For patients with stable neurologic disorders (including seizures) unrelated to vaccination, or for patients with a family history of seizures, vaccine is usually appropriate. A history of Guillain–Barre syndrome (GBS) is a precaution for the following: 1) Tdap; if GBS occurred within 6 weeks of a tetanus-containing vaccine and the decision is made to continue vaccination, if no history of prior Tdap, give Tdap instead of Td; 2) Influenza vaccine (IIV or LAIV); if GBS occurred within 6 weeks of a prior influenza vaccination, give IIV if at high risk for severe influenza complications.

5. Have you had a health problem involving heart, lung (e.g., asthma), kidney, or metabolic disease (e.g., diabetes), anemia, or other blood disorder? [MMR, LAIV, SPV]

A history of thrombocytopenia or thrombocytopenic purpura is a precaution to MMR vaccination. The safety of LAIV in patients with MAJOR disease states is not established. These conditions, including asthma in adults, should be considered precautions for LAIV use.

6. Do you have cancer, leukemia, HIV/AIDS, or any other immune system problem? [Adenovirus, Cholera, LAIV, MMR, SPV, Ty21a, VAR, YF-Vax, ZVL]

Live virus vaccines are usually contraindicated in immunocompromised patients; however, there are exceptions. MMR is recommended and varicella should be considered for adults with CD4+ T-lymphocyte counts of greater than or equal to 200 cells/µL. Immunosuppressed patients should not receive LAIV. For details, consult current ACIP recommendations 4.7,6

7. In the past 3 months, have you taken medications that weaken your immune system, such as prednisone or other steroids; anticancer drugs; biologic drugs for autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, or psoriasis; or had radiation treatments? [Adenovirus, Cholera, MMR, SPV, Ty21a, VAR, YF-Vax, ZVL]

Live virus vaccines should be postponed until after chemotherapy or long-term, high-dose steroid therapy has ended. For details and length of time to postpone, consult the current ACIP statement. Some immune mediator and immune modulator drugs (especially the antinecrosis factor agents adalimumab, infliximab, and etanercept) may be immunosuppressive. The use of live vaccines should be avoided in persons taking these drugs. Specific vaccination schedules for stem cell transplant (bone marrow transplant) patients can be found on the NIH website. LAIV, when recommended, can be given only to healthy, non-pregnant people ages 2 through 49 years.

8. In the past year, have you received a transfusion of blood or blood products, or been given immune (gamma) globulin or an antiviral drug? [MMR, VAR]

Certain live virus vaccines may need to be deferred, depending on several variables. Consult the most current ACIP recommendations for information on intervals between receipt of antiviral drugs, immune globulin or blood products, and live virus vaccines.1.7

9. Have you had (or are you a candidate for) your spleen removed, or do you have sickle cell anemia? [Hib, LAIV, PCV13, PPSV23, MCV4, MenB]

Patients with anatomic or functional asplenia (i.e., sickle-cell disease) are at an increased risk of certain vaccine preventable diseases to include Haemophilus influenzae type b meningococcal, and pneumococcal disease. LAIV is not recommended for people with anatomic or functional asplenia. Hib, PCV13, MCV4, and MenB vaccine should be given 14 days before splenectomy, if possible. Doses given during the 14 days prior to surgery can be counted as valid. Doses that cannot be given prior to surgery should be given as soon as the patient’s condition has stabilized after surgery. For patients 2 years of age and older, the first dose of PPSV23 should be administered 8 weeks after the last dose of PCV13. A second dose of PPSV23 should be administered 5 years after the first dose. A third, final dose of PPSV23 should be administered after age 65 years, if both previous doses were before the age of 65.

10. Have you ever had whooping cough (had varsovagynal syringe) during or after a previous immunization or blood draw? [all vaccines]

Providers should be aware of the potential for syncope (fainting) associated with vaccination, particularly among adolescents. Appropriate measures should be taken to prevent syncope, and to readily respond to the patient who feels faint. Observe all patients for 15 minutes after vaccination for signs and symptoms that precede syncope, such as weakness, dizziness, sweatiness, and pallor. For patients prone to syncope, make sure they are either seated or lying down at the time of vaccination. (If the patient is seated during vaccination, the immunizer should be seated as well, to minimize the risk of SIRVA). If a patient becomes pre-syncope, have them lie flat or sit with head between knees for several minutes; loosen any tight clothing and maintain an open airway; apply cool, damp cloths to the patient’s face and neck. Observe the patient until symptoms completely resolve.

11. Have you received any vaccinations in the past 4 weeks? [LAIV, MMR, SPV, VAR, YF-Vax, ZVL]

Patients who were given either LAIV, SPV, or an injectable live virus vaccine should wait 28 days before receiving another live vaccine. Inactivated vaccines may be given at the same time or at any spacing interval.

12. Are you pregnant, or is there a chance you could become pregnant during the next month? [Adenovirus, HPV, IPV, MMR, LAIV, VAR, SPV, Ty21a, possibly YF-Vax, ZVL]

Live virus vaccines are contraindicated one month before and during pregnancy because of the theoretical risk of virus transmission to the fetus. Sexually active women who receive a live virus vaccine should be instructed to practice careful contraception for one month following receipt. On theoretical grounds, HPV and IPV should not be given during pregnancy; however, IPV may be given if risk of exposure is imminent (e.g., travel to endemic areas). Inactivated influenza vaccine and Tdap are both recommended during pregnancy. Both vaccines may be given at any time during pregnancy, but the preferred time for Tdap administration is at 27-36 weeks gestation.

**Vacine Abbreviations:**
- Hib: Haemophilus influenzae type b
- HPV: human papillomavirus
- IIV: inactivated influenza
- IPV: inactivated poliovirus
- LAIV: live attenuated influenza
- MCV4: meningococcal conjugate, quadrivalent, serogroups A, C, W, Y
- MenB: meningococcal serogroup B
- MMR: measles, mumps, rubella
- PPSV23: pneumococcal polysaccharide (23-valent)
- RV: recombinant influenza
- SIRVA: shoulder injury related to vaccination administration
- SPV: vaccinia (smallpox)
- SDI: diphtheria toxoid
- Tet: tetanus/diphtheria toxoids
- Ty21a: oral typhoid
- VAR: varicella
- YF-Vax: yellow fever
- ZVL: zoster vaccine live
CHECKLIST

Best Practices for Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations

OVERVIEW OF THIS DOCUMENT

This checklist is a step-by-step guide to help clinic supervisors overseeing vaccination clinics held at satellite, temporary, or off-site locations follow Centers for Disease Control and Prevention (CDC) and Department of Defense (DoD) guidelines and best practices for vaccine shipment, transport, storage, handling, preparation, administration, and documentation. It should be used in any non-traditional vaccination clinic setting, including but not limited to: workplaces, community centers, schools, makeshift clinics in remote areas, operational environments, aid stations, and even medical facilities when vaccination occurs in the public areas or classrooms. Temporary clinics also include mass vaccination events, and vaccination clinics held during pandemic preparedness exercises. This checklist outlines CDC and DoD guidelines and best practices that are essential for patient safety and vaccine effectiveness. A clinic supervisor at the site should complete, sign, and date this checklist EACH TIME a vaccination clinic is held. To meet accountability and quality assurance standards, all signed checklists should be kept on file by your supervisor/HQ element.

INSTRUCTIONS

1. An Officer-in-Charge (OIC) who will be at the vaccination clinic should be designated as the clinic supervisor. (This individual will be responsible for completing the steps below and will be referred to as “you” in these instructions.)
2. Review this checklist during the planning stage of the vaccination clinic—well in advance of the date(s) when the clinic will be held. This checklist includes sections to be completed before, during, and after the clinic.
3. Critical guidelines for patient safety and vaccine effectiveness are identified by the stop sign icon: ☣. If “NO” is checked in ONE OR MORE answer boxes that contain ☣, DO NOT move forward with the clinic. Follow your organization’s protocols and/or contact the Defense Health Agency-Immunization Healthcare Division (DHA-IHD) for guidance BEFORE proceeding with the clinic. Do not administer any vaccine until you have confirmed that it is acceptable to move forward with the clinic.
4. Contact the DHA-IHD if you have any concerns about whether vaccine was transported, stored, handled, or administered correctly, concerns about whether patients’ personal information was protected appropriately, or concerns about other responses that you have marked as “NO” on rows that do not have the ☣.
5. This checklist should be used in conjunction with DHA-IHD’s Vaccine Storage and Handling Guide: https://health.mil/vaccineshguide and Toolkit: https://health.mil/Imm_Toolkit. For information about specific vaccines, consult the vaccine manufacturer’s package insert.
6. This checklist applies ONLY to vaccines stored at REFRIGERATED temperatures (i.e., between 2–8° Celsius or 36–46°Fahrenheit).
7. Sign and date the checklist upon completion of the clinic or completion of your shift (whichever comes first). (If more than one clinic supervisor is responsible for different aspects of the clinic, you should complete only the section(s) for which you were responsible.)
8. Attach the staff sign-in sheet (with shift times and date) to the checklist (or checklists if more than one clinic supervisor is overseeing different shifts), and submit the checklist(s) to your organization to be kept on file for accountability.

Name and credentials of clinic supervisor:
Name of facility where clinic was held:
Address where clinic was held (street, city, state):
Time and date of vaccination clinic shift (the portion you oversaw):

<table>
<thead>
<tr>
<th>Time (AM/PM)</th>
<th>Date (MM/DD/YYYY)</th>
</tr>
</thead>
</table>

Time and date when form was completed:

<table>
<thead>
<tr>
<th>Time (AM/PM)</th>
<th>Date (MM/DD/YYYY)</th>
</tr>
</thead>
</table>

Signature of clinic supervisor:

152
### BEFORE THE CLINIC (Please complete each item before the clinic starts)

#### VACCINE SHIPMENT

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>N.A.</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

- Vaccine was shipped directly to the facility clinic site, where adequate storage is available. *(Direct shipment is preferred for cold chain integrity.)*

#### VACCINE TRANSPORT (IF IT WAS NOT POSSIBLE TO SHIP VACCINES DIRECTLY TO THE FACILITY/CLINIC SITE)

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>N.A.</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

- Vaccines were transported using a portable vaccine refrigerator or qualified container and pack-out designed to transport vaccines within the temperature range recommended by the manufacturers. *(i.e., between 2–8° Celsius or 36–46° Fahrenheit for all refrigerated vaccines)*. Coolers available at general merchandise stores or coolers used to transport food are **NOT ACCEPTABLE.** See DHA-IHD's Vaccine Storage Guide for information on qualified containers and pack-outs: [https://health.mil/vaccineshguide](https://health.mil/vaccineshguide).

- The person transporting the vaccines confirmed that manufacturer instructions for packing configuration and proper conditioning of coolants were followed. Each vaccine container should include a completed Vaccine Inventory Issue/Return Receipt form. *(Your qualified container and pack-out should include packing instructions. If not, contact the company or DHA-IHD for guidance.)*

- Each vaccine storage unit had its own certified and calibrated temperature-monitoring device (TMD), placed directly with the vaccines and used to monitor temperatures during transport. The TMD was traceable to the standards maintained by the National Institute of Standards and Technology (NIST), and had a current and valid Certificate of Calibration Testing (or Report of Calibration).

- The amount of vaccine transported was limited to the amount needed for the workday.

#### VACCINE STORAGE AND HANDLING (UPON ARRIVAL AT FACILITY/CLINIC)

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>N.A.</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

- If vaccines were shipped, the shipment arrived within the appropriate time frame (according to manufacturer or distributor guidelines) and in good condition.

- If the vaccine shipment contained a cold chain monitor (e.g., TempTale), it was checked upon arrival at the facility clinic, and there was no indication of a temperature excursion *(i.e., out-of-range temperature)* during transit. A cold chain monitor may not be included when vaccines are shipped directly from the Prime Vendor. *(Note: Follow instruction sheet with vaccine shipment for reading and/or returning TempTale monitors.)*

- Upon arrival at the facility clinic (either by shipment or transport), vaccines were immediately unpacked and placed in proper storage equipment. *(i.e., a portable vaccine refrigerator or qualified container and pack-out specifically designed and tested to maintain the manufacturer-recommended temperature range). Follow the guidance for unpacking and storing vaccines specified in DHA-IHD’s Vaccine Storage and Handling Guide: [https://health.mil/vaccineshguide](https://health.mil/vaccineshguide).*

- Upon arrival at the facility clinic, vaccines were still within the manufacturer-recommended temperature range *(i.e., between 2–8° Celsius or 36–46° Fahrenheit for all refrigerated vaccines).*

- Upon arrival at the facility clinic, vaccines remained protected from light *(per manufacturer’s package insert)* until ready for use at the vaccination clinic.

- Upon arrival at the facility clinic, expiration dates of vaccines and any medical equipment *(syringes, needles, alcohol wipes)* being used were checked, and they had not expired.

#### CLINIC PREPARATION AND SUPPLIES

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>N.A.</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

- A contingency plan is in place in case vaccines need to be replaced. The plan addresses scenarios for vaccine compromised before arrival at the clinic and for vaccine compromised during clinic hours.

- An emergency medical kit *(including epinephrine and equipment for maintaining an airway)* is at the site for the duration of the clinic. See paragraph 2-9 of the Joint Regulation *(Army Regulation 40–562; BUMEDINST 6230.15B; AFI 48–110_IP; CG COMDTINST M6230.4G - Immunizations and Chemoprophylaxis for the Prevention of Infectious Diseases).*

- All on-site vaccination staff are certified in cardiopulmonary resuscitation *(CPR)*, are familiar with the signs and symptoms of anaphylaxis, and know the location of epinephrine and are trained in its indications and use. DHA-IHD strongly suggests having a current Standing Order for anaphylaxis management available, which has been reviewed and discussed with all staff prior to the event.

- There is a designated area at the site for management of patients with urgent medical problems *(e.g., fainting).*

- Adequate infection control supplies are provided, including biohazard containers and supplies for hand hygiene. If administering injectable vaccines, gloves, adhesive bandages, individually packaged sterile alcohol wipes, and a sufficient number of sterile needles, syringes, and sharps containers are provided.

- Needles in a variety of lengths are available to optimize injection based on the prescribed route/technique and patient size.

- Reasonable accommodations *(e.g., privacy screens)* are available for patient privacy during vaccination.

» If you check “NO” in ONE OR MORE answer boxes that contain a ☑, **DO NOT move forward with the clinic.**

- Follow your organization’s protocols and/or contact your DoD Public Health Department or DHA-IHD for guidance **before** proceeding with the clinic.

- Do not administer any vaccine until you have confirmed that it is acceptable to move forward with the clinic.
**CHECKLIST of Best Practices for Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations**

**VACCINE PREPARATION**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>N.A.</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>☐</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
</tbody>
</table>

Staff members administering vaccines have reviewed vaccine manufacturer instructions for administration and have completed vaccine-specific competency training PRIOR to the event.

If using a standing order protocol, the protocol is current and available at the clinic/facility site. (See DHA-IHD website for examples.)

A sufficient number of vaccine information statements (VISs) for each vaccine being offered are available at the clinic/facility site (as required by Federal law).

A sufficient number of screening forms are available at the clinic/facility site (see DHA-IHD website for examples). The screening forms are vaccine and patient-specific, as needed (e.g., routine or readiness, adult or pediatric, etc.).

A designated clean area for vaccine preparation has been identified and set up prior to the clinic, separate from the immediate administration area and away from potentially contaminated items. Location physical space dictates placement (e.g., a separate table versus a separate room).

A qualified individual has been designated to oversee infection control at the clinic.

**DURING THE CLINIC (Please complete each item while the clinic is occurring, and review at the end of your shift)**

**VACCINE STORAGE AND HANDLING (AT FACILITY/CLINIC)**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>N.A.</th>
</tr>
</thead>
<tbody>
<tr>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
</tbody>
</table>

Vaccines are being kept in proper storage equipment that maintains the manufacturer-recommended temperature range (i.e., a portable vaccine refrigerator or qualified container and pack-out specifically designed and tested to maintain correct temperatures when opened and closed during the clinic).

Vaccine temperature is being monitored during the clinic using a certified and calibrated digital data logger or temperature-monitoring device placed directly with vaccines. Follow the temperature monitoring guidance specified in DHA-IHD’s Vaccine Storage and Handling Guide: [https://health.mil/vaccineHandling](https://health.mil/vaccineHandling).

If vaccines are being stored in a medical-grade refrigerator at the site, vaccine temperature data are being reviewed and documented a minimum of 2 times during each clinic workday (preferably at the beginning and middle of an 8-hour shift) to ensure they remain at correct temperatures (i.e., between 2-8° Celsius or 36–46° Fahrenheit for ALL refrigerated vaccines).

If vaccines cannot be stored in a medical-grade refrigerator, they are being kept in the portable vaccine refrigerator or qualified pack-out with a digital data logger or temperature-monitoring device placed as closely as possible to the vaccines, and temperatures are being read and recorded at least once an hour. The container is being kept closed/sealed as much as possible.

Vaccines are being prepared at the time of administration.

Vaccines are being protected from light during the vaccination clinic per the manufacturer’s package insert.

Vaccines are being kept in the recommended temperature range. Questions about specific time limits for being out of the recommended temperature range should be referred to your Immunization Healthcare Specialist (IHS) and/or DHA-IHD via the PC-TSMP process at [https://health.mil/coldchain](https://health.mil/coldchain).

**VACCINE ADMINISTRATION**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>N.A.</th>
</tr>
</thead>
<tbody>
<tr>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>☑</td>
<td>☑</td>
<td>☑</td>
</tr>
</tbody>
</table>

Vaccine information statements (VISs) are being provided to every patient or parent/guardian before vaccination (as required by Federal law). Although laminated copies, posters, and digital versions of VISs may also be used, hard-copy handouts are available for those patients who would like to take one home.

All patients are being screened for contraindications and precautions for the specific vaccine(s) in use before receiving that vaccine(s).

Staff is using proper hygiene techniques to clean hands before vaccine administration, between patients, and anytime hands become soiled. For additional guidance, see [www.cdc.gov/handhygiene/providers/index.html](http://www.cdc.gov/handhygiene/providers/index.html).

» If you check "NO" in ONE OR MORE answer boxes that contain a [☑], **DO NOT move forward with the clinic**.

- Follow your organization’s protocols and/or contact your DoD Public Health Department or DHA-IHD for guidance before proceeding with the clinic.
- Do not administer any vaccine until you have confirmed that it is acceptable to move forward with the clinic.
### Best Practices for Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations

#### Checklist:

**YES** | **NO** | **N.A.**
---|---|---
☐ | ☐ | ☐ If gloves are being worn by staff administering vaccines, they are being changed and hands are being cleaned using proper hygiene techniques before and between each patient.

☐ | ☐ | ☐ Staff is triple-checking labels, contents, and expiration dates or beyond use dates (as noted in the manufacturer’s package insert, if applicable) before administering vaccine.

☐ | ☐ | ☐ Vaccines are normal in appearance (i.e., not discolored, without precipitate, and easily resuspended when shaken).

☐ | ☐ | ☐ Each staff member is administering only the vaccines they have prepared.

☐ | ☐ | ☐ If more than one vaccine type is being administered, separate preparation stations are set up for each vaccine type to prevent medication errors.

☐ | ☐ | ☐ Vaccines are being administered using aseptic technique.

☐ | ☐ | ☐ Staff is administering vaccine to the correct patient (e.g., if a parent/guardian and child or siblings are at the vaccination station at the same time, each patient’s name and date of birth are verified prior to their individual vaccination).

☐ | ☐ | ☐ Staff is administering vaccines using the correct route per manufacturer instructions.

☐ | ☐ | ☐ Staff has checked age indications for the vaccines and is administering vaccines to the correct age groups.

☐ | ☐ | ☐ For vaccines requiring more than 1 dose, staff is administering the current dose at the correct interval, if applicable. *Follow the recommended guidelines in Table 3-1 of the “General Best Practice Guidelines on Immunization” at [https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html#t-01](https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html#t-01)*.

☐ | ☐ | ☐ If vaccine administration errors are observed, corrective action is being taken and incident is immediately reported to the clinic supervisor.

☐ | ☐ | ☐ Any persons with a needlestick injury, a vaccine administration error, or an urgent medical problem are being evaluated immediately by a licensed provider, and referred for additional medical care if needed.

☐ | ☐ | ☐ Patients are being instructed/encouraged to stay at the clinic for 15 minutes after vaccination to be monitored for adverse events.

**ADMINISTRATION OF INJECTABLE VACCINES:** *In this section, N.A. is ONLY an option if the clinic is EXCLUSIVELY using non-injectable vaccines, such as live, attenuated influenza vaccine (LAIV)*

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>N.A.</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>
| ☐  | ☐  | ☐   | A new needle AND new syringe are being used for each injection. (Needles and syringes are NEVER used to administer vaccine to more than one person.)

<table>
<thead>
<tr>
<th>☐</th>
<th>☐</th>
<th>☐</th>
</tr>
</thead>
</table>
| ☐  | ☐  | ☐   | Single-dose vials or manufacturer-filled syringes are being used for only one patient.

<table>
<thead>
<tr>
<th>☐</th>
<th>☐</th>
<th>☐</th>
</tr>
</thead>
</table>
| ☐  | ☐  | ☐   | Vacines are being administered following safe injection practices.

<table>
<thead>
<tr>
<th>☐</th>
<th>☐</th>
<th>☐</th>
</tr>
</thead>
</table>
| ☐  | ☐  | ☐   | Seats are provided so staff and patients are at the same level for optimal positioning of anatomic site and injection angle to ensure correct vaccine administration.

<table>
<thead>
<tr>
<th>☐</th>
<th>☐</th>
<th>☐</th>
</tr>
</thead>
</table>
| ☐  | ☐  | ☐   | Staff is identifying injection site correctly. (For intramuscular route: deltoid muscle of arm [preferred] or vastus lateralis muscle of anterolateral thigh for adults, adolescents, and children aged ≥3 years; vastus lateralis muscle of anterolateral thigh [preferred] or deltoid muscle of arm for children aged 1–2 years; vastus lateralis muscle of anterolateral thigh for infants aged ≤12 months. For subcutaneous route: thigh for infants aged <12 months; upper outer triceps of arm for children aged ≥1 year and adults [can be used for infants if necessary].)

<table>
<thead>
<tr>
<th>☐</th>
<th>☐</th>
<th>☐</th>
</tr>
</thead>
</table>
| ☐  | ☐  | ☐   | Staff is inserting needles quickly at the appropriate angle: 90° for intramuscular injections (e.g., most inactivated vaccines such as influenza, typhoid, etc.) or 45° for subcutaneous injections (e.g., live vaccines such as MMR, etc.).

<table>
<thead>
<tr>
<th>☐</th>
<th>☐</th>
<th>☐</th>
</tr>
</thead>
</table>
| ☐  | ☐  | ☐   | Multidose vials are being used only for the number of doses approved by the manufacturer.

» If you check "NO" in ONE OR MORE answer boxes that contain a ☐, DO NOT move forward with the clinic.

- Follow your organization’s protocols and/or contact your DoD Public Health Department or DHA-IHD for guidance before proceeding with the clinic.
- Do not administer any vaccine until you have confirmed that it is acceptable to move forward with the clinic.
### Checklist of Best Practices for Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations

#### VACCINE DOCUMENTATION

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>N.A.</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☑</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☑</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☑</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

- Each vaccination is being fully documented with name of person vaccinated; vaccination date; vaccine type, lot number, manufacturer; patient receipt of vaccine information statement (VIS), including edition date and date VIS was provided; injection site; vaccination route; dosage; and name, title, and unit/location address of person who administered the vaccine.
- Documentation is being completed in the patient’s service-specific Immunization Tracking System (ITS) (e.g., MEDPROS, ASIMS, MRRS, etc.).
- Patients are given documentation of vaccines received for their personal records and to share with their medical providers.

#### AFTER THE CLINIC (Please complete each item after the clinic is over)

##### POST-CLINIC ACTIONS

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>N.A.</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☑</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☑</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☑</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☑</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

- Temperature of remaining vaccine is checked and recorded at the end of clinic. If not still at manufacturer-recommended temperature (i.e., between 2-8° Celsius or 36–46° Fahrenheit for ALL refrigerated vaccines), follow your organization’s protocols and/or contact DHA-IHD for guidance. The Vaccine Inventory Issue/Return Receipt form is updated with the type/amount of remaining viable vaccine for turn-in.
- Any remaining vaccine in provider-predrawn syringes, opened multidose vials, or activated manufacturer-filled syringes (MFSs) is properly discarded. An MFS is activated when the sterile seal is broken (i.e., cap removed from needle or needle added to the syringe). If absolutely necessary, a partially used multidose vial may be transported to or from an off-site/satellite facility operated by the same provider, as long as the cold chain is properly maintained, the vaccine is normal in appearance, and the maximum number of doses per vial indicated by the manufacturer has not already been withdrawn, or the beyond use date indicated by the manufacturer has not been met. However, a partially used vial cannot be transferred from one provider to another, across state lines, or returned to the supplier for credit.
- Viable, unused vaccine is placed back in proper storage equipment that maintains the manufacturer-recommended temperature range at the end of the clinic day, and was not stored in a dormitory-style or bar-style combined refrigerator/freezer unit under any circumstances. (This includes vaccine transported for a multi-day clinic to a remote location where adequate storage at the site is not available.)
- Any needlestick injuries were reported to the clinic supervisor and appropriate entities (e.g., Public Health/Preventive Medicine), and the injured person was sent for appropriate care (e.g., Emergency Department).
- Any vaccine administration errors were reported to all appropriate entities.

##### POST-CLINIC DOCUMENTATION

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>N.A.</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☑</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☑</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☑</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☑</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>☑</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

- All vaccinations were recorded in the service-specific ITS (and Electronic Medical Record, as applicable).
- Any adverse events were reported to the Vaccine Adverse Event Reporting System (VAERS): [http://vaers.hhs.gov/index](http://vaers.hhs.gov/index).
- All patient medical information was placed in secured storage locations for privacy protection in accordance with Public Law 104-191, “Health Insurance Portability and Accountability Act of 1996” (HIPAA).
- The staff sign-in sheet is attached to this document (with shift times, clinic location, and date).

» If you check "NO" in ONE OR MORE answer boxes that contain a ☑, **DO NOT move forward with the clinic.**
  - Follow your organization’s protocols and/or contact your DoD Public Health Department or DHA-IHD for guidance before proceeding with the clinic.
  - Do not administer any vaccine until you have confirmed that it is acceptable to move forward with the clinic.

» If you check "NO" in ONE OR MORE answer boxes that contain a ☑ in the "After The Clinic" section, contact your DoD Public Health Department or DHA-IHD for guidance.
ADDITIONAL INFORMATION AND RESOURCES

If you are concerned that CDC/ACIP guidelines were not followed during your vaccination clinic held at a satellite, temporary, or off-site location, contact your organization and/or DHA-IHD for further guidance.

» REGULATIONS AND POLICIES:
  • The Joint Regulation (Army Regulation 40–562; BUMEDINST 6230.15B; AFI 48–110_IP; CG COMDTINST M6230.4G - Immunizations and Chemoprophylaxis for the Prevention of Infectious Diseases) [http://www.health.mil/JointImmRegulation]
  • The 8 Standards for Military Immunization - [https://health.mil/immunizationstandards]
  • Vaccine Recommendations by AOR - [https://health.mil/CCMDvaccines]
  • Standing Orders - [https://health.mil/standingorders]
  • The Defense Health Agency-Immunization Healthcare Division home page - [https://health.mil/vaccines]
  • ASIP - [https://health.mil/ASIP]

» VACCINE INFORMATION/EDUCATION
  • Vaccine Information Statements (VISs) - [https://health.mil/VIS]
  • Manufacturer’s product information/package inserts - [https://health.mil/packageinserts]
  • Information Papers - [https://health.mil/vaccineinfopapers]

» VACCINE STORAGE, HANDLING, AND ADMINISTRATION:
  • Vaccine storage and handling:
    o CDC Toolkit - [https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/storage-handling-toolkit.pdf]
    o DHA-IHD Vaccine Storage and Handling Guide - [https://health.mil/vaccineshguide]
    o DHA-IHD Immunization Toolkit - [https://health.mil/Imm_Toolkit]
  • Cold Chain Management:
    o DHA-IHD – [https://health.mil/coldchain]
    o USAMMA - [https://www.usamma.army.mil/Pages/DOC-CCM.aspx]
  • Vaccine administration:
    o ACIP guidelines - [https://health.mil/ACIPguidelines]
    o [https://www.cdc.gov/vaccines/hcp/admin/admin-protocols.html]
    o [https://www.cdc.gov/vaccines/pubs/pinkbook/index.html]
    o [https://www.cdc.gov/vaccines/hcp/admin/resource-library.html]

» SCREENING/RECORDKEEPING:
  • Screening form - [http://www.immunize.org/catg.d/p4065.pdf]
  • Immunization Tracking Systems Resources - [https://health.mil/ITS]

» TRAINING:
  • Competency Checklist (Adult) - [https://health.mil/adultcompetency]
  • Competency Checklist (Pediatrics) - [https://health.mil/pediatriccompetency]
  • JKO Immunization training - [https://health.mil/IHBonlinetraining]

» SAFETY/ADVERSE EVENTS:
  • [https://www.cdc.gov/injectionsafety/providers.html]
  • [https://health.mil/vaccinesafety]
  • Medical management of vaccine reactions in adults - [http://www.immunize.org/catg.d/p3082.pdf]
  • Reporting an adverse event: VAERS - [http://vaers.hhs.gov]

» SMALLPOX RESOURCES:
  • [https://health.mil/smallpoxresourcetcenter]

This checklist is a valuable resource for use in temporary mass vaccination clinics and other vaccination exercises, such as those conducted in an operational environment or aid stations as part of force health protection or public health emergency preparedness (PHEP) program activities.

Medical waste disposal is regulated by DoD and state environmental agencies. Contact your installation or state immunization program/environmental agency to ensure that your disposal procedures comply with state and federal regulations.
Recommended Immunization Schedules for Persons Aged 0 through 18 years

United States, 2020
Table 1

**Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2020**

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Birth</th>
<th>1 mo</th>
<th>2 mos</th>
<th>4 mos</th>
<th>6 mos</th>
<th>9 mos</th>
<th>12 mos</th>
<th>15 mos</th>
<th>18 mos</th>
<th>19-23 mos</th>
<th>2-3 yrs</th>
<th>4-6 yrs</th>
<th>7-10 yrs</th>
<th>11-12 yrs</th>
<th>13-15 yrs</th>
<th>16 yrs</th>
<th>17-18 yrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B (HepB)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td>---</td>
<td>3rd dose</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Diphtheria, tetanus, acellular pertussis (DTaP &lt;7 yrs)</td>
<td>3rd dose</td>
<td>See Notes</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Haemophilus influenzae type b (Hib)</td>
<td>3rd dose</td>
<td>See Notes</td>
<td>---</td>
<td>See Notes</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Pneumococcal conjugate (PCV13)</td>
<td>---</td>
<td>3rd dose</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Inactivated poliovirus (IPV)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>3rd dose</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Influenza (IV)</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Influenza (LAIV)</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Measles, mumps, rubella (MMR)</td>
<td>See Notes</td>
<td>---</td>
<td>1st dose</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Varicella (VAR)</td>
<td>See Notes</td>
<td>---</td>
<td>1st dose</td>
<td>---</td>
<td>---</td>
<td>2nd dose</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Hepatitis A (HepA)</td>
<td>See Notes</td>
<td>2-dose series, See Notes</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Tetanus, diphtheria, acellular pertussis (Tdap ≥7 yrs)</td>
<td>See Notes</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Human papillomavirus (HPV)</td>
<td>See Notes</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Meningococcal (MenACWY-D ≥9 mos, MenACWY-CRM ≥2 mos)</td>
<td>See Notes</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Meningococcal B</td>
<td>See Notes</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Pneumococcal polysaccharide (PPSV23)</td>
<td>See Notes</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
</tbody>
</table>

*Administer recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for extended intervals between doses. When a vaccine is not administered at the recommended age, administer at a subsequent visit. The use of trade names is for identification purposes only and does not imply endorsement by the ACP or CDC.*
## Table 2
**Recommended Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who are More than 1 month Behind, United States, 2020**

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restated, regardless of the time that has elapsed between doses. Use the section appropriate for the child's age. Always use this table in conjunction with Table 1 and the notes that follow.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Minimum Age for Dose 1</th>
<th>Minimum Interval Between Doses</th>
<th>Minimum Age for Dose 2</th>
<th>Minimum Interval Between Doses</th>
<th>Minimum Age for Dose 3</th>
<th>Minimum Interval Between Doses</th>
<th>Dose 3 to Dose 4</th>
<th>Dose 4 to Dose 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B</td>
<td>Birth</td>
<td>4 weeks</td>
<td>6 weeks</td>
<td>8 weeks and at least 16 weeks after first dose.</td>
<td>Minimum age for the final dose is 24 weeks.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus</td>
<td>6 weeks</td>
<td>4 weeks</td>
<td>6 months</td>
<td>6 months</td>
<td>6 months</td>
<td>6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria, tetanus, and acellular pertussis</td>
<td>6 weeks</td>
<td>4 weeks</td>
<td>6 weeks</td>
<td>6 months</td>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenza type b</td>
<td>6 weeks</td>
<td>No further doses needed if first dose was administered at age 15 months or older.</td>
<td>4 weeks</td>
<td>if first dose was administered before the 1st birthday.</td>
<td>8 weeks (as final dose)</td>
<td>if current age is younger than 12 months and first dose was administered at younger than age 7 months and at least 1 previous dose was given before 4 months of age.</td>
<td>8 weeks</td>
<td>if current age is younger than 12 months and first dose was administered at age 7 through 11 months; OR if current age is 12 through 15 months and first dose was administered at age 12 through 14 months; OR if both doses were PRP-OMP (PedvaxHIB, Comvax) and were administered before the 1st birthday.</td>
</tr>
<tr>
<td>Haemophilus influenza type b</td>
<td>6 weeks</td>
<td>No further doses needed for healthy children if first dose was administered at age 24 months or older.</td>
<td>4 weeks</td>
<td>if first dose was administered before the 1st birthday.</td>
<td>8 weeks (as final dose for healthy children)</td>
<td>if previous dose was administered between 7–11 months (wait until at least 12 months old); OR if current age is 12 months or older and at least 1 dose was given before age 12 months.</td>
<td>8 weeks</td>
<td>This dose only necessary for children age 12 through 15 months who received 3 doses before age 12 months or for children at high risk who received 3 doses at any age.</td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td>6 weeks</td>
<td>4 weeks</td>
<td>6 weeks</td>
<td>4 weeks and at least 16 weeks after first dose.</td>
<td>Minimum age for the final dose is 8 months, 0 days.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella</td>
<td>12 months</td>
<td>4 weeks</td>
<td>3 months</td>
<td>6 months</td>
<td>6 months</td>
<td>6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td>12 months</td>
<td>3 months</td>
<td>6 months</td>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>12 months</td>
<td>6 months</td>
<td>6 months</td>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal ACWY</td>
<td>2 months MenACWY- CRM</td>
<td>8 weeks</td>
<td>See Notes</td>
<td>See Notes</td>
<td>See Notes</td>
<td>See Notes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal ACWY</td>
<td>9 months MenACWY-D</td>
<td>8 weeks</td>
<td>See Notes</td>
<td>See Notes</td>
<td>See Notes</td>
<td>See Notes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal ACWY</td>
<td>Not applicable (N/A)</td>
<td>8 weeks</td>
<td>6 weeks</td>
<td>6 months</td>
<td>6 months</td>
<td>6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus, diphtheria, tetanus, and acellular pertussis (DTaP)</td>
<td>7 years</td>
<td>4 weeks</td>
<td>6 weeks</td>
<td>if first dose of DTaP/DT was administered before the 1st birthday.</td>
<td>8 weeks</td>
<td>if first dose of DTaP/DT was administered before the 1st birthday.</td>
<td>8 weeks</td>
<td>if first dose of DTaP/DT was administered before the 1st birthday.</td>
</tr>
<tr>
<td>Pneumococcal conjugate</td>
<td>6 weeks</td>
<td>4 weeks</td>
<td>6 weeks</td>
<td>4 weeks and at least 16 weeks after first dose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td>6 weeks</td>
<td>4 weeks</td>
<td>6 weeks</td>
<td>4 weeks and at least 16 weeks after first dose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella</td>
<td>12 months</td>
<td>4 weeks</td>
<td>3 months</td>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td>12 months</td>
<td>3 months</td>
<td>6 months</td>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>12 months</td>
<td>6 months</td>
<td>6 months</td>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal ACWY</td>
<td>2 months MenACWY- CRM</td>
<td>8 weeks</td>
<td>See Notes</td>
<td>See Notes</td>
<td>See Notes</td>
<td>See Notes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal ACWY</td>
<td>9 months MenACWY-D</td>
<td>8 weeks</td>
<td>See Notes</td>
<td>See Notes</td>
<td>See Notes</td>
<td>See Notes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal ACWY</td>
<td>Not applicable (N/A)</td>
<td>8 weeks</td>
<td>6 weeks</td>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus, diphtheria, tetanus, and acellular pertussis (DTaP)</td>
<td>7 years</td>
<td>4 weeks</td>
<td>6 weeks</td>
<td>if first dose of DTaP/DT was administered before the 1st birthday.</td>
<td>8 weeks</td>
<td>if first dose of DTaP/DT was administered before the 1st birthday.</td>
<td>8 weeks</td>
<td>if first dose of DTaP/DT was administered before the 1st birthday.</td>
</tr>
<tr>
<td>Pneumococcal conjugate</td>
<td>6 weeks</td>
<td>4 weeks</td>
<td>6 weeks</td>
<td>4 weeks and at least 16 weeks after first dose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td>6 weeks</td>
<td>4 weeks</td>
<td>6 weeks</td>
<td>4 weeks and at least 16 weeks after first dose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella</td>
<td>12 months</td>
<td>4 weeks</td>
<td>3 months</td>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td>12 months</td>
<td>3 months</td>
<td>6 months</td>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>12 months</td>
<td>6 months</td>
<td>6 months</td>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal ACWY</td>
<td>2 months MenACWY- CRM</td>
<td>8 weeks</td>
<td>See Notes</td>
<td>See Notes</td>
<td>See Notes</td>
<td>See Notes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal ACWY</td>
<td>9 months MenACWY-D</td>
<td>8 weeks</td>
<td>See Notes</td>
<td>See Notes</td>
<td>See Notes</td>
<td>See Notes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal ACWY</td>
<td>Not applicable (N/A)</td>
<td>8 weeks</td>
<td>6 weeks</td>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus, diphtheria, tetanus, and acellular pertussis (DTaP)</td>
<td>7 years</td>
<td>4 weeks</td>
<td>6 weeks</td>
<td>if first dose of DTaP/DT was administered before the 1st birthday.</td>
<td>8 weeks</td>
<td>if first dose of DTaP/DT was administered before the 1st birthday.</td>
<td>8 weeks</td>
<td>if first dose of DTaP/DT was administered before the 1st birthday.</td>
</tr>
<tr>
<td>Pneumococcal conjugate</td>
<td>6 weeks</td>
<td>4 weeks</td>
<td>6 weeks</td>
<td>4 weeks and at least 16 weeks after first dose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td>6 weeks</td>
<td>4 weeks</td>
<td>6 weeks</td>
<td>4 weeks and at least 16 weeks after first dose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella</td>
<td>12 months</td>
<td>4 weeks</td>
<td>3 months</td>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td>12 months</td>
<td>3 months</td>
<td>6 months</td>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>12 months</td>
<td>6 months</td>
<td>6 months</td>
<td>6 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Maximum age for final dose is 8 months, 0 days.*

## Table 3
**Recommended Child and Adolescent Immunization Schedule by Medical Indication, United States, 2020**

Always use this table in conjunction with Table 1 and the notes that follow.

<table>
<thead>
<tr>
<th>VACCINE</th>
<th>INDICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B</td>
<td>Recommended for persons with an additional risk factor for which the vaccine would be indicated.</td>
</tr>
<tr>
<td>Rotaavirus</td>
<td>Vaccination is recommended, and additional doses may be necessary based on medical condition. See notes.</td>
</tr>
<tr>
<td>Diphtheria, tetanus, &amp; acellular pertussis (DTaP)</td>
<td>Not recommended; contraindicated—vaccine should not be administered.</td>
</tr>
<tr>
<td>Haemophilus influenza type b</td>
<td>Precaution—vaccine might be indicated if benefit of protection outweighs risk of adverse reaction.</td>
</tr>
<tr>
<td>Pneumococcal conjugate</td>
<td>Delay vaccination until after pregnancy if vaccine indicated.</td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td>No recommendation/not applicable.</td>
</tr>
<tr>
<td>Influenza (IV)</td>
<td>Recommended for children 2–4 years of age with asthma or wheezing during the preceding 12 months.</td>
</tr>
<tr>
<td>Influenza (LA)</td>
<td>Recommended for children 2–4 years of age with asthma or wheezing during the preceding 12 months.</td>
</tr>
<tr>
<td>Measles, mumps, rubella</td>
<td>Recommended for children 2–4 years of age with asthma or wheezing during the preceding 12 months.</td>
</tr>
<tr>
<td>Varicella</td>
<td>Recommended for children 2–4 years of age with asthma or wheezing during the preceding 12 months.</td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>Recommended for children 2–4 years of age with asthma or wheezing during the preceding 12 months.</td>
</tr>
<tr>
<td>Tetanus, diphtheria, &amp; acellular pertussis (DTaP)</td>
<td>Recommended for children 2–4 years of age with asthma or wheezing during the preceding 12 months.</td>
</tr>
<tr>
<td>Human papillomavirus</td>
<td>Recommended for children 2–4 years of age with asthma or wheezing during the preceding 12 months.</td>
</tr>
<tr>
<td>Meningococcal ACWY</td>
<td>Recommended for children 2–4 years of age with asthma or wheezing during the preceding 12 months.</td>
</tr>
<tr>
<td>Meningococcal B</td>
<td>Recommended for children 2–4 years of age with asthma or wheezing during the preceding 12 months.</td>
</tr>
<tr>
<td>Pneumococcal polysaccharide</td>
<td>Recommended for children 2–4 years of age with asthma or wheezing during the preceding 12 months.</td>
</tr>
</tbody>
</table>

1 For additional information regarding HIV laboratory parameters and use of live vaccines, see the General Best Practice Guidelines for Immunization, “Altered Immunocompetence,” at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html and Table 4-1 (Redbook Note 3) at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html.
2 Severe Combined Immunodeficiency
3 LAIV contraindicated for children 2–4 years of age with asthma or wheezing during the preceding 12 months.
**Notes**

**Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2020**

**Hepatitis A vaccination (minimum age: 12 months for routine vaccination)**

**Routine vaccination**
- 2-dose series (minimum interval: 6 months) beginning at age 18 months

**Catch-up vaccination**
- Unvaccinated persons through 18 years should complete a 2-dose series (minimum interval: 6 months).
- Persons who previously received 1 dose at age 12 months or older should receive dose 2 at least 6 months after dose 1.

**International travel**
- Persons traveling to countries with high or intermediate endemic hepatitis A (<www.cdc.gov/travel/>)
- Infants age 0–11 months: 1 dose before departure; revaccinate with 2 doses, separated by at least 6 months, between 12 and 23 months of age

**Hepatitis B vaccination (minimum age: birth)**

**Birth dose (monovalent HB vaccine only)**
- **Mother is HBsAg-negative:** 1 dose within 24 hours of birth for all medically stable infants ≥2,000 grams. Infants <2,000 grams: Administer 1 dose at ≤1 month of age and hospital discharge.
- **Mother is HBsAg-positive:**
  - Administer HepB vaccine and hepatitis B immune globulin (HBIG) (in separate limbs) within 12 hours of birth, regardless of birth weight. For infants <2,000 grams, administer 3 additional doses of vaccine (total of 4 doses) beginning at age 1 month.
  - Test for HBsAg and anti-HBs at age 9–12 months. If HepB series is delayed, test 1–2 months after final dose.
- **Mother’s HBsAg status is unknown:**
  - Administer HepB vaccine within 12 hours of birth, regardless of birth weight.
  - For infants ≥2,000 grams, administer HBIG in addition to HepB vaccine (in separate limbs) within 12 hours of birth. Administer 3 additional doses of vaccine (total of 4 doses) beginning at age 1 month.
  - Determine mother’s HBsAg status as soon as possible. If mother is HBsAg-positive, administer HBIG to infants ≥2,000 grams as soon as possible, but no later than 7 days of age.

**Routine series**
- 3 doses at 0, 1, 6, 2–4, 18–24 months (use monovalent HepB vaccine for doses administered before age 6 weeks)

**Diphtheria, tetanus, and pertussis (DTaP) vaccine**
- 5 doses series at 2, 4, 5–6, 15–18 months, 4–6 years
  - **Prospectively:** Dose 4 may be administered as early as age 12 months if at least 6 months have elapsed since dose 3.
  - Retrospectively: A 4th dose that was inadvertently administered as early as 12 months may be counted if at least 4 months have elapsed since dose 3.

- **Catch-up vaccination**
  - Dose 5 is not necessary if dose 4 was administered at age 4 years or older and at least 6 months after dose 3.
  - For other catch-up guidance, see Table 2.

**Haemophilus influenzae type b vaccination (minimum age: 6 weeks)**

**Routine vaccination**
- ActHib, Hiberix, or Pentacel: 4-dose series at 2, 4, 6, 12–15 months
- PedvaxHIB: 3-dose series at 2, 4, 12–15 months

- **Catch-up vaccination**
  - Dose 1 at 7–11 months: Administer dose 2 at most 4 weeks later and dose 3 (final dose) at 12–15 months or 8 weeks after dose 2 (whichever is later).
  - Dose 1 at 12–14 months: Administer dose 2 (final dose) at least 8 weeks after dose 1.
  - Dose 1 before 12 months and dose 2 before 15 months: Administer dose 3 (final dose) after 8 weeks after dose 2.
  - Dose 2 of PedvaxHIB before 12 months: Administer dose 3 (final dose) at least 12 months and at least 6 weeks after dose 2.
  - *Unvaccinated* at 15–19 months: 1 dose
  - Previously unvaccinated children age 60 months or older who are not considered high risk do not require catch-up vaccination.
  - 3-dose series (minimum interval: 4 weeks)
  - Chemotherapy or radiation treatment: 13–19 months
    - Unvaccinated or only 1 dose before 12 months: 2 doses, 8 weeks apart
    - 2 or more doses before age 12 months: 1 dose at least 8 weeks after previous dose
  - Doses administered within 14 days of starting therapy or during therapy should be repeated at least 3 months after therapy completion.

**Special situations**
- Immunocompromising conditions, including HIV infection:
  - 3-dose series as above
- History of sexual abuse or assault: Start at age 9 years.
- Pregnancy: HPV vaccine not recommended until after pregnancy, no intervention needed if vaccinated while pregnant; pregnancy testing not needed before vaccination.

**Influenza vaccination (minimum age: 6 months [IIV], 2 years [LAIV], 18 years [recombiant influenza vaccine, RIV])**

**Routine vaccination**
- Use any influenza vaccine appropriate for age and health status exclusively.
  - 2 doses, separated by at least 4 weeks, for children age 6 months–8 years who have received fewer than 2 influenza vaccine doses before July 1, 2019, or whose influenza vaccination history is unknown (administer dose 2 even if the child turns 9 between receipt of dose 1 and dose 2).
  - 1 dose for children age 6 months–8 years who have received at least 2 influenza vaccine doses before July 1, 2019
  - 1 dose for all persons age 9 years and older.

For the 2020–21 season, see the 2020–21 ACIP influenza vaccine recommendations.

**Special situations**
- **Egg allergy, hives only:** Any influenza vaccine appropriate for age and health status annually.
- **Egg allergy with symptoms other than hives (e.g., angioedema, respiratory distress, need for emergency medical services or epinephrine):** Any influenza vaccine appropriate for age and health status annually in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions
- **LAIV should not be used in persons with the following conditions or situations:**
  - History of severe allergic reaction to a previous dose of any influenza vaccine or to any vaccine component (including egg, see details above)
  - Receiving aspirin or salicylate-containing medications
  - Age 2–4 years with a history of wheezing
  - Immunocompromised due to any cause (including medications and HIV infection)
  - Anatomical or functional asplenia
  - Cochlear implant
  - Cerebrospinal fluid-percutaneous communication
  - Close contacts or caregivers of severely immunosuppressed persons who require a protected environment
- Pregnancy
  - Received influenza antiviral medications within the previous 48 hours

For vaccine recommendations for persons 19 years of age or older, see the Recommended Adult Immunization Schedule.

**Additional information**
- Consult relevant ACIP statements for detailed recommendations at www.cdc.gov/vaccines/hcp/acip-recs/index.html.
- For information on contraindications and precautions for the use of vaccine, consult the General Best Practice Guidelines for immunization at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraind.html and relevant ACIP statements at www.cdc.gov/vaccines/hcp/acip-recs/index.html.
- For calculating intervals between doses, 4 weeks = 28 days; intervals of 24 months are determined by calendar months.
- Within a number range (e.g., 12–19), a dash (-) should be read as “through.”
- Vaccine doses administered ≤4 days before the minimum age or interval are considered valid. Doses of any vaccine administered ≥5 days before the minimum age or minimum interval should not be counted as valid and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see Table 3. Recommended and minimum ages and intervals between vaccine doses, in General Best Practice Guidelines for immunization at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/hbg.html.

**Information on travel vaccine requirements and recommendations is available at www.cdc.gov/travel/.

**For vaccination of persons with immunodeficiencies, see Table 1.**

- For information regarding vaccination in the setting of a vaccine-preventable disease outbreak, contact your state or local health department.

**The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. All routine childhood and adolescent vaccines are covered by VICP except for pneumococcal polyvalent vaccine (PPSV23). For more information, see www.hrsa.gov/vaccinecompensation/index.html.

**Hemophilus influenzae type b vaccination (minimum age: 6 weeks)**

**Routine vaccination**
- **5 doses series at 2, 4, 6, 15–18 months, 4–6 years**
  - **Prospectively:** Dose 4 may be administered as early as age 12 months if at least 6 months have elapsed since dose 3.
  - **Retrospectively:** A 4th dose that was inadvertently administered as early as 12 months may be counted if at least 4 months have elapsed since dose 3.

- **Catch-up vaccination**
  - Dose 5 is not necessary if dose 4 was administered at age 4 years or older and at least 6 months after dose 3.
  - For other catch-up guidance, see Table 2.

**Human papillomavirus vaccination (minimum age: 9 years)**

**Routine and catch-up vaccination**
- HPV vaccination routinely recommended at age 11–12 years (can start at age 9 years)
- Recommended catch-up HPV vaccination recommended for all persons through age 18 years if not adequately vaccinated.
  - 2 or 3-dose series depending on age at initial vaccination:
    - **Age 9 through 14 years at initial vaccination:** 2-dose series at 0–6–12 months (administer 2 doses, repeat if administered too soon)
    - **Age 15 years or older at initial vaccination:** 3-dose series at 0, 1–2 months, 6 months (minimum intervals: dose 1 to dose 2 4 weeks / dose 2 to dose 3 12 weeks / dose 1 to dose 3 5 months, repeat dose if administered too soon)
  - If completed valid vaccination series with any HPV vaccine, no additional doses needed

**Special situations**
- Immunocompromising conditions, including HIV infection:
  - 3-dose series as above
- History of sexual abuse or assault: Start at age 9 years.
- Pregnancy: HPV vaccine not recommended until after pregnancy, no intervention needed if vaccinated while pregnant; pregnancy testing not needed before vaccination.

**Notes**

**Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2020**

**Notes**

**Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2020**
**Notes Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2020**

<table>
<thead>
<tr>
<th>Vaccination Schedule</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Measles, mumps, and rubella vaccination</strong> (minimum age: 12 months for routine vaccination)</td>
<td></td>
</tr>
<tr>
<td><strong>Routine vaccination</strong></td>
<td>2–dose series at 12–15 months, 4–6 years</td>
</tr>
<tr>
<td></td>
<td>2 doses given at least 4 weeks apart</td>
</tr>
<tr>
<td><strong>Catch-up vaccination</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Unvaccinated children and adolescents: 2 doses at least 4 weeks apart</td>
</tr>
<tr>
<td></td>
<td>The maximum age for use of MMRV is 12 years</td>
</tr>
<tr>
<td><strong>Special situations</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>International travel</td>
</tr>
<tr>
<td></td>
<td>Infants age 6–11 months: 1 dose before departure; revaccinate with 2-dose series with dose 1 at 12–15 months (2 months if travel to high-risk areas) and dose 2 at 4 weeks later</td>
</tr>
<tr>
<td></td>
<td>Unvaccinated children age 12 months and older: 2-dose series at least 4 weeks apart before departure</td>
</tr>
<tr>
<td><strong>Meningococcal serogroup A, C, Y vaccination</strong> (minimum age: 2 months [MenACWY-CRM, see MenACWY-D, Menactra])</td>
<td></td>
</tr>
<tr>
<td><strong>Routine vaccination</strong></td>
<td>2–dose series at 11–12 years, 16 years</td>
</tr>
<tr>
<td><strong>Catch-up vaccination</strong></td>
<td>Age 13–15 years: 1 dose now and booster at age 16–18 years (minimum interval: 8 weeks)</td>
</tr>
<tr>
<td></td>
<td>Age 16–18 years: 1 dose</td>
</tr>
<tr>
<td><strong>Special situations</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anatomic or functional asplenia (including sickle cell disease), HIV infection, persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use:</td>
</tr>
<tr>
<td></td>
<td>• Menveo: 1 dose at age 6–11 months or age 12 months and older; 2-dose series at least 8 weeks apart</td>
</tr>
<tr>
<td></td>
<td>• Menactra: Persistent complement component deficiency or complement inhibitor use:</td>
</tr>
<tr>
<td></td>
<td>• Age 2–5 years: 2-dose series at least 12 weeks apart</td>
</tr>
<tr>
<td></td>
<td>• Age 6–11 months or age 12 months and older: 2-dose series at least 8 weeks apart</td>
</tr>
<tr>
<td></td>
<td>Anatomic or functional asplenia, sickle cell disease, or HIV infection:</td>
</tr>
<tr>
<td></td>
<td>• Age 9–23 months: Not recommended</td>
</tr>
<tr>
<td></td>
<td>• Age 2–5 years: 2-dose series at least 8 weeks apart</td>
</tr>
<tr>
<td></td>
<td>Menactra must be administered at least 4 weeks after completion of PCV13 series.</td>
</tr>
</tbody>
</table>

**Sickle cell disease and other hemoglobinopathies:** anatomic or functional asplenia; congenital or acquired immunodeficiency; HIV infection; chronic renal failure; neoplastic syndrome; malignant neoplasms, leukemias, lymphomas, Hodgkin disease, and other diseases associated with immunosuppressive drugs or radiation therapy; solid organ transplantation; multiple myeloma: Age 2–18 years |

Any incomplete* series with: 1. PCV7 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13 dose) 2. Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose and administered 8 weeks apart) 3. No history of PCV7: 1 dose PCV13 (at least 8 weeks after any prior PCV13 dose) Age 2–5 years |

- Doses of OPV administered on or after April 1, 2016, should not be counted. |  |
- Only trivalent OPV (tOPV) counts toward the U.S. vaccination requirements. |  |
- Doses of OPV administered before April 1, 2016, should be counted (unless specifically noted as administered during a campaign). |  |
- Doses of OPV administered on or after April 1, 2016, should not be counted. |  |
- For guidance to assess doses documented as “OPV” see www.cdc.gov/mmwr/volumes/66/wr/mm6606a7.htm, cid=m6606a7_1. |  |
- For other catch-up guidance, see Table 2. |  |

**Rotavirus vaccination** (minimum age: 6 weeks) |

**Routine vaccination** | Rotavirus 2-dose series at 2 and 4 months |  |
| | Rotavirus 3-dose series at 2, 4, and 6 months |  |
| | If any dose in the series is either Rotaleq or unknown, default to 3-dose series |  |
| **Catch-up vaccination** | Do not start the series on or after age 15 weeks, 0 days |  |
| | The maximum age for Rotavirus is 8 months, 4 days |  |
| | For other catch-up guidance, see Table 2. |  |

**Tetanus, diphtheria, and pertussis (Tdap) vaccination** (minimum age: 11 years for routine vaccination, 7 years for catch-up vaccination) |

**Routine vaccination** |

- Adolescents age 11–12 years: 1 dose Tdap |  |
- Pregnancy: 1 dose Tdap during each pregnancy, preferably in early part of gestational weeks 27–28. |  |
- Tdap may be administered regardless of the interval since the last tetanus- and diphtheria toxoid-containing vaccine. |  |

**Catch-up vaccination** |

- Adolescents age 13–18 years who have not received Tdap: 1 dose Tdap, then 1 dose Tdap booster every 10 years |  |
- Persons age 7–18 years not fully vaccinated with DTaP: 1 dose Tdap as part of the catch-up series (preferably the first dose, if additional doses are needed, use Td or Tdap). |  |
- Tdap administered at 7–10 years |  |
- Children age 7–9 years who receive Tdap should receive the Tdap booster dose at age 11–12 years. |  |
- Children age 10 years who receive Tdap do not need to receive a booster dose of Tdap but may receive Tdap if additional doses are recommended. |  |
- DTaP inadvertently administered at or after age 7 years |  |
- Children age 7–9 years: DTaP may count as part of catch-up series. Routine Tdap dose at age 11–12 years should be administered. |  |
- Children age 10–18 years: Count dose of DTaP as the adolescent Tdap booster. |  |
- For other catch-up guidance, see Table 2. |  |
- For information on use of Td or Tdap to treat tetanus prophylaxis in wound management, see www.cdc.gov/mmwr/volumes/69/no/ |  |
- n6702a1.htm. |  |

*Fully vaccinated* = 5 valid doses of DTaP or 4 valid doses of DTaP if 4 was administered at age 4 years or older |

**Varicella vaccination** (minimum age: 12 months) |

**Routine vaccination** | 2-dose series at 12–15 months, 4–6 years |  |
| | Dose 2 may be administered as early as 3 months after dose 1 (a dose administered after a 4-week interval may be counted). |  |
| **Catch-up vaccination** | Ensures persons age 7–18 years without evidence of immunity (www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/Varicella.html) have 2-dose series. |  |
| | Age 7–12 years: routine interval 4 weeks (a dose administered after a 4-week interval may be counted). |  |
| | Age 13 years and older: routine interval 4–8 weeks (minimum interval 4 weeks). |  |
- The maximum age for use of MMVR is 12 years. |  |

**Pneumococcal vaccination** (minimum age: 6 weeks [PCV13], 2 years [PPSV23]) |

**Routine vaccination with PCV13** | 4-dose series at 2, 4, 6, 12–15 months |  |
| **Catch-up vaccination with PCV13** | 1 dose for healthy children age 24–29 months with any incomplete* PCV13 series. |  |
| | For other catch-up guidance, see Table 2. |  |

**Special situations** |

High-risk conditions: When both PCV13 and PPSV23 are indicated, administer PCV13 first, PCV13 and PPSV23 should not be administered during the same visit. |  |
- Chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure), chronic lung disease (including asthma treated with high-dose, oral corticosteroids), diabetes mellitus: Age 2–5 years |
- Any incomplete* series with: 3 PCV13 doses: 1 dose PCV13 (at least 8 weeks after any prior PCV13 dose) Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks after the most recent dose and administered 8 weeks apart) |  |
- No history of PPSV23: 1 dose PPSV23 at least 8 weeks after any prior PCV13 dose Age 6–18 years |
- No history of PPSV23: 1 dose PPSV23 (at least 8 weeks after any prior PCV13 dose) |  |
- For information on use of Tdap or Td as tetanus prophylaxis in wound management, see www.cdc.gov/mmwr/volumes/69/no/n6702a1.htm. |  |
- *Fully vaccinated* = 5 valid doses of DTaP or 4 valid doses of DTaP if 4 was administered at age 4 years or older |  |
Recommended Immunization Schedules for Adults

United States, 2020
How to use the adult immunization schedule

1. Determine recommended vaccinations by age (Table 1)
2. Assess need for additional recommended vaccinations by medical condition and other indications (Table 2)
3. Review vaccine types, frequencies, and intervals and considerations for special situations (Notes)

Vaccines in the Adult Immunization Schedule*

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Abbreviations</th>
<th>Trade names</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemophilus influenzae type b vaccine</td>
<td>Hib</td>
<td>ActHIB®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hibrix®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PedvaxHib®</td>
</tr>
<tr>
<td>Hepatitis A vaccine</td>
<td>HepA</td>
<td>Havrix®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vaqta®</td>
</tr>
<tr>
<td>Hepatitis A and hepatitis B vaccine</td>
<td>HepA-HepB</td>
<td>Twinrix®</td>
</tr>
<tr>
<td>Hepatitis B vaccine</td>
<td>HepB</td>
<td>Engerix®B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Recombivax HB®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Heplavax-B®</td>
</tr>
<tr>
<td>Human papillomavirus vaccine</td>
<td>HPV vaccine</td>
<td>Gardasil®P</td>
</tr>
<tr>
<td>Influenza vaccine (inactivated)</td>
<td>IV</td>
<td>Many brands</td>
</tr>
<tr>
<td>Influenza vaccine, live, attenuated</td>
<td>LAIV</td>
<td>Flumist® Quadrivalent</td>
</tr>
<tr>
<td>Influenza vaccine (recombinant)</td>
<td>RV</td>
<td>Flublok® Quadrivalent</td>
</tr>
<tr>
<td>Measles, mumps, and rubella vaccine</td>
<td>MMR</td>
<td>M-M-R® II</td>
</tr>
<tr>
<td>Meningococcal serogroups A, C, W, Y vaccine</td>
<td>MenACWY</td>
<td>Menactra®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Menveo®</td>
</tr>
<tr>
<td>Meningococcal serogroup B vaccine</td>
<td>MenB-4C</td>
<td>Beaxser®</td>
</tr>
<tr>
<td></td>
<td>MenB-214p</td>
<td>Trumenba®</td>
</tr>
<tr>
<td>Pneumococcal 13-valent conjugate vaccine</td>
<td>PCV13</td>
<td>Prevnar 13®</td>
</tr>
<tr>
<td>Pneumococcal 23-valent polysaccharide vaccine</td>
<td>PPV23</td>
<td>Prevnar 23</td>
</tr>
<tr>
<td>Tetanus and diphtheria toxoids</td>
<td>Td</td>
<td>Tdrix®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tdva®</td>
</tr>
<tr>
<td>Tetanus and diphtheria toxoids and acellular pertussis vaccine</td>
<td>Tdap</td>
<td>Adacel® Boostrix®</td>
</tr>
<tr>
<td>Varicella virus</td>
<td>VAR</td>
<td>Varivax®</td>
</tr>
<tr>
<td>Zoster vaccine, recombinant</td>
<td>RZV</td>
<td>Shingrix</td>
</tr>
<tr>
<td>Zoster vaccine live</td>
<td>ZVL</td>
<td>Zostavax®</td>
</tr>
</tbody>
</table>

*Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine series if there are extended intervals between doses. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department
- Clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System at www.vaesn.hhs.gov or 800-822-7967

Injury claims

All vaccines included in the adult immunization schedule except pneumococcal 23-valent polysaccharide (PPSV23) and zoster (RZV, ZVL) vaccines are covered by the Vaccine Injury Compensation Program. Information on how to file a vaccine injury claim is available at www.hrsa.gov/vaccinecompensation.

Questions or comments

Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.

Download the CDC Vaccine Schedules App for providers at www.cdc.gov/vaccines/schedules/hcp/schedule-app.html.

Helpful information

- Complete ACIP recommendations: www.cdc.gov/vaccines/hcp/acip-recs/index.html
- General Best Practice Guidelines for Immunization: www.cdc.gov/vaccines/hcp/guidelines-recommendations/index.html
- Vaccine information statements: www.cdc.gov/vaccines/hcp/vis/index.html
- Travel vaccine recommendations: www.cdc.gov/travel
- Recommended Child and Adolescent Immunization Schedule, United States, 2020: www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html
- Clinical decision-making: www.cdc.gov/vaccines/hcp/guides/general/clinical-guideline-faculty-directory.html
- Injury claims: www.hrsa.gov/vaccinecompensation
- VA Vaccine Compensation Program: www.va.gov/vaccprev
- VA Tricare Vaccine Program: www.tricare.mil/VaccineGuide

Table 1 Recommended Adult Immunization Schedule by Age Group, United States, 2020

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>19–26 years</th>
<th>27–49 years</th>
<th>50–64 years</th>
<th>≥65 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza inactivated (IV) or Influenza recombinant (IV)</td>
<td>1 dose annually</td>
<td>1 dose annually</td>
<td>1 dose annually</td>
<td>1 dose annually</td>
</tr>
<tr>
<td>Influenza live, attenuated (LAIV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus, diphtheria, pertussis (Tdap or Td)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella (MMR)</td>
<td>1 or 2 doses depending on indication (if born in 1957 or later)</td>
<td>2 doses (if born in 1980 or later)</td>
<td>2 doses</td>
<td>1 dose</td>
</tr>
<tr>
<td>Varicella virus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zoster recombinant (RZV) (preferred)</td>
<td></td>
<td></td>
<td></td>
<td>2 doses</td>
</tr>
<tr>
<td>Zoster live (ZVL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus (HPV)</td>
<td>2 or 3 doses depending on age at initial vaccination or condition</td>
<td>27 through 45 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal conjugate (PCV13)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal polysaccharide (PPSV23)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A (HepA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B (HepB)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal A, C, W, Y (MenACWY)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal B (MenB)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenzae type b (Hib)</td>
<td></td>
<td></td>
<td></td>
<td>1 dose depending on indication</td>
</tr>
</tbody>
</table>

U.S. Department of Health and Human Services
Centers for Disease Control and Prevention

CS310021-A
Table 2: Recommended Adult Immunization Schedule by Medical Condition and Other Indications, United States, 2020

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Pregnancy</th>
<th>Immuno-compromised (excluding HIV infection)</th>
<th>HIV infection CD4 count</th>
<th>Asplenia, complement deficiencies</th>
<th>End-stage renal disease or on hemodialysis</th>
<th>Heart or lung disease, alcoholism†</th>
<th>Chronic liver disease</th>
<th>Diabetes</th>
<th>Health care personnel*</th>
<th>Men who have sex with men</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tdap or Td</td>
<td>1 dose Tdap each pregnancy</td>
<td><strong>NOT RECOMMENDED</strong></td>
<td>1 dose Tdap, then Td or Tdap booster every 10 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMR</td>
<td><strong>NOT RECOMMENDED</strong></td>
<td>1 or 2 doses depending on indication</td>
<td>2 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VAR</td>
<td><strong>NOT RECOMMENDED</strong></td>
<td>2 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RZV (preferred)</td>
<td>DELAY</td>
<td>2 doses at age ≥50 years</td>
<td>1 dose at age ≥60 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZVL</td>
<td><strong>NOT RECOMMENDED</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV</td>
<td>DELAY</td>
<td>3 doses through age 26 years</td>
<td>2 or 3 doses through age 26 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCV13</td>
<td></td>
<td>1 dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPSV23</td>
<td></td>
<td>1, 2, or 3 doses depending on age and indication</td>
<td>2 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HepA</td>
<td></td>
<td>2 or 3 doses depending on vaccine</td>
<td>2 or 3 doses depending on vaccine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HepB</td>
<td></td>
<td>2 or 3 doses depending on vaccine</td>
<td>2 or 3 doses depending on vaccine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MenACWY</td>
<td>1 or 2 doses depending on indication, see notes for booster recommendations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MenB</td>
<td>2 or 3 doses depending on vaccine and indication, see notes for booster recommendations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hib</td>
<td>3 doses HSCT recipients only</td>
<td>1 dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes

Haemophilus influenzae type b vaccination

**Special situations**
- Anatomical or functional asplenia (including sickle cell disease): 1 dose if previously did not receive Hib; if elective splenectomy, 1 dose, preferably at least 14 days before splenectomy
- Hematopoietic stem cell transplant (HCT): 3-dose series 4 weeks apart starting 6–12 months after successful transplant, regardless of Hib vaccination history

**Hepatitis A vaccination**

**Routine vaccination**
- Not at risk but want protection from hepatitis A (identification of risk factor not required): 2-dose series HepA (Havrix 6–12 months apart or HepatVac 6–18 months apart [minimum interval: 6 months] or 3-dose series HepA-Heplisav-B [Twinrix] at 0, 1, 6 months [minimum intervals: 4 weeks between doses 1 and 2; 1/2 months between doses 2 and 3])

**Special situations**
- At risk for hepatitis A virus infection: 2-dose series HepA or 3-dose series HepA-Heplisav-B as above
  - Chronic liver disease (e.g., persons with hepatitis B, hepatitis C, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, alanine aminotransferase [ALT] or aspartate aminotransferase [AST] level greater than twice the upper limit of normal)
  - HIV infection
  - Men who have sex with men
  - Injection or noninjection drug use
  - Persons experiencing homelessness
  - Work with hepatitis A virus in research laboratory or with nonhuman primates with hepatitis A virus infection
  - Travel in countries with high or intermediate endemic hepatitis A
    - Close, personal contact with international adoptee (e.g., household or regular babysitting) in first 60 days after arrival from country with high or intermediate endemic hepatitis A (adoption delay at least 2 weeks before adoptee's arrival)

Hepatitis B vaccination

**Routine vaccination**
- Not at risk but want protection from hepatitis B (identification of risk factor not required): 2- or 3-dose series (2-dose series Heplisav-B at least 4 weeks apart [2-dose series Heplisav-B only applies when 2 doses of Heplisav-B are used at least 4 weeks apart] or 3-dose series Engerix-B or Recombivax HB at 0, 1, 6 months [minimum intervals: 4 weeks between doses 1 and 2; 8 weeks between doses 2 and 3])

**Special situations**
- At risk for hepatitis B virus infection: 2-dose series (Heplisav-B) or 3-dose series (Engerix-B, Recombivax HB) series or 3-dose series (Heplisav-B (Twinrix)) as above
  - Chronic liver disease (e.g., persons with hepatitis C, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, alanine aminotransferase [ALT] or aspartate aminotransferase [AST] level greater than twice the upper limit of normal)
  - HIV infection
  - Sexual exposure risk (e.g., sex partners of hepatitis B surface antigen [HBsAg]-positive persons; sexually active persons not in mutually monogamous relationships; persons seeking evaluation or treatment for a sexually transmitted infection; men who have sex with men)
  - Current or recent injection drug use
  - Perinatal or mucosal risk for exposure to blood (e.g., household contacts of HBsAg-positive persons; residents and staff of facilities for developmentally disabled persons; health care and public safety personnel with reasonably anticipated risk for exposure to blood or blood-contaminated body fluids; hemodialysis, peritoneal dialysis, home dialysis, and predialysis patients; persons with diabetes mellitus age younger than 60 years and, at discretion of treating clinician, those age 60 years or older)
  - Incarcerated persons
  - Travel in countries with high or intermediate endemic hepatitis B
  - Pregnancy if at risk for infection or severe outcome from infection during pregnancy (Heplisav-B not currently recommended due to lack of safety data in pregnant women)

Human papillomavirus vaccination

**Routine vaccination**
- HPV vaccination recommended for all adults through age 26 years: 2- or 3-dose series depending on age at initial vaccination and condition
  - Age 15 years or older at initial vaccination: 3-dose series at 0, 1–2, 6 months (minimum intervals: 4 weeks between doses 1 and 2/12 weeks between doses 2 and 3) [3-dose series Heplisav-B at least 4 weeks apart]
  - Age 9 through 14 years at initial vaccination and received 1 dose or 2 doses less than 5 months apart: 1 dose
  - Age 9 through 14 years at initial vaccination and received 2 doses at least 5 months apart: HPV vaccination complete, no additional dose needed.
- If completed valid vaccination series with any HPV vaccine, no additional doses needed

Shared clinical decision-making
- Age 27 through 45 years based on shared clinical decision-making: 2- or 3-dose series as above
- Specific situations
  - Pregnancy through age 26 years: HPV vaccination is not recommended until after pregnancy; no intervention needed if vaccinated while pregnant; pregnancy testing not needed before vaccination
Influenza vaccination

Routine vaccination
- Persons age 6 months or older: 1 dose any influenza vaccine appropriate for age and health status annually
- For additional guidance, see www.cdc.gov/vaccines

Special situations
- Egg allergy, hives only: 1 dose any influenza vaccine appropriate for age and health status annually
- Egg allergy more severe than hives (e.g., angioedema, respiratory distress): 1 dose any influenza vaccine appropriate for age and health status annually in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions
- LAIV should not be used in persons with the following conditions or situations:
  - History of severe allergic reaction to any vaccine component (excluding egg) or to a previous dose of any influenza vaccine
  - Immunocompromised due to any cause (including medications and HIV infection)
  - Anatomic or functional asplenia
  - Cerebrospinal fluid- oropharyngeal communication
  - Close contacts or caregivers of severely immuno suppressed persons who require a protected environment

Pregnancy
- Received influenza antiviral medications within the previous 48 hours

History of Guillain-Barré syndrome within 6 weeks of previous dose of influenza vaccine: Generally should not be vaccinated unless vaccination benefits outweigh risks for those at higher risk for severe complications from influenza

Notes

Recommended Adult Immunization Schedule, United States, 2020

Meningococcal vaccination

Special situations for MenACWY
- Anatomical or functional asplenia (including sickle cell disease), HIV infection, persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use: 2-dose series MenACWY (Menactra, Menveo) at least 8 weeks apart and revaccinate every 5 years if risk remains
- Travel in countries with hyperendemic or epidemic meningococcal disease, microbiologists routinely exposed to Neisseria meningitidis: 1 dose MenACWY (Menactra, Menveo) and revaccinate every 5 years if risk remains
- First-year college students who live in residential housing (if not previously vaccinated at age 16 years or older) and military recruits: 1 dose MenACWY (Menactra, Menveo)

Shared clinical decision-making for MenB
- Adolescents and young adults age 16 through 23 years (age 16 through 18 years preferred) not at increased risk for meningococcal disease: Based on shared clinical decision-making, 2-dose series MenB-4C at least 1 month apart or 2-dose series MenB-FHbp at 0, 6 months (if dose 2 was administered less than 6 months after dose 1, administer dose 3 at least 4 months after dose 2); MenB-4C and MenB-FHbp are not interchangeable (use same product for all doses in series)

Special situations for MenB
- Anatomical or functional asplenia (including sickle cell disease), persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use, microbiologists routinely exposed to Neisseria meningitidis: 2-dose primary series MenB-4C (Bexsero) at least 1 month apart or 3-dose primary series MenB-FHbp (Trumenba) at 0, 1–2, 6 months (if dose 2 was administered at least 6 months after dose 1, dose 3 not needed); MenB-4C and MenB-FHbp are not interchangeable (use same product for all doses in series); 1 dose MenB booster 1 year after primary series and revaccinate every 2–3 years if risk remains
- Pregnancy: Delay MenB until after pregnancy unless at increased risk and vaccination benefits outweigh potential risks

Pneumococcal vaccination

Routine vaccination
- Age 65 years or older (immunocompetent—see www.cdc.gov/mmwr/volumes/68/wr/mm6806a6.htm\__cid=mm6806a6\_wv): 1 dose PPSV23
  - If PPSV23 was administered prior to age 65 years, administer 1 dose PPSV23 at least 5 years after previous dose

Shared clinical decision-making
- Age 65 years or older (immunocompetent): 1 dose PCV13 based on shared clinical decision-making
- Both PCV13 and PPSV23 are to be administered, PCV13 should be administered first
- PCV13 and PPSV23 should be administered at least 1 year apart
- PCV13 and PPSV23 should not be administered during the same visit

Special situations
- Age 19 through 64 years with chronic medical conditions (chronic heart [excluding hypertension], lung, or liver disease, diabetes, alcoholism, or cigarette smoking): 1 dose PCV13
- Age 19 years or older with immunocompromising conditions (congenital or acquired immunodeficiency [including B- and T-lymphocyte deficiency, complement deficiencies, phagocytic disorders, HIV infection], chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancy, iatrogenic immunosuppression [e.g., drug or radiation therapy], solid organ transplant, multiple myeloma) or anatomical or functional asplenia (including sickle cell disease and other hemoglobinopathies): 1 dose PCV13 followed by 1 dose PPSV23 at least 8 weeks later, then another dose PPSV23 at least 5 years after previous PPSV23; at age 65 years or older, administer 1 dose PPSV23 at least 5 years after most recent PPSV23 (note: only 1 dose PPSV23 recommended at age 65 years or older)
- Age 19 years or older with cerebrospinal fluid leak or coiled implant: 1 dose PCV13 followed by 1 dose PPSV23 at least 8 weeks later; at age 65 years or older, administer another dose PPSV23 at least 5 years after previous PPSV23 (note: only 1 dose PPSV23 recommended at age 65 years or older)

Tetanus, diphtheria, and pertussis vaccination

Routine vaccination
- Previously did not receive Tdap at or after age 11 years: 1 dose Tdap, then Td or Tdap every 10 years

Special situations
- Previously did not receive primary vaccination series for tetanus, diphtheria, or pertussis: At least 1 dose Tdap followed by 1 dose Td or Tdap at least 4 weeks after Tdap and another dose Td or Tdap 6–12 months after last Td or Tdap (Tdap can be substituted for any Td dose, but preferred as first dose); Td or Tdap every 10 years thereafter
- Pregnancy: 1 dose Tdap during each pregnancy, preferably in early part of gestational weeks 27–36
- For information on use of Td or Tdap as tetanus prophylaxis in wound management, see www.cdc.gov/mmwr/volumes/67/nr/6702a1.htm

Varicella vaccination

Routine vaccination
- No evidence of immunity to varicella: 2-dose series: 4–8 weeks apart if previously did not receive varicella-containing vaccine (VAR or MMRV [measles-mumps-rubella-varicella vaccine] for children); if previously received 1 dose varicella-containing vaccine, 1 dose at least 4 weeks after first dose
- Evidence of immunity: U.S.-born before 1980 (except for pregnant women and health care personnel [see below]), documentation of 2 doses varicella-containing vaccine at least 4 weeks apart, diagnosis or verification of history of varicella or herpes zoster by a health care provider, laboratory evidence of immunity or disease

Notes

Recommended Adult Immunization Schedule, United States, 2020

Zoster vaccination

Routine vaccination
- Age 50 years or older: 2-dose series RZV (Shingrix) 2–6 months apart (minimum interval: 4 weeks; repeat dose if administered too soon), regardless of previous herpes zoster or history of ZVL (Zostavax) vaccination (administer RZV at least 2 months after ZVL)
- Age 60 years or older: 2-dose series RZV 2–6 months apart (minimum interval: 4 weeks; repeat if administered too soon) or 1 dose ZVL if not previously vaccinated. RZV preferred over ZVL (if previously received ZVL, administer RZV at least 2 months after ZVL)

Special situations
- Pregnancy: ZVL contraindicated; consider delaying RZV until after pregnancy of RZV is otherwise indicated
- Severe immunocompromising conditions (including HIV infection with CD4 count <200 cells/μL) ZVL contraindicated; recommend use of RZV under review

1/29/2020
Centers for Disease Control and Prevention Recommended Adult Immunization Schedule, United States, 2020